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Mycobacterium tuberculosis (MTB) can persist for decades in the host after 
primary infection – this is called latent infection. Latent mycobacteria exist in a state of 
non-replicating persistence (NRP) or ‘dormancy’, and are resistant to conventional anti-
mycobacterials. Reactivation results in active disease following impairment of host 
immunity. It is believed that hypoxia is a major factor inducing NRP in MTB.  
Menaquinone (vitamin K) is a lipid-soluble molecule required for bacterial 
electron transport. The MTB genome contains homologues of all the Escherichia coli 
men genes, which encode enzymes required for menaquinone biosynthesis. menA-
deficient E. coli are growth-inhibited in anaerobic environments when limited to utilising 
certain substrates. Mycobacterium membranes contain abundant menaquinones, but their 
role in mycobacterial physiology and particularly their contribution to mycobacterial 
latency is unknown. Based on the E. coli model, it was hypothesised that since hypoxia 
induces mycobacterial latency, menaquinone-mediated electron transport and respiratory 
pathways should be required for maintaining mycobacterial persistence within the host.  
This project explores evidence that menaquinone is required by latent 
mycobacteria in hypoxic conditions and uncovers inhibitory effects of exogenous vitamin 
K analogues. The study is based on Mycobacterium bovis bacille Calmette-Guérin 
(BCG). Using the Wayne model for generating latent mycobacteria in vitro through 
progressive oxygen depletion in broth cultures, it was found that levels of expression of 
men genes were increased much more than in aerobic cultures, and this was reversible 
upon re-aeration. menA gene expression was likewise elevated in BCG extracted from 
infected mouse organs. A menA-‘knockdown’ BCG strain, with reduced menaquinone 
 ix 
production, was generated using an anti-sense strategy. Relative to the control strain, its 
in vitro growth was reduced. Growth was more significantly retarded in hypoxic than 
aerobic cultures, and its recovery from NRP was severely affected. This was associated 
with reduced anaerobic nitrate reductase activity, and with induction of genes regulated 
by the mycobacterial DosR regulon for entry into dormancy. Both intracellular survival 
and host cell lysis were also reduced. The menaquinone-deficient strain showed a 19-fold 
attenuation in survival in murine spleens at 8 weeks post-infection, relative to the control 
strain. Menaquinone structural analogue, vitamin K1, reduced growth of wild-type BCG 
in the Wayne model, with greatest inhibition noted at the stage of hypoxia-induced NRP, 
associated with elevated menA expression. In anaerobically-grown BCG cultures, vitamin 
K1 treatment resulted in 32-fold greater growth inhibition than pyrazinamide alone. In 
BCG-infected mice treated orally with vitamin K1 3 weeks post-infection, there were 
significant reductions in bacterial counts in the organs. Following low-dose BCG murine 
infection, vitamin K1 treatment limited the resurgence of bacteria growth in the lungs 
following steroid immunosuppression, suggesting a role for vitamin K1 in inhibiting 
mycobacterial reactivation from latency.
  
Overall, the work supports the hypothesis that menaquinone is important in 
mycobacterial latency and survival in the host. Drugs specifically targeting latent MTB 
are needed to reduce the duration of TB chemotherapy and menaquinone is identified as 
such a target. Moreover, the observed preferential inhibitory activity of vitamin K1 
against latent over actively growing BCG provides an example of such a drug.  
 x 
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CHAPTER 1: LITERATURE REVIEW 
 
 1.1 MYCOBACTERIA AND TUBERCULOSIS 
1.1.1 Epidemiology of TB 
 Tuberculosis (TB) was declared a global health emergency by the World Health 
Organization (WHO) in 1993. There are around 9 to 10 million new cases of TB being 
reported each year (WHO, 2005) and TB claims approximately 1.7 million lives per 
annum (Dye et al., 2005). Hence, TB is responsible for more deaths than any other single 
bacterial infection. In recent decades, a deadly synergy between MTB and the human 
immunodeficiency virus (HIV) (Corbett et al., 2003) has emerged, in addition to the 
increasing occurrence of multidrug-resistant (MDR) strains (WHO, 2004).  
In Singapore (MOH, 2006), the TB incidence in 2005 was 37 cases per 100,000 
population or 1,316 new cases of TB among Singapore residents. The highest incidence 
group was older males as 754 cases (57.3%) were 50 years old and above, and 914 cases 
(69.5%) were males. There were 64 deaths from TB among Singapore residents, giving a 
mortality rate of 1.7 cases per 100,000 population. TB accounted for 0.4% of all deaths in 
Singapore in 2005. This moderately high incidence rate was attributed to migrant workers 
who had perhaps been latently infected in their younger years prior to settling down in 
Singapore. Extra-pulmonary incidences constitute a minor proportion (13.2%) of TB 
cases in Singapore, thus the majority of local cases are of pulmonary TB alone. The local 
case-detection rate is well above the 70% global target (WHO report, 2005).  
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1.1.2 Bacteriology of Mycobacteria 
There are more than 120 known species in the Mycobacterium genus (Tortoli, 
2006). Most species as free-living saprophytes, only a minority are human pathogens 
causing TB (M. tuberculosis, M. bovis, and M. africanum) and leprosy (M. leprae) 
(Grange, 1996; Jarlier and Nikaido, 1994; Wayne, 1984). The cultivable members of the 
genus Mycobacterium are clinically grouped as the M. tuberculosis complex and the non-
tuberculous (atypical) mycobacteria. Mycobacterium leprae, which causes leprosy, is not 
cultivable in vitro (van Beers et al., 1996).  
The members of the M. tuberculosis complex are M. tuberculosis (MTB), M. 
bovis, M. africanum, M. microti and M. canettii. The diseases caused by these subspecies 
are clinically very similar. Pulmonary diseases caused by MTB and M. bovis are 
clinically, radiographically, and pathologically indistinguishable. However, M. bovis 
appears to have a diminished propensity to reactivate and spread from person to person 
(O'Reilly and Daborn, 1995). MTB complex isolates are difficult to distinguish by 
biochemical tests or growth characteristics and require a whole-genome fingerprinting 
techniques (e.g. genome-sequence-based fluorescent amplified-fragment length 
polymorphism (FAFLP) typing (Goulding et al., 2000) ) for speciation. By passage 
through artificial media, Calmette and Guérin attenuated a strain of M. bovis to generate 
bacille Calmette-Guerin (BCG), which is used as a vaccine.  
The atypical mycobacteria are a genetically heterogeneous group of acid-fast 
bacteria. Based on pigment production and growth rate, atypical mycobacteria can be 
distinguished into four groupings: I, photochromogens; II, scotochromogens; III, 
chromogens; and IV, rapid growers (Runyon, 1959). Most of these atypical bacteria can 
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be isolated from environmental sources. The atypical mycobacteria exhibit limited 
pathogenicity in humans, but bacteria of particular species, such as Mycobacterium 
kansasii, Mycobacterium malmoense and Mycobacterium avium, are capable of causing 
tuberculosis-like syndromes, especially in immunocompromised patients (Havlik et al., 
1993; Horsburgh, 1992; Horsburgh et al., 1997; Nightingale et al., 1992; Portaels, 1995).  
Skin and subcutaneous infections by M. marium, M. chelonae and M.fortuitum are not 
uncommon (Petrini, 2006).  
 Mycobacteria are weakly Gram-positive rods and are acid-fast on Ziehl-Neelsen 
staining. MTB growth on Lowenstein-Jensen or Middlebrook agar permits visual colony 
formation; these have a dry and wrinkled surface, and require 3 to 4 weeks of growth on 
solid media to become visible (Bloom and Murray, 1992). Mycobacterium cultures 
usually require sodium pyruvate for growth of large colonies whereas minute colonies are 
observed on media containing glycerol as carbon source. Addition of casein hydrolysate 
improves the growth of some fastidious strains of MTB (Cohn et al., 1968). For culture 
of MTB on liquid and solid media under laboratory condtions, it is important that 
Middlebrook media are supplemented with oleic acid, albumin, dextrose and catalase 
(OADC). The generation time of MTB is around 24 h in both synthetic medium and in 
infected animals. They do not form flagella, spores, toxins or capsules.  
 
1.1.3 Mycobacterial lipids 
An interesting feature of mycobacteria is the extraordinarily high lipid content of 
the cell envelope (fig. 1), constituting up to 40% of their dry weight (Anderson, 1940). In 
addition to conferring unique structural properties that aid in the diagnosis of clinical 
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specimens, the mycobacterial cell envelope is important in directing host–pathogen 
interactions (Besra and Chatterjee, 1994; Brennan and Nikaido, 1995) as well as  
providing the bacteria with a formidable protective barrier against breakage, antibiotics 
and the macrophage’s bactericidal arsenal (Gao et al., 2003). A table of important 











Figure 1. Schematic representation of the cell envelope of Mycobacterium 
tuberculosis 
Components of the cell envelope include (A) plasma membrane (B) plasma membrane- and cell 
envelope-associated proteins (C) peptidoglycan (D) arabinogalactan (E) mycolic acids (F) 
glycolipid surface molecules associated with the mycolic acids (G) mannose-capped 









Mycobacterial Lipids Functions References 
Arabinogalactan 
(AG) 
Covalent bound to the peptidoglycan (PG); as known as mycolyl-arabinogalactan-
peptidoglycan (mAGP) complex; strong immunogen; INH is a potent inhibitor of 
mycolic acid biosynthesis; EMB inhibits mycolic acid transfer to cell wall via 
disruption of arabinan component synthesis of AG 
 
(Dover et al., 2004; 
Dover et al., 2007) 
 
Cord factor (trehalose 6,6’-
dimycolate) 
Virulence determinant; induce cytokine-mediated events; inhibit calcium-induced 
fusion between phospholipid vesicles and migration of leukocytes 





Virulent strains of MTB show mannose capping of LAM (Man-LAM). Differences in 
LAM mannosylation determine pathogenicity of mycobacteria by changes in the 
ability of mycobacteria to evade or activate host immunity. 
 
(Misaki et al., 1977) 
 
Menaquinones    Electron carriers in the respiratory chains between electron donors 
(dehydrogenases) and electron acceptors (reductases and oxidases) to maintain 
homeostatic balance of reducing equivalents (i.e. NADH) generated from 





Mycolic acids   Component of the mycobacteria cell envelope; mediate resistance to certain drugs
  
(Gao et al., 2003) 
  
Non-extractable mycolates  
   
A complete monolayer around the cell, forming inner leaflet of an outer membrane 
structure  
(Christensen et al., 
1999) 
PDIM and phthiocerol 
diphthiocerates  
Composed of two mycocerosic acid chains attached to phthiocerol backbone; 
required for the multiplication of MTB during acute phase of infection  
 
(Cox et al., 1999) 
Phosphatidylinositol mannosides 
(PIMs). Major species:PI-
dimannoside (PIM2) and PI-
hexamannoside (PIM6)  
 
For extensive mannosylation to form higher PIMs (PIM5-6), lipoglycans, lipomannan 
(LM) and lipoarabinomannan (LAM); Induce TNF-α and IL-8 secretion by human 
and murine macrophages   
(Besra et al., 1997) 
Sulfatides (SL)  
   
Inhibit phagosome activation; virulence determinants in MTB infection of guinea 
pigs  
 
(Goren et al., 1974) 
Table 1. Mycobacterial lipids and their roles in physiology 5
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1.1.4 Natural history and pathogenesis of TB infection 
After inhalation of air-borne droplet nuclei containing MTB, it is estimated that 
30% of individuals would become infected and of these, 40% would develop active TB 
(Parrish et al., 1998). Symptomatically, these infected individuals may have persistent 
fatigue, anorexia, progressive weight loss, low-grade fever, and a chronic cough.  
The rest of the MTB-infected individuals (60%) would show no clinical signs of 
the disease and are not infectious. However, they would have a delayed-type 
hypersensitivity response to TB antigens, commonly administered as a skin-test with 
purified protein derivative (PPD) of MTB. In such people, a residual population of viable 
bacteria may be maintained in a poorly understood state of clinical latency for extended 
periods of time (Lillebaek et al., 2002). These people with latent TB infection (LTBI) are 
‘reservoirs’ for re-activation of the bacilli (2 to 23% lifetime risk) (Gedde-Dahl, 1952). 
This risk increases to 10% annually should the immune system become compromised, as 
is frequently observed in individuals coinfected with the human immunodeficiency virus 
(Honer zu Bentrup and Russell, 2001). Other factors associated with the likelihood of 
MTB reactivation from latency are conditions known to suppress the immune system 
including steroid therapy, age, and malnutrition (Styblo, 1991). The possible outcomes of 









Figure 2. Outcomes associated with exposure to MTB 
Modified from (Parrish et al., 1998)   
 
MTB in the lungs reside in phagocytic cells such as alveolar macrophages and 
dendritic cells, but there is also evidence that they may populate the pneumocytes 
(Hernandez-Pando et al., 2000). The bacteria replicate within the macrophage and induce 
cytokines that initiate the inflammatory response in the lungs. Macrophages and 
lymphocytes migrate to the site of infection and form a granuloma (Dannenberg and 
Rook, 1994). The human granuloma consists of macrophages surround by a ring of CD4+ 
and CD8+ T cells, and secrete a range of chemokines, cytokines, adhesins and integrins to 
coordinate the recruitment, migration and retention of cells in the granuloma (Saunders 
and Cooper, 2000). The extensive inflammatory response within the granulomas may 
cause tissue necrosis. A balance with host immunity is reached when the mycobacterial 
infection has been controlled, but the bacilli inside the granuloma have not been 
destroyed (Russell, 2001). Live bacilli have been isolated from granulomas or tubercles 
in the lungs of persons with clinically inactive tuberculosis, indicating that the organism 
can persist in a granulomatous lesion for many years (Opie and Aronson, 1927; 
Robertson, 1933). In active TB disease, the bacteria may disseminate within infected 





(2 to 23% per lifetime)
HIV infection-Reactivation 
(5 to 10% per year)
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macrophages through blood and lymphatics to other organs. Pleuritis and lymphadenitis 
are common, but any organ can become infected, the highest mortality being associated 
with TB meningitis and miliary TB. 
 
 
1.1.5 Host factors related to TB susceptibility 
 
It has been suggested that certain HLA class II genes, by selecting certain sets of 
antigenic peptides and specific helper T cells, may contribute to the development of 
tuberculosis (Goldfeld et al., 1998). Interferon γ receptor ligand-binding chain (IFNγR1) 
deficiency and other rare genetic mutations in IFN-γ and IL-12 (Casanova and Abel, 
2002) have been linked to susceptibility to mycobacteria, showing the importance of the 
type-1 helper T cell-mediated responses in immune control of TB. Natural resistance 
associated macrophage protein-1 (Nramp1) was the first mycobacterial susceptibility 
gene (Bcg) identified in the mouse (Casanova and Abel, 2002). NRAMP polymrphisms 
in humans have been associated with pulmonary TB and heterozygosity for both 
polymorphisms is associated with the highest risk (Bellamy et al., 1998). Protein, zinc 
and iron deficiency (Barclay, 1985; Chandra and Newberne, 1977; Mayer, 1971; 
Suskind, 1977), as well as vitamin D deficiency (van Lettow et al., 2004; Van Lettow et 
al., 2004) have also been epidemiologically associated with poor TB risk. 
 
1.1.6 Host defence mechanisms and strategies for TB survival within the host 
Many studies have shown that pathogenesis and virulence of mycobacteria are 
tightly associated with the ability of the bacteria to survive in host macrophages (Russell, 
2001; Vergne et al., 2004). It is well established that murine macrophages possess anti-
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mycobacterial function in tissue culture systems (Lurie, 1942; Mackaness, 1969; Suter, 
1952). Macrophages activated by supernatants of immunologically stimulated 
lymphocytes, exhibit various degrees of anti-mycobacterial activity (Chan and 
Kaufmann, 1994).  
The fully matured phagosome, known as the phagolysosome, is competent in cell 
killing and digestion because it has a highly acidic pH, an active NADPH oxidase 
complex that is crucial for the microbicidal function of phagosomes, and it contains 
lysosomal hydrolases (Botelho et al., 2004; Jutras and Desjardins, 2005). MTB and 
related pathogenic mycobacteria are able to resist phagosome fusion with lysosomes with 
the pH of mycobacterial-containing phagosomes remaining at pH 6.5 (Sturgill-Koszycki 
et al., 1994). Hence, they can multiply to moderate levels during the initial stages of 
infection within macrophages (Russell, 2001; Vergne et al., 2004).  
Hydrogen peroxide (H2O2), one of the reactive oxygen intermediates (ROI) 
generated by macrophages via the oxidative burst, was the first identified effector 
molecule that mediated mycobactericidal effects of mononuclear phagocytes (Walker and 
Lowrie, 1981). Subsequently, gamma-interferon (IFN-γ) was found to be the key 
endogenous activating agent that triggers the anti-mycobacterial effects of murine 
macrophages (Flesch and Kaufmann, 1987; Rook et al., 1986), synergising with tumor 
necrosis factor-alpha (TNF-α) (Flesch and Kaufmann, 1990). The major effector 
mechanism is induction of the production of nitric oxide (NO) and related reactive 
nitrogen intermediates (RNI) by macrophages via inducible nitric oxide synthase (NOS2) 
(Ding et al., 1988). Evidence also exists for NOS2 activation in lungs of TB patients 
(Nicholson et al., 1996). However, it is likely that there are additional mechanisms by 
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which IFN-γ contributes to control of tuberculosis, since IFN-γ-/- mice are more 
susceptible than mice deficient in NOS2 (Chan et al., 1995; Flynn et al., 1993; 
MacMicking et al., 1997). Patients treated for rheumatologic conditions with anti-TNF-α 
antibodies have an excessive risk for developing TB reactivation (Keane et al., 2001), 
suggesting that this is a major host factor keeping LTBI in check. TNF-α deficient mice 
have impaired granuloma formation and succumb to MTB infection  (Bean et al., 1999; 
Flynn et al., 1995). Both CD4+ and CD8+ T cells participate in control of acute TB in 
mice (Flynn and Ernst, 2000). CD4+-deficient mice have defects in overall IFN-γ 
production and macrophage activation (Caruso et al., 1999). Studies of cytokine 
expression in lung tissue, lung lavage, pleural fluid, and peripheral blood mononuclear 
cells in human TB disease demonstrate a strong induction of IFN-γ and other T helper 1 
(Th-1) cytokines, (Condos et al., 2000; Flynn and Chan, 2001b) as well as small variable 
component of T helper 2 (Th-2) cytokine production (IL-4, IL-10) which may have 
negative effects on host immunity (Lin et al., 1996).  
 
1.1.7 Antibiotics against mycobacteria  
The aims of anti-TB therapy are to ensure a cure without relapse, prevent death, 
eradicate MTB transmission, and prevent the emergence of drug-resistance (Frieden et 
al., 2003). A multi-drug regimen is necessary to minimise the risk of emergence of drug 
resistance due to infection by mutant bacteria with natural single drug resistance.  
The first- line drugs available for the treatment of TB (Blumberg et al., 2005) are 
rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), streptomycin (STR) and 
ethambutol (EMB). Their modes of action and known resistance mechanisms are listed in 
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Table 2. There are 2 phases of treatment for patients with TB – 2 months of 3 - 4 drugs 
(bactericidal or intensive phase), followed by the continuation phase, typically 4 months 
with 2 drugs (subsequent sterilising phase). RIF and INH are typically used for the 
continuation phase. In the case of cavitary TB, INH and RIF are effective because there is 
an important extracellular population with many actively growing bacilli (Grosset, 1980; 
Mitchison, 1979). Those patients with a high risk of relapse after 6 months of therapy, 
such as those with cavitary pulmonary TB or persistently positive TB cultures after 2 
months of therapy (Benator et al., 2002), may require additional 3 months of continuation 
phase for a total of 9 months. The prolonged treatment has resulted in a high incidence of 
non-compliance, but a much reduced duration of treatment has been clinically proven to 
increase risk of relapse (Korenromp et al., 2003). 
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Inhibition of RNA synthesis; inhibition of bacterial RNA polymerase 
(RNAP); drug binds RNAP subunit within the DNA/RNA channel, 
directly blocking the path of the elongating RNA   
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targets) 
Multiple targets including 
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The frontline drugs are highly effective in significantly reducing bacteria load 
within the first 2 weeks of chemotherapy. However, differences in drug susceptibilities 
between replicating and non-dividing bacterial cells can be significant (Hobby and 
Lenert, 1957; Xie et al., 2005). It is believed that dormant mycobacteria in a state of non-
replicating persistence (NRP) cannot be fully eradicated until they are actively replicating 
and this imposes the limit on shortening the treatment regimen (Jindani et al., 2003) 
(Cardona et al., 2002; Olsen et al., 2004). Other contributory factors to reduced drug 
efficacies in vivo include poor antibiotic penetration, heterogeneity of host environments, 
altered bacterial physiology and metabolic activity within those environments. However, 
the influence of the in vivo environment on drug efficacy should not be viewed as 
inevitably negative. Pyrazinamide (PZA), for example, is inactive in vitro under standard 
culture conditions but displays strong sterilising activity in vivo (Zhang and Mitchison, 
2003; Zhang et al., 2003). This is because the activity of PZA in vivo is enhanced under 
low pH (Zhang and Mitchison, 2003) and limiting oxygen (Wade and Zhang, 2004). 
Treatment trials with macrolide-containing regimens for atypical mycobacteria such as 
Mycobacterium avium complex lung disease have yielded generally favorable outcomes 
(Griffith, 2007). 
 
1.1.8 Diagnosis and management principles 
The decision to initiate anti-TB chemotherapy is based on epidemiological 
information, clinical history and physical examination, and supported by radiological, 
pathological, and microscopic examination. Acid-fast bacilli (AFB) in stained sputum 
smears and cultures for mycobacteria (Blumberg et al., 2003) are the commonest 
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methods for detecting pulmonary TB. Before culture confirmation, therapy with an 
appropriate multidrug regimen must be initiated upon high clinical suspicion for active 
disease. Hence, nucleic acid amplification tests may be useful in selected cases for an 
immediate definitive diagnosis (Brodie and Schluger, 2005).  
To enhance TB control and ensure higher completion rates with the long-term 
nature of anti-TB drug regimen, a directly observed therapy (DOT) programme is 
recommended by WHO (Blumberg et al., 2005). Patients undergoing treatment for TB 
should be seen on a monthly basis to assess adverse effects and monitor progress by 
sputum culture at least once a month until 2 consecutive specimens are culture-negative 
(Blumberg et al., 2003). The sputum conversion result after 2 months of therapy is an 
important risk predictor of relapse. Drug susceptibility tests should be performed on the 
initial positive culture and repeated on MTB isolates obtained from patients after 3 
months of treatment with positive cultures.  
 
1.1.9 Drug-resistant TB 
A major limitation of the treatment of TB is poor completion rates for self-
administered therapy (Blumberg, 2004; Marks et al., 2000). Very little progress has been 
made in the identification of new, shorter, and safer regimens for the treatment of LTBI 
(Blumberg, 2004; Nolan, 2003).  
Infection with an MTB strain that is resistant to the two most commonly used 
frontline anti-TB drugs, RIF and INH, is defined as MDR-TB (Heifets and Cangelosi, 
1999). MDR strains constitute 1 to 3% of global TB isolates, with 300,000 new cases of 
emerging worldwide each year (Farmer et al., 1999; Pablos-Mendez, 2000; WHO, 2004).  
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Treatment of MDR-TB comprises combinations of second-line drugs that are more 
expensive, more toxic, and less effective than the drugs used in standard therapy (Iseman, 
1993). A worrying new trend is the emergence of X-DR strains resistant to at least three 
of the four frontline TB drugs, the best second-line medications (fluoroquinolones) and 
often at least one of three injectable drugs (i.e., amikacin, kanamycin, or capreomycin). 
In Singapore in 2005, the overall drug resistance rate was 6.4%, with 4.3% (38 cases) 
being resistant to one drug and 2.3% (20 cases) being resistant to two or more drugs 
(MOH, 2006). Among the cases resistant to more than one drug, two cases were MDR-
TB.  
 
1.1.10 Animal models of TB  
Unfortunately, there is currently a critical lack of an animal model which 
replicates all aspects of human TB (Boshoff and Barry, 2005; Kaufmann et al., 2005). In 
both mice and humans, protection against mycobacterial infections depends on IFNγ 
produced by Th-1 cells and TNF-α produced by activated macrophages. The essential 
parameters to check virulence are survival, bacilli loads (in lung, spleen, liver), and lung 
histopathology.  
The BALB/c mouse model is based on the direct deposition of high numbers of 
bacilli in the lung; the rate of bacterial multiplication correlates with the extent of tissue 
damage (pneumonia) and mortality (Hernandez-Pando et al., 1997b). When mice are 
infected with MTB H37Rv strain, there is a rapid and strong production of TNF-α by 
activated macrophages, accompanied by a progressively increasing expression of IFN-γ 
and nitric oxide synthase-2 (NOS-2) culminating at maximal levels after 3 weeks. This 
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response temporarily controls bacterial growth (Hernandez-Pando et al., 1997a; 
Hernandez-Pando et al., 2001). Then, the disease enters a progressive phase with 
continuing bacterial proliferation, rising expression of IL-4, IL-10, and TGFβ, and falling 
expression of TNFα, IFN-γ, and NOS2 (Hernandez-Pando et al., 1997a; Hernandez-
Pando et al., 2001). Similar abnormalities have been observed in human tuberculosis 
(Seah et al., 2000; Seah and Rook, 2001; van Crevel et al., 2000). For mouse models, it is 
important to determine virulence in immunocompetent animals, as well as in severely 
immunodeficient ones, such as SCID mice (Kamath et al., 2005). 
Despite its considerable impact in mycobacterial research, the mouse model 
suffers from the inherent limitation of being an experimental model of infection. Firstly, 
the organisms of interest for humans (MTB and M. bovis BCG) are not natural mouse 
pathogens. Secondly, the modes of infection used (e.g., the intravenous inoculation of 
mice kept in an artificial environment with large amounts of a laboratory mycobacterial 
strain) differ markedly from natural modes of infection (e.g., exposure of wild animals to 
low numbers of natural, air-borne mycobacteria). Finally, laboratory mice form a small 
and poorly diverse group of inbred strains, are less resistant and healthy than outbred 
wild mice when compared to humans, an expanding and outbred population (Casanova 
and Abel, 2002). 
In the guinea pig model of tuberculosis infection, the pathology caused by the 
disease is more similar to the human disease and guinea pigs are outbred animals 
(Kamath et al., 2005). However, guinea pigs are highly susceptible and chronic pathology 
cannot be observed over prolonged periods. The use of non-human primates can also 
contribute substantially to the determination of vaccine safety, particularly for live MTB 
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vaccines using attenuated mutants, but it has the disadvantage of high costs and small 
experimental group size (Kamath et al., 2005). 
Reed et al. have shown that a specific MTB antigen which provided good efficacy 
in mice and guinea pig models fails in non-human primate studies. This same antigen 
when added to a very good vaccine preparation worsens efficacy in the non-human 
primate model. These findings suggest that vaccine testing in multiple animal models 
may provide valuable information particularly when choosing among candidate antigens, 
and that combination vaccines need to be carefully investigated in more than one animal 
model (Reed et al., 2003).  
 
1.1.11 Bacille Calmette-Guérin (BCG)  
BCG is administered live to newborns in Singapore and most countries with a 
moderate to high incidence of TB. At least 3 billion doses of BCG vaccine have been 
administered, more than any other vaccine; and is accepted as a safe vaccine (Brewer et 
al., 1995). The ability of BCG to prevent childhood forms of the disease (such as Miliary 
TB and TB meningitis) is well established, but it is difficult to demonstrate that BCG has 
had any major effect on reducing the incidence of adult pulmonary tuberculosis (Fine, 
1995). Nevertheless, BCG is the gold standard against other experimental vaccines are 
compared, although the protection provided by BCG varies depending according to the 
animal model chosen (Wiegeshaus and Smith, 1989).  
There is a diversity of BCG substrains used around the world, and genetic 
differences between strains reflect the evolutionary distance from the common ancestor. 
Whole genome DNA microarray techniques have identified 129 MTB open reading 
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frames (ORFs) that are absent in the genomes of BCG vaccine strains (Behr et al., 1999). 
These ORFs are clustered in 16 regions of deletions (RDs) – regions that were deleted 
from BCG vaccines relative to the MTB H37Rv reference strain. These deletions are 
probably a progressive adaptation of BCG strains to laboratory conditions, which has 
compromised their capacity to survive within the host, impairing their ability to stimulate 
a durable immune response. A total of 61 ORFs clustered in 9 RDs are missing in all M. 
bovis strains, including BCG. There are only 39 ORFs clustered in 3 RDs that are missing 
in all BCG strains, relative to M. bovis (Collins and De Lisle, 1985; van Soolingen et al., 
1997). A region of 10 kb DNA sequence is found to be absent from BCG, but present in 
both M. bovis and MTB. This region contains a regulatory gene responsible for the 
repression of at least 10 proteins (Mahairas et al., 1996) and a number of genes, such as 
esat6 that encodes a small protein antigen that is strongly recognized in TB patients 
(Brandt et al., 2000). None of the ORFs present in M. bovis but deleted from BCG strains 
have been classified as a virulence element (Cole et al., 1998). 
 
1.1.12 Differences between BCG, M. bovis and MTB 
MTB is the major causative pathogen of TB in humans but in developing 
countries, up to 10% are caused by the bovine tuberculosis organism M. bovis (O'Reilly 
and Daborn, 1995). Despite the different host tropisms, the members of the MTB 
complex are characterized by 99.9% or greater similarity at the nucleotide level, and by 
virtually identical 16S rRNA sequences (Brosch et al., 2002; Huard et al., 2006; 
Sreevatsan et al., 1997). The average sequence divergence between MTB  and M. bovis is 
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less than 0.05% (Garnier et al., 2003); this is substantially less than a divergence of 1.6% 
between two strains of Escherichia coli (Perna et al., 2001).  
The largest sequence variation between the human and bovine bacilli is in genes 
encoding cell wall and secreted proteins, demonstrated by the elevated expression of two 
serodominant antigens in the bovine bacillus (MPB70 and MPB83). MPB83 is a 
glycosylated cell wall-associated protein, while MPB70 is a secreted protein that 
accounts for 10% of M. bovis culture filtrate proteins (Hewinson et al., 1996) with 
structural similarity to eukaryotic intracellular matrix proteins involved in interactions 
between the cell membrane and the extracellular milieu (Carr et al., 2003). MPB70 and 
MPB83 show greatest variation in regions that are exposed to solvents, suggesting 
functionally distinct roles and in determining host preference. BCG substrains also show 
variation in expression of MPB83 and MPB70; BCG Russia producing high levels of 
both antigens whereas BCG Pasteur is a low producer (Wiker et al., 1996). The genetic 
basis for this difference in expression is due to a mutation in some BCG strains in the 
positive regulator of mpb83/mpb70 (Charlet et al., 2005). 
Microbiological characteristics between the two mycobacterial species differ 
slightly; virulent stains such as MTB grows in cultures as serpentine cords (Nitti and 
Taliercio, 1953) and adsorb cationic phenazine dye (neutral red) (Cardona et al., 2006) 
whereas avirulent strains like BCG do not. Virulent (H37Rv) and avirulent (H37Ra) 
strains of MTB, but not BCG, have been shown to exhibit a contact-dependent 
haemolytic activity (King et al., 1993), a common feature of clinical isolates examined 
that correlates with the survival of strains in mice spleen (Brzychcy et al., 1997). Unlike 
MTB, M. bovis requires pyruvate to be added to media where glycerol is the sole carbon 
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source, presumably reflecting a defect in the metabolism of glycerol by M. bovis. This is 
due to a point mutation in the gene for pyruvate kinase (PK), the enzyme that catalyses 
the final irreversible step in glycolysis, the dephosphorylation of phosphoenolpyruvate to 
pyruvate (Keating et al., 2005). Hence, in vivo M. bovis must rely on amino acids or 
fatty-acids as a carbon source. Lipid differences between MTB and M. bovis are best 
represented by the key variation in the production of a phenolic glycolipid (PGL) in M. 
bovis. It has been demonstrated that pks1 codes for the biosynthesis of PGL in M. bovis, 
while in many MTB strains the gene is disrupted so no PGL is produced (Constant et al., 
2002). 
There are also some differences noted in host-pathogen interactions in MTB when 
compared to BCG. BCG has a relatively low intrinsic ability to induce the CD8+ T-cell 
response (Kaufmann, 2000) compared to MTB. The immuno-stimulatory properties of 
BCG are less enhanced than MTB (Ohara and Yamada, 2001). Pathogenic mycobacteria 
such as MTB possess the capability to inhibit fusion between phagosomes and lysosomes 
(Clemens and Horwitz, 1995) a phenomenon that appears to be linked to exclusion of the 
proton ATPase from phagosomal membranes (Sturgill-Koszycki et al., 1994) and arrest 
maturation of the phagosome at an early endosome stage (Clemens and Horwitz, 1995). 
The ability of BCG to be able to prevent phagosome maturation is controversial, though 
live BCG in phagosomes retain Rab5, a small GTPase associated with sustained fusions 
between early endosomes (Via et al., 1997), similar to phagosomes containing live MTB 
(Clemens et al., 2000). IFNγ, in conjunction with TNF-α, activates anti-mycobacterial 
microbicidal mechanisms in mouse macrophages. Although IFN γ can affect the growth 
of BCG in human macrophages, there are conflicting reports of a similar role for IFNγ in 
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human macrophages infected with MTB (Flynn and Chan, 2001b). MTB can inhibit IFN-
R and STAT1 signaling and IL-12 production by human macrophages (Nau et al., 2002; 
Ting et al., 1999) while BCG has been reported to impair IL-12 production and induce 
dendritic cells to secrete IL-10 (Gagliardi et al., 2005). 
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1.2 LATENCY 
1.2.1 Clinical aspects of latent TB infection (LTBI) 
 The unique ability of MTB to establish a state of latent infection in the human 
host has been described in the section 1.1.4.  Human LTBI is difficult to diagnose with 
certainty. Patients with LTBI may not have a definite exposure history, usually have no 
symptoms or clinical signs, and sputum culture and radiological appearances are usually 
normal. Two categories of persons who should undergo LTBI testing are those who are 
likely to have been recently infected (such as contacts to infectious TB cases) and persons 
who are at increased risk to TB disease because of certain clinical conditions (HIV 
infection and selected medical conditions) or migration from high TB-burden countries 
(ATS-CDC, 2000).  
Over the last 100 years, the only test to identify LTBI was the tuberculin skin test 
(TST) (ATS-CDC, 2000). However, limitations of the tuberculin skin test include reader 
variability, false-positive results due to cross-reactivity with environmental mycobacteria 
and with previous BCG vaccination, as well as false-negative results due to anergy in 
immunosuppressed individuals. In recent years, peripheral blood T-cell–based interferon 
γ (IFN-γ) assays (QuantiFERON-TB Gold; Cellestis Ltd and T SPOT-TB; Oxford 
Immunotec) have been made available and might present better sensitivity and specificity 
in the diagnosis of MTB infection (Barnes, 2004; Ewer et al., 2003; Lalvani et al., 2001; 
Mori et al., 2004; Pai et al., 2004).  
Isoniazid (INH) remains the drug of choice for treatment of LTBI (ATS-CDC, 
2000; CDC, 2003). The success rate of using INH for LTBI treatment range from 25% to 
92% (ATS-CDC, 2000). However, the protective efficacy of INH was about 90% and 
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restricted to those compliant with the medication. The preferred duration of treatment 
with INH for LTBI in all patient populations is 6 - 9 months because clinical trial data 
suggest that the maximal benefit is achieved by this period (ATS-CDC, 2000; Comstock, 
1999). The most important adverse effect of INH is hepatitis, which is estimated to occur 
at a rate of 0.1 to 0.3% (LoBue and Moser, 2003; Nolan et al., 1999). Rifampicin is 
recommended in patients with INH-resistant strains of MTB (ATS-CDC, 2000; CDC, 
2003). 
 
1.2.2 Latent TB infection (LTBI)  
Patients with LTBI have a cell-mediated immune response that controls 
progression of the infection in the initial focus of infection and in the local draining 
lymph nodes (the ‘‘Ghon complex’’) by granuloma formation (Lucas, 1998). However, in 
the absence of actively growing bacteria, there is reduced local inflammation and 
immunological responses (Cardona et al., 2002; Olsen et al., 2004). The nature of the 
bacterium that lies dormant within the granulomas is of much interest – knowledge of its 
physiology and metabolic needs in this state are central to attempts at targeted destruction 
of latent MTB or prevention of latency.  
 
1.2.3 Life within a granuloma 
A newly formed granuloma is composed of immature mononuclear phagocytes 
surrounded by lymphocytic effector cells including CD4+ and CD8+ T cells. During 
maturation into productive granulomas, mononuclear phagocytes differentiate into 
macrophages and become highly activated, aggregating into multinucleated giant cells, 
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and larger epithelioid-like cells that contain tightly inter-digitated cell membranes. This 
structure acts like a barricade and limits further dissemination to additional sites of 
infection (Chan and Flynn, 2004).  
Within the granuloma, it is generally thought that MTB must adapt to a highly 
dynamic growth environment. The surrounding tissue is either calcified or necrotic, the 
interior of the granuloma contain high carbon dioxide concentrations as well as increased 
levels of aliphatic organic acids and hydrolytic enzymes but is thought to be devoid of, or 
contain low levels of oxygen. The activation of macrophages and other immune effector 
cells surrounding the granuloma results in the release of numerous anti-microbial 
compounds (Saunders and Cooper, 2000). Tubercle bacilli are frequently observed 
extracellularly in infected human tissues and thus are likely to encounter such conditions 
during the course of the disease (Ducati et al., 2006).  
 
1.2.4 Factors that drive MTB latency 
One important model for MTB latency is based on the postulate that the 
environment in the granulomas is hypoxic, and the adaptations of the pathogen to low 
oxygen conditions constitute a major part of its adaptations to persist in the host. There is 
a reasonable body of evidence supporting the probability that hypoxic conditions do exist 
in human TB lesions. In inflammatory or necrotic regions, there is a state of depleted 
oxygen (Cannetti, 1955; Hirsch, 1955; Hobby, 1957; Imboden and Schoolnik, 1998). In 
human disease, the bacilli are predominantly extracellular (Grosset, 1978) but tubercle 
bacilli have been cultivated readily from at least 20% of old blocked lesions (Hurford and 
Valentine, 1957; Medlar et al., 1952; Salkin and Wayne, 1956). Tuberculosis lesions are 
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essentially avascular (Hirsch, 1955; Russell et al., 1955), so a blocked lesion has little 
access to oxygen. From more than 90% of closed lesions from patients, only about half of 
them yielded positive cultures and, only about 0.1% of the number of bacilli seen on 
smear grew on culture (Salkin and Wayne, 1956). Carbon dioxide produced in necrotic 
tissue may enhance the bactericidal effect of anaerobiosis on tubercle bacilli (Dubos, 
1953). Although pulmonary alveolar macrophages have access to atmospheric air, 
macrophages encountered in later stages of infection are facultative anaerobes and respire 
in hypoxic sites (Pearsall and Weiser, 1970).  
Latent bacilli have also been termed as ‘dormant’, subsisting in a state of low 
metabolic activity. Some studies even suggest they are unable to divide or to form a 
colony but this point is controversial (Kell and Young, 2000; Shleeva et al., 2002). It has 
been suggested that mycobacterial latency might also be an adaptation to a lack of 
nutrients, thus resembling the bacterial population found in the steady state of 
conventional liquid cultures (Shleeva et al., 2002). The plateau in bacterial numbers 
observed in vivo during the chronic phase of infection in murine TB thus most likely 
represents an equilibrium between the host and MTB (Munoz-Elias et al., 2005). In such 
a model, the chronic phase of TB infection arises due to immunity elicited against 
growing MTB (Lazarevic et al., 2005). This immunity triggers mechanisms that induce 
bacterial cell death (low pH, reactive oxygen intermediates, reactive nitrogen 
intermediates). As a consequence, ‘latent’ bacilli in the mouse model are the remaining 
population in the chronic phase that survive the activated host immunity.  
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1.2.5 Dynamic host-pathogen interactions in LTBI  
The ability of MTB to maintain a state of long-term persistence is the result of a 
dynamic balance between host defence mechanisms and bacterial-mediated adaptation 
mechanisms. (Flynn and Chan, 2001a; Zahrt and Deretic, 2002). Evidence supporting this 
dynamic interaction for MTB persistence in granuloma are summarised as follows. (1) 
viable bacilli can still be recovered from granulomas of individuals that are clinically 
asymptomatic (Ducati et al., 2006), (2) activated macrophages but not resting 
macrophages are able to kill MTB (Dannenberg, 1994; Walker and Lowrie, 1981), (3) 
depletion of CD4+ and/or CD8+ T cells in mice persistently infected with MTB results in 
disease reactivation, increased bacillary growth, and a significant decline in the mean 
time-to-death (Scanga et al., 2000; van Pinxteren et al., 2000), (4) antibody depletion of 
IFN-γ and TNF-α during persistent stages of MTB infection in mice results in rapid 
disease reactivation (Scanga et al., 2000), (5) chemical inhibition of NOS2, or MTB 
infection of nos2–/– mice, results in greatly increased bacillary burden (Hernandez-Pando 
et al., 2001), and (6) MTB infection of phox–/– mice, lacking the superoxide-generating 
NADPH phagocyte oxidase, results in increased neutrophilic infiltrate and tissue damage 
within the resulting granulomatous lesions (Cooper et al., 2000; Ng et al., 2004).  
 
1.2.6 Subversion of host immune responses 
MTB-infected macrophages are rather ineffective at stimulating proliferation of 
and cytokine production by mycobacteria-specific CD4+ T cells (Bodnar et al., 2001; 
Hirsch et al., 1997; Serbina and Flynn, 1999). Infection of macrophages with MTB can 
result in down-regulation of major histocompatibility complex class II expression or 
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presentation (Hmama et al., 1998; Mazzaccaro et al., 1996; Noss et al., 2000; Pancholi et 
al., 1993; Wojciechowski et al., 1999). MTB-infected macrophages are rendered 
refractory to the effects of IFN-γ, a major mediator of macrophage activation (Ting et al., 
1999). Other studies indicate that MTB induces macrophages to produce 
immunosuppressive cytokines, such as IL-10 or TGF-β. These cytokines impair the 
ability of infected macrophages to stimulate T cells effectively (Hirsch et al., 1994; 
Hirsch et al., 1996; Rojas et al., 1999). Thus, MTB uses multiple mechanisms to subvert 
macrophage-mediated immunity and ensure its long-term persistence in the host. 
 
1.2.7 Metabolic adaptations to latency 
 Intracellular mycobacteria utilise the nutrients including intermediates of host cell 
metabolism as substrates. They are able to scavenge amino acids, purines, pyrimidines, 
that are available in the host (Marz et al., 1979). Most mycobacteria synthesise all their 
nitrogenous compounds from either ammonium or a single, simple amino acid like 
asparagine or glutamate (Lyon et al., 1970) or take up a variety of amino acids. This is an 
adaptation to growth in a host as it is desirable to produce little antigenically active 
material to avoid detection by the host’s immune system, and to conserve nitrogen since 
supply within the host would be restricted. Macrophages are facultative aerobes and they 
are especially active in lipid metabolism (Pearsall and Weiser, 1970), so mycobacteria are 
able to obtain tricarboxylic acid cycle (TCA) intermediates and lipids from these cells. 
Latent MTB up-regulate of isocitrate lyase in the glyoxylate shunt, an enzyme that allows 
bacteria to utilise fatty acids as carbon and energy sources when the availability of 
primary carbon sources is limiting (McKinney et al., 2000). 
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The production of ATP from ADP in oxidative phosphorylation is the objective of 
energy metabolism. This is achieved by the reduction of cytochromes by the reduced 
coenzymes NADH, NADPH and FADH which are generated when carbon sources are 
oxidized in the TCA cycle. Weinstein and coworkers (Weinstein et al., 2005) found in 
MTB the presence of a respiratory chain with menaquinone as the physiologic electron 
donor. Under low-oxygen conditions, cytochrome bd oxidase (a quinol oxidase encoded 
by cydABCD) is induced in mycobacteria and is important for microaerophilic growth. 
The product of oxidative metabolism, ATP, is thus generated in in vivo mycobacteria by 
stimulating final oxygen consumption to metabolize carbon sources oxidatively.  
Intracellular MTB can adapt to changes in dissolved oxygen tension. When 
oxygen is available, oxidative metabolism occurs, albeit slowly, but when oxygen 
becomes limiting, probably during tissue necrosis, intracellular mycobacteria repress 
their respiratory metabolism (Wayne, 1982). Mycobacteria decrease their oxidative 
metabolism including TCA cycle activity, and increase the activity of the alternative, 
anaplerotic pathway (Wayne, 1982). Their replication ceases (Wayne, 1977) and they 
become more able to survive anaerobic conditions than actively respiring, growing 
tubercle bacilli (Wayne, 1982). Hence, these hypoxic MTB have been widely used as a 
model for dormant tubercle bacilli, in method pioneered by Wayne (Wayne and Hayes, 
1996). Additionally, tubercle bacilli starved of nutrients in vitro are able to survive 
without nutrition for several years (Nyka, 1974). Thus, dormancy may be an adaptive 
mechanism to enable mycobacteria to survive at times when they are losing competition 
for nutrients between themselves and the host cell.  
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1.2.8 Model systems of persistent infection 
Much is known about host factors limiting MTB growth during latent stages but 
very little is known about the bacterial factors required for persistent infection. This is 
due in part to difficulties in experimentally re-creating conditions encountered by MTB 
during periods of latency in the host, resulting in the inability to define the physiological 
state of the tubercle bacilli for the identification of relevant genetic determinants required 
for persistence. The in vitro and in vivo systems developed to mimic aspects of latent 
infection are limited in their ability to fully recapitulate host and bacterial characteristics 
but they form a basis to initiate studies into specific aspects of the infection process. 
Some of the most widely used models are described here. 
   
Low-dose murine model 
In this model (Orme, 1988), low-dose bacterial inocula (102 cfu) are administered 
to mice via the aerosol or intravenous route. MTB grows relatively unimpeded in the 
lungs (and spleen) of mice for the first 2 to 4 weeks (Orme, 1994), at which point these 
mice generate an effective immune response upon infection, and remain able to control 
bacillary proliferation (bacterial numbers reach a plateau of 105 to 106 cfu/lung). This 
‘persistent’ MTB infection can be maintained for many months (Flynn et al., 1998; 
Orme, 1988). Such a model of LTBI is frequently used (Adams et al., 1995; Flynn et al., 
1998; Mohan et al., 2001; Orme, 1988; Scanga et al., 2000). 
This low-dose model also recapitulates many characteristics of MTB during 
infection. For example, MTB exhibits relatively unimpeded growth in infected tissues 
during the initial stages of infection, and this growth reach a plateau following the 
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emergence of an adaptive immune response. The drawback is that bacterial burden in 
persistently infected tissues remains higher than that typically observed during latent 
infection in humans, but such mice undergo chronic infection without disease symptoms, 
a state that can be maintained for extended periods with little variation in bacterial 
burden. Furthermore, such latently infected animals can be induced to have reactivation 
disease (by immunosuppression), and also, with time, exhibit rates of spontaneous 
reactivation similar to those observed during human latency. It is an attractive model in 
that it represents equilibrium between host immunity and bacillus, which is true for the 
human latent infection.  
 
Cornell mouse model 
Another mouse LTBI model developed by McCune (McCune et al., 1966a; 
McCune et al., 1966b; McCune et al., 1956) has the mice infected intravenously with a 
high dose of virulent MTB and immediately treated with anti-mycobacterial drugs, such 
as isoniazid and pyrazinamide, for a defined period (usually 12 weeks) to reduce bacterial 
numbers to low levels. There are no observable acid-fast bacilli in infected tissues, lack 
of viable bacilli as measured by plating organ homogenates, and an inability to retransmit 
the disease to susceptible mice or guinea pigs. Although ‘clinically sterile’, spontaneous 
reactivation of persistent MTB can be observed as early as 4 weeks following the 
cessation of antibiotic treatment or in response to immunosuppressive agents, such as 
glucocorticoids.  
While this model has the advantage of achieving and maintaining low or 
undetectable bacterial burdens in infected tissues, as is observed during human latent 
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infection, it does not directly mimic human latency in that administration of antibiotics is 
required to induce latent infection. Furthermore, infected mice exhibit higher rates of 
spontaneous reactivation following cessation of antibiotic treatment compared to 
reactivation rates observed during human latency. In addition, the effects of long-term 
antibiotics on the growth or survival characteristics of organisms in vivo introduces an 
additional variable (Scanga et al., 1999). A recent publication on the testing of various 
modifications of the Cornell model, described this model as technically difficult, 
expensive, and unpredictable for studies on the immunologic basis of latent and 
reactivation of tuberculosis (Scanga et al., 1999).  
 
In vitro systems 
The two most widely used in vitro systems for tuberculous latency are modelled, 
respectively, after anaerobic conditions and the stationary-growth phase, both of which 
are generally thought to be associated with the persistent state. In addition, it has been 
shown that adaptation of MTB to the in vivo environment involves differential expression 
of genes that respond to iron limitation, alternative carbon metabolism and cellular 
hypoxia (Timm et al., 2003). This evidence adds further credence that anaerobic and 
starved cultures can be used as models to study the molecular basis of dormancy 
(Cunningham and Spreadbury, 1998; Dick et al., 1998; Wayne and Hayes, 1996).  
 
The Wayne non-replicating persistence model 
The “non-replicating persistence” model (Wayne and Diaz, 1967; Wayne and 
Hayes, 1996), established by Wayne, is based on the assumption that MTB encounters 
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hypoxic or anaerobic conditions during its residence within granulomatous lesions in the 
host. In this model, cultures of in vitro grown bacteria are subjected to gradual oxygen 
depletion by incubation in sealed cultured tubes. Oxygen depletion using this method 
triggers a dormancy response in the bacilli that is termed non-replicating persistence 
(NRP), which is believed to be the physiological state of MTB during latency.  
In the Wayne model, the transition of MTB to a state of NRP is characterised by 
three distinct growth stages. In the first stage, the dissolved oxygen concentration in the 
medium is high and the bacilli exhibit normal logarithmic growth. This stage represents 
the physiological growth state of MTB in vivo prior to the emergence of cell-mediated 
immunity.  
The second stage, termed NRP-1, occurs when the concentration of dissolved 
oxygen in the medium reaches 1%. MTB in this stage exhibits an abrupt discontinuation 
in DNA, and limited RNA synthesis. The bacilli also limit protein synthesis, become 
resistant to several anti-mycobacterial drugs including isoniazid and rifampicin.  There is 
also the induction of genes involved in the utilisation of alternative energy sources, 
stabilise and protect essential cellular products as well as regulate downstream effector 
genes mediating adaptive responses. Although bacilli in NRP-1 stop DNA synthesis, 
culture turbidity increases due to thickening of the bacterial cell wall. This stage 
represents the physiological growth state of MTB in vivo following the emergence of 
acquired immunity.  
During the third and final stage, NRP-2, dissolved oxygen concentrations drop 
below 0.06% in the culture medium, and bacilli switch from aerobic respiration to 
anaerobiosis. Bacilli in this state arrest growth at a uniform stage of the cell cycle and 
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exhibit no further increase in cell turbidity. In addition, they exhibit sensitivity to 
metronidazole, a drug active against anaerobically growing organisms (Wayne, 1994; 
Wayne and Hayes, 1996), and remain competent for growth reactivation following 
transfer into an oxygen-rich medium. The NRP-2 growth stage represents the 
environment that MTB encounters in vivo during periods of extended persistence within a 
mature granuloma.  
While the NRP model cannot mimic the influence of the host’s immune system, it 
may explain some characteristics observed during persistent infection of MTB in humans. 
A major protein induced during the transition of MTB into NRP-1 is Acr, a homolog of 
the α-crystalline protein and a member of the heat shock family of proteins that acts as 
ATP-independent chaperones. In vivo, Acr is induced in MTB following infection in 
macrophages (Yuan et al., 1998), and is recognised by the sera of TB patients (Lee et al., 
1992). The expression of Acr during NRP-1 also correlates with pronounced thickening 
of the MTB cell wall (Cunningham and Spreadbury, 1998), a process that may act to 
protect the bacilli from the activity of anti-TB antibiotics, help the bacilli survive oxygen-
deficient conditions in vivo, or alternatively protect the organism against the hostile 
environment of the granuloma.  
 
The nutrient starvation model 
A second in vitro growth model, the nutrient starvation model (Betts et al., 2002), 
is based on the assumption that MTB resides in tissues where nutrients and other essential 
cofactors are likely to be limiting. This model was developed to support previous 
observations that MTB isolated from lung lesions frequently display altered colony 
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morphology (cell wall thickening) and uncharacteristic staining properties (no longer 
acid-fast) (Nyka, 1974).  
Nutrient starvation using this model (Betts et al., 2002) involved the growth of 
MTB in a nutrient-rich medium followed by a transfer of the culture to a nutrient-limiting 
medium such as phosphate-buffered saline over a prolonged period of time. The 
characteristics of starved MTB cultures are (1) no loss in viability over a 6-week 
incubation period, (2) significant reduction in their rate of respiration, (3) increased 
resistance to the anti-tubercular drugs, isoniazid and rifampicin, (4) remain resistant to 
metronidazole, and (5) display an unusual colony morphology with staining properties 
that can be reversed following a transfer back to the nutrient-rich medium.  
At the genetic level, nutrient-starved cultures exhibit a global shiftdown in gene 
expression that are involved in amino acid biosynthesis, biosynthesis of cofactors, 
prosthetic groups and carriers, DNA replication, repair, recombination and 
restriction/modification, energy metabolism, lipid biosynthesis, translational and post-
translational modification, and virulence, as determined by microarray analyses (Betts et 
al., 2002; Hampshire et al., 2004).   
 
1.2.9 MTB genes required for persistent infection 
The ability of MTB to undergo persistence requires the coordinated expression of 
numerous bacterial virulence determinants at specific times during infection. The 
identification of genes specifically utilised by MTB during periods of persistence (thus 
known as ‘persistence genes’), is of particular interest because they may (1) define host 
conditions encountered by MTB during latent infection, (2) allow the development of 
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novel antibiotics that could target bacilli during latent stages, and (3) provide alternative 
strategies for the development of rationally attenuated MTB vaccines that are safer and 
more efficacious than the current Mycobacterium bovis BCG vaccine. To date, a handful 
of genes have been implicated in persistent infection by MTB (reviewed in (Honer zu 
Bentrup and Russell, 2001). A ‘master controller’ of these has been identified as the 
DosR regulon. 
 
DosR-DosS/DosT- two component response regulator 
The DosR–DosS/DosT two component response regulator (Roberts et al., 2004; 
Voskuil et al., 2003) is implicated in the MTB dormancy response, and is referred to the 
‘dormancy regulon’. Transcriptional profiling has indicated that exposure of MTB to low 
concentrations of nitric oxide leads to the up-regulation of a set of genes, several of 
which are controlled by this regulon. Quantitative RT-PCR confirms that the transcription 
of several genes in this regulon is also up-regulated in infected mouse lung tissues. The 
DosR regulon is also up-regulated under microaerophilic conditions (Sherman et al., 
2001; Voskuil et al., 2003) and is essential for anaerobic survival of M. bovis BCG and 
MTB in vitro in studies with the Wayne model (Boon and Dick, 2002; Voskuil et al., 
2003). The dormancy regulon, composed of at least 48 genes is a major finding in studies 
of oxygen limitation (Bacon et al., 2004; Kendall et al., 2004a; Muttucumaru et al., 2004; 
Voskuil et al., 2004).  
The DosR regulon contains several genes that might have a role in respiration 
using alternative electron acceptors, including the narK2–narX operon. The transcription 
of the narK2 nitrate transporter is responsible for the DosR/DevR mediated up-regulation 
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of nitrate reductase activity seen in NRP cultures (Sohaskey and Wayne, 2003) and 
responds to hypoxia and NO (Ohno et al., 2003; Voskuil et al., 2003). It has been 
suggested that oxygen limitation may be the important signal for NRP in humans, but in 
mice it may be NO (Boshoff and Barry, 2005). The reduction of nitrate to nitrite serves to 
provide energy as the bacteria adapt to anaerobiosis (Wayne and Hayes, 1998; Wayne 
and Sohaskey, 2001). Nitrate reduction by MTB is regulated by control nitrate transport 
into the cell by NarK2. It is proposed that NarK2 senses the redox state of the cell, 
possibly by monitoring the flow of electrons to cytochrome oxidase, and adjusts its 
activity so that nitrate is transported under reducing, but not under oxidizing, conditions. 
This could be carried out by monitoring the quinone pool of MTB (Sohaskey and Wayne, 
2003; Sohaskey, 2005). Quinone/quinol are non-protein components of electron transport 
and freely diffusible in the membrane. They serve as an electron source for the nitrate 
reductase enzyme as well as an indirect indicator of oxygen levels (Sohaskey, 2005).  
The dosR-deficient mutant is not attenuated for growth and survival in mouse 
tissues (Parish et al., 2003), but is required for virulence in guinea pigs (Malhotra et al., 
2004). This highlights limitations of different animal models for latency with respect to 
mimicking human LTBI – oxygen is likely to be limited in the caseous lesions that occur 
in the guinea pig model (McMurray et al., 1996), which is in pathology more similar to 
human TB than the murine lesions which do not caseate.  
 
1.2.10 Genetic studies for identification of persistence genes  
The quest to identify persistence mechanisms in MTB, and to develop drugs 
targeting these pathways, has prompted the widespread microarray study of genes 
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upregulated in dormancy models and development of genetic strategies to generate 
mutant strains which fail to establish a latent state by targeted deletion of candidate 
persistence genes. 
 
1.2.11 Mycobacterial gene expression 
Analysis of MTB gene expression profiles in models of latency have largely 
validated the relevance of many in vitro latency models to in vivo conditions (reviewed 
by (Kendall et al., 2004b)). In addition, selective in situ analysis of RNA expression 
levels in murine and human lung tissue has corroborated key findings of the in vitro 
models (Fenhalls et al., 2002; Shi et al., 2003; Talaat et al., 2004; Timm et al., 2003). 
The activity of a key enzyme of the glyoxylate cycle, isocitrate lyase encoded by icl, has 
been shown to increase in long-term cultures of MTB (Murthy et al., 1973), under 
minimal growth conditions when the medium is supplemented with acetate or palmitate, 
as well as in the infected mouse (Honer Zu Bentrup et al., 1999; McKinney et al., 2000). 
One of the adaptive responses of bacteria to nutritional stress is to up-regulate relA, 
which is responsible for the ‘stringent response’ (Ojha et al., 2000) where a characteristic 
feature is the accumulation of a nucleotide tetraphosphate, ppGpp (Cashel et al., 1996). It 
functions concurrently to down-regulate the genes for stable RNAs, ribosomal proteins 
and lipid biosynthetic enzymes among others while it activates other genes that are 
involved in stress resistance (Chatterji and Ojha, 2001). The narX protein encoded by 
narX, is involved in nitrate reduction and implicated in persistence in murine and in vitro 
models (Fenhalls et al., 2002; Fritz et al., 2002; Hutter and Dick, 1999) The acr gene, 
which encodes α-crystallin homologue, is another gene specifically induced during 
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bacteriological persistence, where it acts as a chaperonin that assists in protein refolding 
(Yuan et al., 1998) and this has also been proven both in vitro and in vivo (Desjardin et 
al., 2001; Shi et al., 2003).  
 
1.2.12 Gene deletion in mycobacteria 
The lipid-rich cell wall of MTB has slowed the development of simple genetic 
techniques due to difficulties in delivering DNA across the mycobacterial cell wall during 
the transformation process. The lipid abundance also causes a high tendency for the cells 
to clump, making it difficult to obtain colonies from single clones. MTB and BCG 
undergo illegitimate recombination with linear DNA fragments at a frequency of 10-5 to 
10-4 relative to the number of transformants obtained (Kalpana et al., 1991). In E. coli, 
transformation efficiencies reaches over 108-109 per µg of DNA have been reported 
(Dower et al., 1988). However, in BCG, transformation efficiencies of 103-105 per µg of 
DNA by electroporation have been shown (Dellagostin et al., 1993; Lugosi et al., 1989; 
Snapper et al., 1988). Thus it is difficult to obtain true mutations by homologous 
recombination which occurs at a low frequency of 10-6 (Bardarov et al., 2002).  Only in 
the past decade has MTB genetic manipulation been successful with the use of long, 
linear DNA substrates (Balasubramanian et al., 1996), short, linear DNA substrates 
(Armitige et al., 2000; Buchmeier et al., 2000; Piddington et al., 2001; Yuan et al., 
1998), counter-selectable suicide plasmids (Parish and Stoker, 2001; Pelicic et al., 1996; 
Sander et al., 2001), a thermo-sensitive, counter-selectable replicating plasmid (Pelicic et 
al., 1997), UV-irradiated suicide plasmids (Hinds et al., 1999), single-stranded 
phagemids (Hinds et al., 1999), and thermo-sensitive mycobacteriophages (Bardarov et 
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al., 1997; Bardarov et al., 2002) for targeted gene disruptions. The addition of glycine to 
young BCG cultures of 4 to 7 days old and the maintenance of BCG in a mid-log phase 
of growth over several months have been shown to improve the efficiency of 
transformation (Aldovini et al., 1993; Husson et al., 1990). 
Proteins that have been shown by genetic methods to be essential for growth in 
vitro obviously represent high-priority targets for rational drug design. However, the 
apparent lack of essentiality for MTB growth in vitro should not automatically disqualify 
a gene for consideration as a target because the in vitro growth conditions under which 
essentiality of gene function would be probed (aerobic growth in Middlebrook media) 
can reveal only a limited component of the metabolic repertoire of this exquisitely 
adapted intracellular pathogen. This point is powerfully illustrated by the example of the 
glyoxylate shunt enzyme, isocitrate lyase. This enzyme is dispensable for growth in vitro, 
yet is specifically required for the persistence of MTB in an immunocompetent animal 
(McKinney et al., 2000).  
Mutants with growth impairment, compared to wild-type MTB, fail to attain peak 
tissue bacillary burden during the initial rapid replicative phase in the host (Cox et al., 
1999). Three phenotypic categories of growth-impaired MTB mutants have been defined 
by Glickman and Jacobs based on the murine TB infection model (Glickman and Jacobs, 
2001) namely: (1) those unable to replicate at all in vivo (sgiv); (2) those defective for 
replication in the initial stage of infection (giv); and (3) those able to replicate normally 
until the onset of host immunity, after which time the bacillary load declines (per). Thus, 
persistence mutants, while exhibiting no growth defect, cannot sustain the peak tissue 
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bacillary load usually stably maintained by wild-type bacilli for a prolonged period of 
time.  
 
1.2.13 Anti-sense technology 
An alternative approach to gene ‘knockout’ (or gene-deletion) mutant 
construction is to use anti-sense technology to ‘knockdown’ or reduce gene expression. 
For situations where the gene deletion is lethal, the ‘gene knockdown’ strain could assist 
in determining gene function. The usefulness of anti-sense technology was demonstrated 
by Parish et al. who used an acetamide inducible system to control expression of anti-
sense RNA directed against hisD5 and showed that this gene is required for growth in 
vitro (Parish and Stoker, 1997). Using constitutive promoters, anti-sense knockdown 
MTB strains have been extended to in vivo studies (e.g. the role of sodA and sigA in 








Figure 3. Achieving “knock-down” of gene expression by anti-sense RNA  
Messenger RNA (mRNA) from the bacterial DNA is called "sense" because it results in a gene 
product (protein). Normally, its unpaired nucleotides are "read" by transfer RNA anticodons as the 
ribosome proceeds to translate the nucleotide sequence. To prevent translation of the sense 
mRNA, a second strand (anti-sense strand) is created that is the complement of the sense 
mRNA. Therefore, a duplex with the complementary anti-sense RNA sequence is formed, such 
that the ribosome cannot gain access to the nucleotides in the mRNA and duplex RNA is quickly 
degraded by ribonucleases in the cell.  
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1.3 MENAQUINONE 
 
1.3.1 Discovery of Vitamin K in bacteria  
Twort and Ingram first established that a growth requirement from dead tubercle 
bacilli was required when culturing Mycobacterium paratuberculosis in egg medium 
(Twort, 1911; Twort and Ingram, 1912). Mycobacterium phlei was discovered as an 
excellent source of the ‘Essential Substance’, obtained by extraction with ethanol or 
chloroform. Eventually, vitamin K was biochemically characterized as a methyl 
naphthquinone and it was noted that Mycobacterium tuberculosis also had vitamin K 
activity (Almquist and Klose, 1939). However, its function was first identified in 1929 
when Henrik Dam found that young chicks on a fat-free diet developed a bleeding 
diathesis (Dam, 1935a), curable by supplementation with bacteria-contaminated, rotten 
fishmeal. He named the fat soluble compound vitamin K for koagulation (Dam, 1935b) 
and showed it to be essential for preventing bleeding in newborns. It was later uncovered 
that vitamin K is essential for carboxylation of coagulation factors.  
 
1.3.2 Sources and forms of Vitamin K  
 
Vitamin K comprises of several molecular forms that have a common 2-methyl-
1,4-napthquinone ring but differ in the structures of the isoprenoid side chain at the 3-
position (fig. 4). In plants, the only important molecular form is phylloquinone (vitamin 
K1) whereas bacteria synthesise a spectrum of molecular forms based on repeating 
unsaturated 5-carbon (prenyl) units. As an example, MK-9 means menaquinone with an 
isoprenoid chain of nine repeating prenyl units. Some bacteria also synthesise 
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menquinones in which one or more of the double bonds in the side chain is saturated. The 








Figure 4. Chemical structures of naturally occurring quinone vitamins 
(a) Vitamin K1 (also known as phylloquinone, phytomenadione or phytonadione) 
(b) Vitamin K2 (also known as menatetrenone) 
(c) Vitamin K3 (also known as menadione) 
(d) Ubiquinone (also known as coenzyme Q) 
 
Vitamin K1 was originally isolated from alfafa and vitamin K2 from fish meal 
(Binkley et al., 1939). Vitamin K1 is found mainly in green leafy vegetables such as kale, 
spinach, and broccoli (Booth et al., 1993) while vitamin K2 is found in liver, milk, 
cheese, and fermented soy products such as Natto as well as in animal livers. Humans do 
not synthesise vitamin K. Major intestinal forms in humans are MK-10 and MK-11 
produced by Bacteriodes, MK-8 by enterobacteria. Microflora synthesis contributes a 
significant proportion of vitamin K as 90% of human liver content is made up of 
menaquinones (MK-7 to 13) in similar relative proportions (Conly and Stein, 1992). 
However, the exact contribution by bacterial synthesis may be less than previously 
thought and remains unclear (Suttie, 1995). Therefore, majority of vitamin K comes from 
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60% of total intakes in both the United States and the United Kingdom (Booth and Suttie, 
1998). However, bioavailability of vitamin K1 from spinach is only about 5% to 15% of 
that from pure vitamin preparations (Garber et al., 1999; Gijsbers et al., 1996). One form 
of menaquinone (MK-4) is atypical of the series. It is not a major product of bacterial 
synthesis but bird and mammalian tissues including humans can derive it from the 1,4-
naphthoquinone precursor (menadione) (Shearer, 1995).  
 
1.3.3 Physiological and clinical importance in humans  
It was thought that the only function of vitamin K was to act as a co-substrate for 
carboxylation of the vitamin K-dependent proteins (Akedo et al., 1992; Booth et al., 
2000) such as coagulation factors VII, IX, X, prothrombin, protein Z, S and C  as well as 
the bone-related proteins (osteocalcin and matrix Gla protein) (Kulman et al., 2001). 
However, it has now been reported that vitamin K2 can directly stimulate mRNA 
production of osteoblast mRNA markers and that vitamin K2 is a transcriptional regulator 
of bone-specific genes (Tabb et al., 2003), thereby having a role in increasing bone 
mineralisation. Vitamin K has also been implicated in calcium homeostasis. The presence 
of Gla residues facilitates calcium-binding of osteocalcin to the hydroxyapatite matrix of 
bone. The measurement of osteocalcin (bone Gla protein) in blood has become a 
clinically important diagnostic marker of osteoblast activity in bone (Shearer, 1992). 
These indirect but several lines of evidence showed that vitamin K is important to early 
skeletal developments and to the maintenance of healthy mature bone.  
Injection of vitamin K1 in neonates prophylactically can prevent haemorrhagic 
disease of the newborn especially in those exclusively breast-fed, reducing the incidence 
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of permanent brain damage in the first 6 months of life (Hanawa et al., 1988; Hanawa et 
al., 1990; Loughnan and McDougall, 1993) and this is recommended for all newborns by 
several international organisations (Thorp et al., 1995). Adults at risk of vitamin K 
deficiency include those with significant liver damage or disease and those taking vitamin 
K antagonist drugs (Olson, 1999) like warfarin for anti-coagulant therapy.  
Various studies have suggested different recommended oral doses for vitamin K; 
from 1 µg/kg body weight per day (DH, 1991) to 90 to 120 µg/day in female and male 
adults respectively by the Food and Nutrition Board (FNB) of the Institute of Medicine in 
the United States (IOM, 2001). Supplementation studies using 1 mg/day of vitamin K1 
(more than 10 times the adequate intake (AI)) over 36 months results in a decrease of 
undercarboxylated osteocalcin in postmenopausal women and increases several 
biochemical markers of bone formation (Braam et al., 2003). High pharmacologic doses 
(45 mg/day) of menatetrenone (MK-4) (fifty times higher than AI) in hemodialysis 
patients and osteoporotic women have led to significant reductions in bone loss (Iwamoto 
et al., 2001; Vermeer et al., 1995). A selected list of trials and guidelines conducted with 
vitamin K are shown in Table 3.  
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Table 3. Selected clinical trials or accepted clinical guidelines for oral 
administration of vitamin K1 and vitamin K2 in humans 
Adapted from Cockayne and colleagues (Cockayne et al., 2006). BMD: bone mineral density.  
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In this respect, no known toxicity has been associated with these high doses of 
vitamin K1 and vitamin K2 (IOM, 2001) and these vitamins are sold as supplements in the 
U.S. and Singapore. However, this is not true for vitamin K3 (menadione) and its 
derivatives, which have been found to interfere with the function of glutathione and result 
in oxidative damage to cell membranes. Injection of vitamin K3 has been associated with 
liver toxicity, jaundice and anaemia and thus, this not administered as treatment for 
vitamin K deficiency (IOM, 2001).  
 
1.3.4 Analysis of quinones in bacteria 
The inherent structural variation exhibited by isoprenoid quinones produced by 
different bacteria is of value in microbial systematics. As isoprenoid quinones are soluble 
in lipid solvents (acetone, diethyl ether, chloroform, ethanol, and petroleum ether), 
extraction with these components can be achieved from bacterial cells with acetone-
petroleum ether (Dunphy et al., 1971) or a chloroform-methanol (2:1, vol/vol) mixture 
(Collins et al., 1977; Dunphy et al., 1971). Both of these extraction procedures yield a 
complex mixture of lipids from which isoprenoid quinones can be isolated by a variety of 
chromatographic procedures; the most common of these are adsorption column 
chromatography and adsorption thin-layer chromatography (Dunphy et al., 1971). Other 
methods for isoprenoid analyses include physicochemical techniques (Sommer and 
Kofler, 1966), particularly ultraviolet spectroscopy which enables the investigation of the 
category or class to which an unknown isoprenoid quinone belongs.  
Several genera within the family Enterobacteriaceae (e.g., Escherichia) are 
unusual as they contain mixtures of menaquinones (MK), demethylmenaquinones 
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(DMK), and ubiquinones (UQ). Structural studies have indicated that the lengths of the 
side chains of the major components of these three quinone structural types are the same 
(eight isoprene units). However, the relative proportions of MK, DMK, and UQ are 
influenced by the degree of aeration. Thus, cultivation of Escherichia coli and other 
facultative organisms at a low oxygen tension increases the level of menaquinones but 
reduces the amount of ubiquinones produced (Polglase et al., 1966; Whistance and 
Threlfall, 1968).  
Gram-positive bacteria synthesise either MK or DMK, or they lack isoprenoid 
quinones. UQ are not formed (Collins and Jones, 1981). The genus Bacillus has 
remarkably uniform MK profiles of predominately unsaturated MK-7 (Hess et al., 1979).  
All members of the genus Staphylococcus possess unsaturated MK as their sole 
respiratory quinones. Staphylococcus aureus contain MK-8 as their major component, 
although MK-7 is also present at substantial levels (Yamada et al., 1976). Mycobacterium 
species, by comparison, contain a diverse range of isoprenologues (MK-7 to MK-9) in 
addition to different hydrogenated forms. However, the major form is predominately 
MK-9(H2) (Collins et al., 1977). Some quinone forms of selected bacteria are listed in 
Table 4. 
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Whistance et al., 
1969) 
Bacillus sop. 
   
GPB Aerobic MK-7 None (Hess et al., 1979) 
Staphylococcus 
aurous  
   
GPB Facultative 
anaerobe 
MK-8 MK-9,7 (White and 
Frerman, 1967; 
Yamada et al., 
1976)  
 
Table 4. Distribution of isoprenoid quinones in selected bacteria 
UQ=Bunion, MK=menaquinone, DMK=demethylmenaquinone. GPB=Gram-positive bacteria, 
GNB=Gram-negative bacteria. Adapted from Collins and Jones (Collins and Jones, 1981). 
 
1.3.5 Quinone biosynthesis 
In 1964, phylloquinone and 2-methyl-1,4-naphthoquinone were shown to be 
converted to MK by Bacteroides melaninogenicus (then termed Fusiformis 
nigrescens)(Martius and Leuzinger, 1964). The primary precursors of the two side chains 
of menaquinones are recognised as methionine and mevalonate (Threlfall et al., 1967) for 
the biosynthesis of MK-9(H2) by Mycobacterium phlei (Guerin et al., 1965) and for MK-
8 in E. coli (Cox and Gibson, 1966; Ellis and Glover, 1968; Jackman et al., 1967). The 
isoprenoid side chain was contributed by pyrophosphate esters of polyisoprenoid 
alcohols. A schematic diagram (fig. 5) illustrates the order of formation of the 
compounds. 
 








Figure 5. Major intermediates in menaquinone biosynthesis 
OSB = o-succinylbenzoate (4-[2'-carboxyphenyl]-4-oxobutyrate); DHNA = 1,4-dihydroxy-2-
naphthoate; DMK = demethylmenaquinone; MK = menaquinone. Reproduced as illustrated in 
Bentley and Meganathan (Bentley and Meganathan, 1982). 
 
The bacterial naphthoquinones, MK and DMK, as well as ubiquinones (UQ) are 
derived from the shikimate pathway. The prenyl side chain of both quinones is derived 
from prenyl diphosphate, and the methyl groups are derived from S-adenosylmethionine. 
Although both quinones originate from the shikimate pathway, there are important 
differences in their biosynthesis. The quinone nucleus of MK is derived from chorismate 
via isochorismate whereas UQ is derived directly from chorismate. MK biosynthesis 
requires 2-ketoglutarate, ATP, coenzyme A (CoASH), and thiamine pyrophosphate; the 
prenyl side chain is introduced prior to the last step, accompanied by loss of the carboxyl 
group. In UQ biosynthesis, the prenyl side chain is introduced at the second step, with 
retention of the carboxyl group. All the reactions of the pathway up to the prenylation 
(next to last step) of MK biosynthesis are carried out by soluble enzymes in cytoplasm, 
whereas all the enzymes involved in UQ biosynthesis are membrane-bound except the 
first. The last step in MK synthesis is a C-methylation; the last step in UQ biosynthesis is 
an O-methylation. Additionally, a second C-methylation and O-methylation take place in 
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the middle part of the UQ biosynthetic pathway. In spite of the fact that UQ and MK 
biosynthesis diverges at chorismate, the C-methylations involved in both pathways are 
carried out by the same enzyme. Under aerobic conditions, UQ biosynthesis requires 
molecular oxygen whereas anaerobic biosynthesis of UQ and MK incorporates oxygen 
atoms derived from water. Finally, MK is considered an essential vitamin and is not 
synthesized by mammals. UQ is not considered an essential nutrient since it can be 
synthesized from the amino acid tyrosine (reviewed by Meganathan) (Meganathan, 
2001).  
 
1.3.6 Genetics of Menaquinone Biosynthesis  
The most complete genetic information relating to menaquinone biosynthesis was 
obtained with mutant strains of E. coli. Seven separate men genes have been identified, 
and the present understanding of the relationship of the men genes to the biosynthetic 
pathway is summarised in fig. 6.  























Figure 6. Menaquinone biosynthesis pathway in Escherichia coli with the 
putative homologues in Mycobacterium tuberculosis H37Rv genome 
Adapted from R. Meganathan, In Escherichia coli and Salmonella typhimurium: Biosynthesis of 
the Isoprenoid Quinones; Menquinone (Vitamin K2) and Ubiquinone (Coenzyme Q) (Meganathan, 
1996). Names of enzymes are shown in boxes. The proposed homologues in the published MTB 
genome are based on information on Tuberculist (http://genolist.pasteur.fr/TubercuList/) and Rv 
numbers indicate the unique gene annotation number assigned for each gene by the Sanger 
database for M. tuberculosis H37Rv.  
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1.3.7 Effects of men gene products revealed by men mutants 
The first men mutant of E. coli was isolated during a search for ubiquinone-
deficient mutants (Cox et al., 1968). Young et al isolated menaquinone-deficient E. coli 
mutants (Shineberg and Young, 1976; Young, 1975) that were unable to grow on 
succinate as a sole carbon source, but able to grow on glucose; they classified menA 
mutants as those unable to attach the isoprenyl side chain and accumulated DHNA. A 
second group of mutants for menB was found to accumulate OSB (Shineberg and Young, 
1976; Young, 1975). It was later shown to consist mutation in both menE and menB 
genes (Shaw et al., 1982). From mutants unable to use fumarate as a terminal electron 
acceptor, two other groups of mutants blocked in the formation of OSB were identified 
(menC and menD) (Guest, 1977, 1979). A gene encoding for the isochorismate synthase 
specifically involved in MK synthesis was identified as menF and placed upstream of 
menD (Daruwala et al., 1996). The last men gene in the pathway was identified as menG 
after the sequence of the methylase was determined (Koike-Takeshita et al., 1997) and 
adjacent to menA. The nature of E. coli men mutants, their growth limitations and their 
contribution to the present knowledge of MK functions are summarised in Table 5.  
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1. Anaerobic growth on glucose minimal medium 
impaired  
2. Restored growth with uracil or 2-
succinylbenzoate (OSB) 
3. OSB promoted normal anaerobic growth on 
lactate + fumarate  
 
1. MK participates in redox reactions of  
glucose to fumarate  
2. Participates in anaerobic uracil synthesis in 
oxidation of dihydroorotate to orotate 
3. menC involved in MK production using OSB, 










1. Anaerobic growth on glucose impaired but 
restored with uracil 
2. No anaerobic growth occurred on fumarate, 
formate + fumarate, lactate + fumarate or 
glycerol + fumarate 
1. Anaerobic growth on glycerol and formate, 
requires MK, with fumarate as the final 
electron acceptor from MK 




Tyson et al., 
1997) 
menA-  E. coli 1. MK absent, growth on glucose alone is 
impaired under anaerobic conditions, but 
normal aerobic growth  
2. Uracil restored growth to normal 
3. Membranes from this strain grown 
anaerobically are poor in oxidizing 
dihydroorotate and reduction of fumarate 
 
1. MK mediates electron transfer reactions 
predominantly in anaerobic conditions 
2. MK involved in anaerobic pyrimidine 
biosynthesis by oxidation of dihydroorotate 












E. coli 1. Mutants do not have UQ, DMK or MK 
2. Growth on glucose alone impaired aerobically 
unless casamino acids added 
3. No aerobic NADH, lactate, glycerophosphate 
and succinate oxidase activity unless 
exogenous UQ added.  
4. MK supplementation restored anaerobic nitrate 
reduction, glycero-phosphate oxidation and 
partially, lactate oxidation 
1. UQ is the primary quinone in electron 
transfer to oxygen under aerobic conditions 
2. MK required for glycerophosphate oxidation, 
dispensable in lactate and not involved in 
NADH and succinate oxidation 








Table 5. Properties of E. coli men mutants 
MK = menaquinone, DMK = demethylmenaquinone, UQ = ubiquinone, OSB = 2-succinylbenzoate 53
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men gene mutants in B. subtilis are interesting as this organism has no UQ and 
depends on MK for electron transport. The mutants displayed simultaneous resistance to 
two aminoglycoside antibiotics (Taber et al., 1981a). The use of aminoglycoside 
antibiotic resistance for the selection of men mutants derives from the role of quinones in 
transport of these antibiotics into the bacterial cell (Bryan et al., 1979; Taber et al., 
1981b). The extent of aminoglycoside entry is related to the presence and efficiency of 
electron transport and the generation of an electrochemical proton gradient. This concurs 
with evidence from Staphylococcus aureus, which is another organism without UQ. 
Some S. aureus mutants obtained with neomycin selection were shown to require 
menadione supplementation (Sasarman et al., 1968). The deficiency also resulted in 
aminoglycoside resistance in spite of general poor growth and reduced biochemical 
activity and respiration. These vitamin K-deficient mutants were subsequently shown to 
be deficient at the level of the common aromatic pathway, prior to naphthoquinone ring 
formation, and at the level of synthesis of the isoprenoid side chain (Sasarman et al., 
1969, 1971). MK deficiency is accompanied in every case by an impaired nitrate 
respiration. Re-initiation of MK biosynthesis by addition of shikimate restored electron 
transport, implicating MK in nitrate respiration (Sasarman et al., 1974).  
 
1.3.8 Differential functions of quinones  
Many bacteria biosynthesise both ubiquinones and menaquinones (Collins and 
Jones, 1981) and the complex patterns in the amounts of the various quinones are 
influenced by aerobic or anaerobic growth. There are significant differences in the 
standard redox potentials of the two naphthoquinones (Hollander, 1976, 1981). For MK, 
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mid-point potential (E'o) =-74 mV; for DMK, E'o = +36 mV and for UQ, E'o = +113 mV. 
It has been shown in Haemophilus influenzae that in electron transport from NADH to 
fumarate, MK and DMK are more active than UQ by a factor of 4 to 5. For electron 
transport from succinate to O2, UQ and DMK were effective but MK had only a slight 
effect. It appears that electron transport depends not only on the redox potential but also 
on the chemical structure of the quinone (Hollander, 1981). The availability of oxygen in 
the growth medium as well as variations in the concentrations of cellular components that 
reflect the internal redox potential of the cells may be controlling parameters (Wimpenny, 
1969).  
In E. coli, the quinone functions of the naphthoquinones are very different from 
those in the benzoquinones. The increased biosynthesis of MK in E. coli under anaerobic 
conditions is apparently related to its role as an obligatory hydrogen carrier for the 
oxidation of dihydroorotate coupled to fumarate reduction (Newton et al., 1971). Under 
aerobic growth of E. coli with an oxidizable substrate (e.g., succinate) in the presence of 
potassium cyanide (prevents aerobic respiration), an approximately nine fold increase in 
MK content was observed whereas the UQ content is essentially unchanged (Ashcroft 
and Haddock, 1975). This implicates MK as the respiratory quinone under anaerobic 
respiration and can replace ubqiuinone as the obligatory electron carrier. At the same 
time, the cytochromes synthesised are typically the same as those in anaerobically grown 
cells. The oxygen-dependent synthesis of UQ-8 in E. coli appears to have a standby 
position in the anaerobic cell and can be activated quickly if oxygen becomes available 
(Knoell, 1981). MK involvement in anaerobic pyrimidine biosynthesis is evidenced by 
the growth requirement for uracil in MK-deficient strains, although ubiquinone may 
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partially replace menaquinone in its absence. Conversely, a ubiquinone-deficient strain 
showed no requirement for uracil when grown anaerobically (Cox et al., 1970). Hence, in 
E. coli, where there are both quinones to function as electron carriers, MK and UQ 
function specifically under anaerobic and aerobic conditions respectively.  
 
1.3.9 Quinones in mycobacteria 
Several pieces of data support the notion that MTB, like B. subtilis, utilises only 
MK in the electron transport chain. Studies classifying bacteria based on their quinone 
content by lipids extraction and thin-layer chromatography identified only menaquinones 
and not ubiquinone in MTB (Collins et al., 1977; Collins and Jones, 1981; Lester and 
Crane, 1959; Noll and Jackim, 1958). However there is a homologue of E. coli ubiE in 
MTB, although this is now termed menG since the putative gene function is the same 
(Johnston et al., 2003). Goldman and co-workers (Kusunose and Goldman, 1963; Segel 
and Goldman, 1963) isolated the NADH oxidase system from MTB and demonstrated 
that it catalysed the reduction of naphthoquinones. In E. coli, the MK biosynthetic 
pathway involves either seven or eight enzymes (Meganathan, 2001). Sequence 
comparisons have found homologues for seven of these enzymes in the Mycobacterium 
tuberculosis (MTB) H37Rv strain based on annotated genes in Tuberculist 
(http://genolist.pasteur.fr/TubercuList/).  
Based on combined knowledge from E. coli respiratory chain functions (Ingledew 
and Poole, 1984) and work done on MTB respiration (Schnappinger et al., 2003; 
Weinstein et al., 2005) the possible electron acceptors utilising MK for transfer of 
electrons from NADH are illustrated in Figure 7.  Electrons from reducing equivalents 
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generated as NADH by intermediary metabolism are transferred to the membrane-bound 
menaquinone pool by dehydrogenases. MTB encodes two types of NADH 
dehydrogenases (NDH-1 and -2). Reduction of dioxygen is catalysed by 2 terminal 
oxidases: aa3-type cytochrome c oxidase (ctaBCDE), forming a supercomplex with 
cytochrome bc1 complex (qcrCAB) and bd-type menaquinol oxidase (cydABCD). Under 
conditions of reduced oxygen, the bd-type menaquinol oxidase is induced as it has a 
higher oxygen affinity than cytochrome c oxidase. MTB and BCG utilises nitrate as an 
alternative electron acceptor under conditions of anaerobicity and possess genes that 
encode a nitrate transport protein NarK2 and the “fused” nitrate reductase NarX (Hutter 
and Dick, 1999, 2000; Shi et al., 2005; Sohaskey and Wayne, 2003). 










Figure 7. Respiratory chain in MTB (a predicted model) 
A simplified depiction of the role of MK in selected respiratory pathways of MTB and the flow of 
electrons in the electron transport chain. Electrons travel via dehydrogenases from donor 
substrates to a common quinone pool (DMK, demethylmenaquinone; MK, menaquinone), from 
which they pass to electron acceptors. Solid and dotted arrows indicate pathways that are 
induced and repressed respectively, in intraphagosomal MTB in activated macrophages based on 
the pattern of gene expression after 24 hours of infection (Schnappinger et al., 2003). This is 
likely to reflect the pathways preferentially used by mycobacteria in anaerobic and aerobic 
conditions respectively. 
 
1.3.10 Quinones in anti-bacterial treatment 
The naphthoquinone (and related) ring systems of rifamycins and similar 
antibiotics were probably derived from the shikimate pathway (Bentley, 1975). This has 
been upheld by the discovery of 3-amino-5-hydroxybenzoate, a rifamycin precursor 
commonly derived from the shikimate pathway as quinones (Kibby et al., 1980). Most of 
the 1,4-naphthoquinones found in nature, however, are produced by plants and fungi 
(Bentley, 1975) while some bacterial naphthoquinones (5,8-dihydroxy-2,7-dimethoxy-
1,4-naphthoquinone) are produced by a Streptomyces strain (Gram-positive bacteria) 
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Many of the naphthalenoid compounds have been shown to exhibit toxicity to 
bacteria (Armstrong et al., 1943). In particular, substituted naphthoquinones are quite 
inhibitory to the growth of bacteria (Leahy et al., 1968). Even in a bacterium with a 
specific growth requirement, quinone toxicity may occur beyond a critical concentration 
(Lev, 1959). In Bacillus cereus, the antibacterial action of menadione results from a 
specific inhibition of RNA synthesis in growing cells (Klubes and Cerna, 1972). 
Although menaquinones and ubiquinones have been demonstrated to be essential 
for electron transport, they are also capable of diverting electron flow from the 
respiratory chain and cause increased intracellular production of superoxide radicals and 
hydrogen peroxide in E. coli under nutrient limitation or subjected to protein inhibition. 
Under such conditions, increased biosynthesis of the defensive enzymes, superoxide 
dismutase and catalase helps to counteract the toxicity (Hassan and Fridovich, 1979). The 
toxicity of quinones has been demonstrated by menadione (vitamin K3; 2-methyl-1,4-
naphthoquinone), effects of which have been extensively studied in mammalian cells 
(Brunmark et al., 1987; Iyanagi and Yamazaki, 1970). Due to their high electrophilicity, 
menadione exhibit substantial thiol reactivity that results in their rapid reduction to 
semiquinone intermediate by one-electron reduction (Lind et al., 1982; Lind et al., 1990; 
Thor et al., 1982). The high redox potential is responsible for generating quinone 
cytotoxicity (O'Brien, 1991) that causes oxidation of cellular macromolecules (Bolton et 
al., 2000). The use of dual analogues to vitamin K and coenzyme Q as anti-
mycobacterials was shown by Gangadharam et al. (Gangadharam et al., 1978). Their 
interest in this group of compounds was due to the presence of the naphthoquinone 
moiety that is also found in menadione (Panisset et al., 1952) and rifampin, an effective 
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anti-mycobacterial drug (Prelog, 1963). In this study, eight quinone compounds were 
tested for activity in vitro against several strains of Mycobacterium intracelllulare. 
Bactericidal activity was shown by one compound (6-cyclo-octylamino-5,8-quino-
linequinone; CQQ) at a concentration of 8 µg/ml against M. intracellulare after 48 hours 
of exposure. This compound was also active against MTB at 1 µg/ml. This shows that 
certain quinone compounds possess anti-mycobacterial activity but the mechanism of 
killing remains unknown. Another study screened 28 quinone compounds for anti-
mycobacterial activity and of these, the MBC values for 1,4-naphthquinone derivatives 
were in a wide range of 50 to more than 6400 µg/ml (Tran et al., 2004). Comparisons 
between different napthaquinone compounds revealed solubility of the compounds to be 
of minor importance and that the one-electron potential does not predict activity. The 
mechanism of killing appears to be different from that in mammalian cells as judged by 
differential cytotoxicity to rat hepatocytes (Miller et al., 1986; O'Brien, 1991) despite 
similar activity in the compounds studied.  
The closest prediction of the mode of killing in mycobacteria by naphthoquinones 
comes from studies on a novel experimental class of anti-TB drug (phenothazines) that 
target the type II NADH:menaquinone oxidoreductase encoded by the ndh gene in MTB 
(Weinstein et al., 2005; Yano et al., 2006). Phenothazine analogs exhibit tuberculocidal 
activity in in vitro and in vivo studies and the mechanism is postulated to be blockage of 
electron flow to menaquinone, resulting in the oxidised state of the respiratory chain and 
preventing entry into the Dos-mediated state that has been implicated in maintenance of 
mycobacterial dormancy persistence in vivo (Georgellis et al., 2001; O'Toole et al., 
2003). This indirectly indicates the importance of menquinone in the maintenance of the 
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electron flow in MTB. Such electron flow is crucial for the balance of the NADH/NAD+ 
ratio in the respiratory chain. This homeostasis in intermediary metabolism is linked to 
membrane energetics which can affect ATP production and pH balance in the bacteria 
(Deckers-Hebestreit and Altendorf, 1996; Rao et al., 2001).  
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CHAPTER 2: men GENE EXPRESSION IN LATENT MYCOBACTERIA 
2.1 INTRODUCTION  
Studies in E. coli K-12, a strain that produces both menaquinone (MK) and 
ubiquinone (UQ), reveal that MK is the preferred quinone for anaerobic electron 
transport (Newton et al., 1971). This differential requirement may be due to the 
availability of oxygen in the growth medium influencing redox potential within the cells 
(Wimpenny, 1969).  The differences in the electron transfer capacity of MK and UQ have 
been reviewed in section 1.3.8. 
Mycobacteria also encounter hypoxic conditions in host tissues during chronic 
infections (Cannetti, 1955; Hobby, 1957; Imboden and Schoolnik, 1998; Russell et al., 
1955), and such hypoxic stresses in vivo induce a state of mycobacterial dormancy or 
non-replicating persistence (Wayne and Sohaskey, 2001). This is reasonable to 
hypothesise that mycobacteria may similarly require MK to survive under those 
conditions. The Mycobacterium tuberculosis (MTB) genome reveals multiple 
homologues of E. coli MK biosynthesis genes (Cole et al., 1998). Mycobacterial lipid 
extractions suggest that this genus produces only MK and not UQ  (Collins et al., 1977; 
Collins and Jones, 1981; Lester and Crane, 1959; Noll and Jackim, 1958) and 
mycobacteria utilise MK in the electron transport chain (Kusunose and Goldman, 1963; 
Segel and Goldman, 1963). Hence, it is of interest to investigate the role of MK in the 
metabolic processes that allow MTB to adapt from aerobic growth to conditions of low 
oxygen, which drive the organism into dormancy.  
  Some prior studies have already established that MTB adaptation to the in vivo 
environment involves significant up-regulation of many genes which allow the organism 
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to respond to cellular hypoxia and alternative carbon metabolism, amongst many other 
factors within the host (Timm et al., 2003). Such genes have been called ‘persistence 
genes’ or ‘dormancy genes’ as it is surmised that the gene products are crucial to MTB 
long-term survival under conditions inducing persistence. In studies of TB-infected 
murine and human lung tissue, it is found that MTB can respond to specific 
microenvironments in vivo by adopting a variety of metabolic states depending on host 
immune status and stage of infection (Fenhalls et al., 2002; Kaplan et al., 2003; Timm et 
al., 2003). Our hypothesis is that MK is one of several mycobacterial factors that mediate 
these different metabolic states because of its role in electron transfer between key 
respiratory intermediates.  
The interest in mycobacterial persistence mechanisms has spawned several in 
vitro models attempting to generate in vitro MTB in a state analogous to the persistent 
bacilli in latent TB disease – these have been called ‘dormancy models’. Comparisons of 
global gene expression profiles of MTB in host tissues with MTB grown under these in 
vitro dormancy models reveal many remarkable similarities (Kendall et al., 2004b). The 
most well-established dormancy model was pioneered by Wayne (Cunningham and 
Spreadbury, 1998; Dick et al., 1998; Wayne and Hayes, 1996). By monitoring the 
consumption of oxygen in this model using an oxygen sensor and by visual inspection of 
methylene blue decolorisation as an indicator of oxygen depletion , he showed that MTB 
grown under a gradient of progressively reduced oxygen stop replicating but remain 
viable (Wayne, 1977; Wayne and Hayes, 1996). Such MTB are in a state of non-
replicating persistence (NRP) and have been shown to persist up to 76 days (Voskuil et 
al., 2003; Voskuil et al., 2004). MTB cultures in NRP express dormancy genes different 
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from stationary phase cultures or cultures under nutrient limitation, in which only a 
subset of dormancy genes were expressed (Voskuil et al., 2003; Voskuil et al., 2004). 
Hence, Wayne’s dormancy model establishes that hypoxia induces a transcriptional 
program implicated in long-term dormancy survival. Wayne’s dormancy model was used 
together with in vivo experiments in this chapter to study MK gene expression in dormant 
mycobacteria. In view of constraints in containment facilities, Mycobacterium bovis 
bacille Calmette-Guérin strain was used as a surrogate organism for MTB, as their 
genomes share 99.9% similarity and specifically there is more than 99% sequence 
identity in their MK biosynthetic (men) genes.   
 
Objectives of the experiment in this chapter: 
(1) To verify the growth kinetics and survival of wild-type BCG in an in vitro model 
of latency (Wayne model) 
(2) To investigate the gene expression profile of men genes involved in the 
menaquinone biosynthetic pathway in the Wayne model of mycobacterial 
dormancy 
(3) To investigate BCG survival and men gene expression in an in vivo murine model 
of infection  
(4) To determine how a menaquinone analogue may influence growth and men gene 
expression in actively growing and persistent BCG  
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2.2 MATERIALS AND METHODS 
2.2.1 Bacteria and growth conditions.  
All experiments were conducted with Mycobacterium bovis bacille Calmette-
Guérin (BCG) Pasteur strain. Single BCG colonies on agar plate cultures were picked for 
culture in broth media, and stored as seed stocks maintained in 50% glycerol at minus 
80°C. Thawed BCG stocks were grown initially as ‘starter cultures’ in snap-capped 
tubes, then transferred to roller bottles (490 cm2) for better aeration and to synchronise 
cultures. Cultures were grown to mid-log phase before use in experiments.  The broth 
medium used for BCG culture was Middlebrook 7H9 (Difco) containing 10% (vol/vol) 
oleic acid-albumin-dextrose-catalase (BD), 0.5% (vol/vol) glycerol (Sigma) and 0.05% 
vol/vol Tween-80 (Sigma). Middlebrook 7H10 agar (Difco), with the same supplements 
as above, was used for agar cultures.  The broth and agar media are hereafter abbreviated 
as ‘7H9’ and ‘7H10’ respectively. All BCG cultures were incubated at 37°C. The number 
of broth-grown BCG cells used for each experiment was initially estimated by measuring 
the absorbance at 600 nm (A600) in a spectrophotometer, and then confirmed by culturing 
known dilutions onto agar for counting colony-forming units (cfu). 
 
2.2.2 Dispersal of mycobacteria in broth cultures 
Mycobacteria in broth cultures are prone to clumping, thus prior to use dispersal 
of clumps in cultures was performed to limit errors in spectrophotometric measurements. 
This was done either by gentle dispersal of the culture in a sealed tube within a water-
bath in a cup-horn sonicator (Sonics, Vibra cell) for 3 x 30s at a setting of 45% power or 
by repeated passage of the broth culture through a 27G needle 5 to 10 times.   
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2.2.3 Wayne model of non-replicating persistence  
This is an established in vitro method of generating a state of mycobacterial non-
replicating persistence (NRP) through progressive oxygen depletion (Wayne and Hayes, 
1996), first described by Wayne (Wayne and Lin, 1982). This model results in up-
regulation of M. tuberculosis (MTB) ‘persistence’ genes, many of which are similar to 
genes upregulated by mycobacteria found in vivo (Boon and Dick, 2002; Fenhalls et al., 
2002; Hutter and Dick, 1999; Shi et al., 2003; Timm et al., 2003; Voskuil et al., 2004) – 
hence it is widely used as a model of mycobacterial latency or ‘dormancy’. Although 
Wayne’s NRP model was performed on MTB, others have shown that NRP can also be 
induced in BCG through this method (Hutter and Dick, 1999, 2000; Lim et al., 1999; 
Murugasu-Oei and Dick, 2000; Peh et al., 2001; Sander et al., 2001). 
Briefly, BCG cultures were grown in roller bottles in 7H9 media to a mid-
exponential phase of A600 0.400 and diluted 100-fold to achieve a final optical density of 
A600 0.004 in all tubes. For oxygen-limited cultures, bacteria were transferred to sealed 
tubes (20 x 125 mm) in a final volume of 17 ml culture such that the ratio of headspace 
air to that of medium (headspace ratio, HSR) was 0.5. In these tubes, 8 mm magnetic stir 
bars were placed to allow gentle stirring of the broth cultures at 120 rpm on a magnetic 
stirring platform (Velp Scientifica) (‘stirring tubes’). In such cultures, the stirring does 
not lead to disturbance of the fluid-level on the surface of the cultures, and there is no 
clumping of bacteria in the tubes. To re-aerate stirred cultures, tubes were opened after 12 
days of stirring. The bacterial cultures were diluted 1:100 in triplicate tubes each with 
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final volume of 10 ml fresh 7H9 media. The tubes were loosely capped and vigorously 
shaken on a rotary shaker at 230 rpm, 37°C.   
To achieve aerated cultures as controls, 10 ml bacteria from the roller-bottle 
cultures described above were transferred to same type of tubes but with caps loosened. 
The tubes were vigorously shaken (‘shaking tubes’) on a rotary shaker-incubator at 230 
rpm and caps on these tubes were opened daily under sterile conditions to further 
facilitate exchange of air. Growth was monitored daily by turbidity measurements at
 
A600 
in a spectrophotometer (Bausch & Lomb). Bacteria from triplicate tubes per time-point 
were harvested at various stages in the progression of anaerobiosis and cultured in 
various dilutions on triplicate agar plates for colony enumeration.  
 
2.2.4 RNA extraction and Gene expression analysis 
Bacterial pellets harvested from various growth conditions in vitro or from 
infected murine organs were resuspended in TRIzol® Reagent (Invitrogen) to stabilise 
RNA and prevent post-harvest transcriptional changes. Bacterial cells (1 x 108/ml) 
suspended in TRIzol were aliquoted into 2 ml RNase-free screw-capped vials containing 
1.5 ml of 0.1 mm zirconium-silica beads (Biospec Products). The vials were subjected to 
2 cycles of rapid freeze thawing. Subsequently, mechanical lysis of the bacteria in a 
Mini-Beadbeater (Biospec Products) was performed by vigorous agitation of the bacterial 
pellet against the beads at 42,000 rpm for 1 min at room temperature.  This step was 
carried out for 3 cycles and vials cooled on ice between each cycle. RNA was extracted 
as described by TRIzol manufacturers, with a minor modification of using 0.4 ml of 
chloroform per millilitre of TRIzol reagent. After Trizol extraction, residual DNA was 
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removed using DNA-free™ (Ambion). The RNA was further purified by ethanol-
precipitation, washed once in 70% ethanol, and redissolved in RNase-free water. To test 
for DNA contamination in extracted RNA, PCR amplification using the 16S rRNA 
primers with the extracted RNA (not reverse-transcribed) as template were performed 
and analysed by agarose gel electrophoresis. RNA templates that do not produce any 
PCR amplicons were considered free of DNA contamination. Expression analysis of 
several mycobacterial men genes, with 16S rRNA gene as a control, was performed by 
reverse transcription and polymerase chain reaction (RT-PCR).  Briefly, 1 µg of bacterial 
RNA was reverse transcribed with 0.5 µg of random hexamers (Promega) before cDNA 
synthesis.  cDNA synthesis was initiated with 200U M-MLV RT (Promega) in a buffer 
containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 0.5 mM 
dNTPs, 25 units rRNAsin® RNase inhibitor (Promega) for 1 h at 37°C.  The reaction was 
terminated at 95°C for 5 min.   PCR was carried out in a final volume of 50 µl containing 
10 mM Tris.HCl (pH 8.8), 3 mM MgCl2, 50 mM KCl, 10 mM of each primer, 0.1 mM of 
dNTPs, 10 % Q solution (Qiagen) and 0.5U Taq polymerase (Qiagen).  PCR 
amplification was performed in a thermocycler (iCycler, Bio-Rad). The cycling 
parameters, details of the primers and PCR amplicon sizes are listed in the Table 6. 
Aliquots of 20 µl of the PCR products were analysed by 1.2 % agarose gel 
electrophoresis. The gel image was captured using a variable mode fluorescent imaging 
system (Typhoon 9200, GE Healthcare Life Science) which has a linear dynamic range of 
five orders of magnitude (5-log range). Density analysis software (ImageQuant) was used 
to quantify the image intensity of PCR amplicons against a standard curve generated by 
serial dilutions of known amounts of cDNA for each amplicon. Generation of the cDNA 
  69 
standards is described below. Expression of the 16S rRNA gene was used to normalise 
the data from different RNA extractions, thus results were expressed as [target mRNA]/ 
[16S rRNA].  
Gene Primer Sequences Annealing Product PCR parameters
 temp (°C) size (bp)
menA (F) 5'-cgctgttggcactggctgtt-3' 60 458 10 min at 96°C,  
40 s at 98°C, (40 cycles)
30 s at 60°C, 
30s at 72°C 
(R) 5'-gatgtcgcgcaggttgttgg-3' 10 min at 72°C
menC (F) 5'-ctgctggaccgcctgtatgt-3' 60 798 10 min at 96°C,  
40 s at 98°C, (40 cycles)
30 s at 60°C, 
1 min at 72°C 
(R) 5'-ctcggccacgtcctcttcaa-3' 10 min at 72°C
menD (F) 5'-atgaacgcaccgccggctac-3' 60 304 10 min at 96°C,  
40 s at 98°C, (40 cycles)
30 s at 60°C, 
30s at 72°C 
(R) 5'-gatcgccaggtcgcgttgag-3' 10 min at 72°C
menE (F) 5'-tgctgactcacgcgaacctc-3' 60 229 10 min at 96°C,  
40 s at 98°C, (40 cycles)
30 s at 60°C, 
30s at 72°C 
(R) 5'-atcccggtgaccttctctgc-3' 10 min at 72°C
ubiE (F) 5'-ccgcaagtatgacctgacca-3' 60 616 10 min at 96°C,  
40 s at 98°C, (40 cycles)
30 s at 60°C, 
1 min at 72°C 
(R) 5'-gtatccggcatgcagagcta-3' 10 min at 72°C
16S rRNA (F) 5'-ctggcggcgtgcttaacaca-3' 55 718 10 min at 96°C,  
40 s at 98°C, (40 cycles)
30 s at 55°C, 
1 min at 72°C 
(R) 5'-cgctcctcagcgtcagttac-3' 10 min at 72°C
 
Table 6. Table of PCR amplification parameters and primers for men genes
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2.2.5 Generation of cDNA standards 
A large quantity of cDNA amplicons for each gene to be studied was sequenced, 
purified and quantified by spectrophotometric readings at A260 before 10-fold serial 
dilutions to give a series of cDNA standards containing 1 x 104 to 1 x 1011 cDNA copies, 
which were stored in small aliquots. For each gene, one single set of the appropriate 
cDNA standards were used throughout the study. An appropriate range of gene-specific 
cDNA standards was amplified in the same thermocycler, using the same PCR master 
mix, as the corresponding unknown cDNA sample to be quantified. Electrophoresis of 
the amplicons from the standard cDNA series revealed bands with an intensity gradient 
corresponding to the known quantity of cDNA used as the PCR template, and this was 
used to plot a standard curve of density versus cDNA quantity. If the amplicon gradient 
for the standards was non-linear, the unknown sample could not be quantified and the 
entire set of experiments was repeated. Thus, the curve also served as a quality control to 
prevent analysis of results if there was evidence of saturation of the PCR reaction or PCR 
inhibitors in the master mix, as well as to ensure parity of results in data generated when 
repeating the same experiment on different occasions.   
 
2.2.6 Removal of mammalian RNA 
When bacterial RNA had to be extracted from infected murine tissues for BCG 
gene expression studies, the MICROBEnrich (Ambion) kit was used to minimise 
contamination of the microbial RNA sample by mammalian RNA. Briefly, RNA 
extracted from murine tissues was purified by sodium acetate-ethanol precipitation to 
remove excess salt. The purified RNA was incubated with the Capture Oligonucleotide 
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Mix (COM) in binding buffer at 37°C, 60 min which hybridises with homologous regions 
of the 18S and 28S mammalian rRNAs. Mammalian mRNA (18S rRNA, 28S rRNA, and 
polyadenylated mRNAs) were subsequently captured by magnetic beads that were 
derivatised with an oligonucleotide that hybridised to the capture oligonucleotide, 
together with the polyadenylated 3' ends of eukaryotic mRNAs (COM mixture) after 
incubation at 37°C, 15 min. This enabled the eukaryotic RNA to be magnetically 
separated, thus enriching the bacterial RNA in the supernatant obtained. This was 
precipitated with ethanol to obtain the final bacterial RNA that was used for gene 
expression analysis. 
 
2.2.7 Infection of mice  
Protocols used were approved by the departmental animal care committee (the 
institutional committee was not in existence then). Female Balb/c mice (6-8 weeks old) 
were given 108 BCG intravenously in 0.1 ml of phosphate buffered saline (PBS) via the 
lateral tail vein, or given PBS alone. At different time-points post-infection, the mice 
were sacrificed by CO2 overdose. Spleen, liver and lung from each mouse were 
harvested. For the extraction of bacteria from the murine tissues, the tissues were 
incubated in 200 U collagenase D (Roche) at 37°C for 1 h and then homogenised in PBS 
with 0.05% Tween 80 through 60 µm cell strainers (BD Biosciences). The cell 
suspensions were diluted and plated onto agar for BCG colony enumeration.  
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2.2.8 Histology  
Fresh tissues were collected and placed in cryovials, immediately snap-frozen and 
stored in liquid nitrogen until required. Sectioning was performed using facilities at the 
National University of Singapore Medical Institutes (NUMI). Prior to cryo-sectioning, 
tissues were embedded in embedding medium (OCT, Fisher) and frozen in the chamber 
of the cryostat (Leica CM3050) at -20°C. Each tissue was cut into 5 µm-thick sections 
and placed on 0.01% poly-L-lysine-coated glass slides (Sigma). Histological changes 
were observed by hematoxylin and eosin staining. Briefly, the tissue sections were fixed 
in 100% ethanol for 1 min, stained with Mayer’s Hematoxylin for 10 min, followed by 
three rinses with distilled water. The slides were further soaked in distilled water for 5 
min prior to dipping in alkaline solution for 3 sec and rinsed twice before counterstained 
with eosin for 3 s. The slides were rinsed in distilled water and dehydrated with 70%, 
95% and 100% ethanol for 3 min each. Finally, the slides were cleared in xylene for 5 
min twice before mounting on 22 x 60 mm cover slips using mounting medium (DePeX).  
 
2.2.9 Vitamin K1 treatment of Wayne cultures  
BCG broth cultures in 7H9 were set up according to the Wayne model as 
described above and treated with vitamin K1. Vitamin K1 (Sigma) was diluted in 
chloroform to a stock concentration of 250 mg/ml and stored at -20°C protected from 
light. The stock concentration was serially diluted to a final concentration of 12 µg/ml in 
0.5% chloroform and ethanol. Vitamin K1-treated and control (diluent alone) tubes were 
set up in triplicates. Bacteria harvested at various time-points were plated in triplicates on 
agar for colony enumeration, and analysis of gene expression. 
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2.2.10 Statistics 
Statistical comparisons for data of triplicate experiments were performed using 
Student t-test. In all figures, data shown represent means + 2 standard deviations (SD) 
unless otherwise stated. Each set of experiments was performed at least three times. The 
differences between groups were considered statistically significant if p<0.05.  
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2.3 RESULTS 
2.3.1 Culture dynamics of in vitro model of hypoxic non-replicating persistence 
using wild-type BCG  
The Wayne in vitro model of generating latent mycobacteria, by inducing NRP 
through progressive oxygen depletion, was used as described in Methods. BCG cultures 
grown according to this model are hereafter referred to as ‘Wayne cultures’. Cultures of 
BCG in this slowly-stirred model produced a distinctive three-stage growth curve (fig. 8) 











Figure 8. Wayne model for latent BCG 
The Wayne model for generating mycobacteria in a state of non-replicative persistence (NRP) 
through progressive oxygen depletion was performed as described in Methods using wild-type 
BCG (‘stirring’ cultures). Vigorously aerated ‘shaking’ cultures were used as controls. The stages 
of NRP (NRP-1 and NRP-2) described in the text are as originally defined by Wayne. Means of 
triplicates shown in each data point, error bars represent 2 standard deviations (2SD). 
 
In the first stage of the ‘stirring’ cultures, there were 4 days of exponential 
growth, corresponding to a period when oxygen was not yet limiting. By day 4, the 
stirred cultures entered a stage (termed ‘NRP-1’ by Wayne) when the growth rate 
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declined. After day 9, the cultures reached the ‘NRP-2’ stage where there was no further 
increase in turbidity, reflecting a stage of adaptation to anaerobic conditions (Lim et al., 
1999; Wayne and Hayes, 1996). When the stirred cultures at NRP-2 were aerated and 
diluted 1:100 into fresh, oxygen-rich medium after day 14, the initial exponential growth 
resumed, demonstrating that the NRP cultures were viable. These distinct stages of BCG 
growth under progressive oxygen limitation in stirred cultures, and the evidence that 
NRP-2 cultures were capable of renewed exponential growth after prolonged oxygen 
deprivation, shows that BCG can establish a state of ‘dormancy’ and ‘reactivation’ as 
defined by Wayne in his experiments with MTB. In contrast, aerated (‘shaking’) cultures 
showed a logarithmic growth curve culminating in culture saturation after 9 days of 
incubation (fig. 8).   
 
2.3.2 Up-regulation of men genes in BCG non-replicative persistence  
Many mycobacterial genes specifically induced during their intracellular growth 
within activated macrophages are also induced with exposure to low oxygen conditions in 
vitro (Schnappinger et al., 2003), suggesting that oxygen limitation in vivo might be a 
factor influencing mycobacterial in vivo transcriptional changes for survival.  Since men 
gene products are known to participate in the bacterial respiratory chain during anaerobic 
growth of E. coli, we investigated the expression profile of BCG men genes under 
conditions of progressive oxygen depletion in the Wayne cultures by reverse-
transcription of extracted RNA combined with polymerase chain reaction (RT-PCR) (fig. 
9, Table 7).  




Day 2 Day 3 Day 5 Day 7 Day 9 Day 12 
menD Rv0555 0.0 0.8 2.9 1.8 3.9 2.5 
menE Rv0542c 0.0 0.0 9.7 2.4 5.5 132.9 
menA Rv0534c 0.1 1.3 60.1 1.4 1.1 29.2 
menC Rv0553 20.1 6.2 2424.0 0.1 2.2 0.9 
ubiE Rv0558 2.8 0.1 0.0 0.1 0.8 0.9 
 
Table 7. Ratio of men gene expression in stirring versus shaking cultures 
at different time-points 
Based on cultures generated in the Wayne model (fig. 8), gene expression was determined at 
various time-points from stirring cultures and shaking cultures, and the expression ratio of stirring 
over shaking cultures is shown. Results shown are representative of one out of three independent 
experiments, using pooled RNA from 3 to 10 replicates. 
 
As most bacterial transcripts have half-lives of less than 8 min (Bernstein et al., 
2002), the expression profile of genes of the BCG MK biosynthetic pathway should 
represent de novo transcription in response to oxygen limitation over time.  In shaking 
cultures (fig. 9), expression of menA, menD, menE and menC declined sharply in the 
early phase of growth until day 5. Interestingly, as these shaking cultures became 
progressively saturated between days 5 - 7, there was a general reversal in the expression 
trend, and the expression levels reached a plateau upon reaching the phase of culture 
saturation (stationary phase). The expression of menD increased at an earlier time-point 
(after day 3) when compared to the other men genes.  However, in the shaking tubes, all 
men gene expression levels remained about 1 to 2.5 logs below stirring tubes at their 
respective peaks (fig. 9). This suggests that there was less requirement for these men gene 
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products – and therefore for menaquinone itself – in aerobic growth of BCG relative to 
oxygen-limited stirring cultures. The trend observed also supports the hypothesis that the 
expression levels may relate to oxygen content as even in shaking tubes there is reduced 
oxygenation as the culture saturates.  
The expression of men genes in stirred cultures followed a similar trend but 
changes occurred earlier. There was progressive increase in men gene expression almost 
from the start of the cultures, and expression levels generally remained above the levels 
observed in shaking cultures (except for menC), prior to and upon entry into NRP-1 (day 
5) (fig. 9a-d). men gene expression was up-regulated as much as 3 logs when BCG 
entered NRP (after day 9) in stirring cultures.  The fold differences of men gene induction 
in stirring culture over shaking cultures are shown in Table 7. Overall, relative to shaking 
cultures, increased expression was already noted as early as day 3 for menD, menC and 
menA. In most cases, the greatest increase in expression of men genes in stirring over 
shaking cultures was observed on day 5 (3 to 2,400-fold) at the point of entry into NRP-1, 
as well as on day 9 (4 to 6-fold), corresponding to entry into the NRP-2 phase. In cultures 
of stirred tubes that were opened for re-aeration and diluted 100-fold into fresh, oxygen-
rich media, there was a clear reversal in the trend of expression of men genes – all 
declined substantially with the exception of menC (fig. 9d). The decline in expression 
corresponded with the pick-up of growth, reverting to the conditions noted at the start of 
the experiment.  


















Figure 9. Up-regulation of men genes in a state of non-replicative 
persistence 
Analysis of menA, menD, menE, menC and ubiE expression by RT-PCR using RNA extracted 
from BCG at different time-points corresponding to the Wayne model growth curve shown in fig. 
8. Ratio of expression of each gene to 16S rRNA (housekeeping gene) is shown. Results are 
from one of three independent experiments with similar results. At each time-point, RNA is pooled 
from 3 to 10 replicate tubes. Solid line represents aerated (‘shaking tubes’) and dotted line 
represents hypoxic (‘stirring’) tubes. 
 
To demonstrate that this differential men gene expression is reflective of 
increased menaquinone (MK) requirements in NRP rather than global metabolic gene up-
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regulation, ubiE gene expression in the same cultures were studied as a control since this 
is also a gene involved in quinone biosynthesis. Unlike MK, UQ are generally utilised by 
bacteria for electron transfer under aerobic growth conditions only (Newton et al., 1971; 
Wissenbach et al., 1990). We noted that BCG ubiE expression was lower (fig. 9e) in 
stirring cultures compared to shaking cultures and the ratio did not reverse in NRP-1 and 
-2 phase (Table 7). These results shown support our hypothesis that there is an up-
regulation of MK biosynthesis with progressive hypoxia, and thus MK could be a 
requirement in the adaptation of BCG to oxygen limitation.  
 
2.3.3 Increased menA expression in BCG recovered from infected mice   
menA encodes the penultimate enzyme in the MK biosynthetic pathway. We used 
this as one representative men gene and indirectly as a marker for MK biosynthesis since 
E. coli studies suggest that menA deletion mutants are defective in MK production 
(Newton et al., 1971; Young, 1975). We wished to investigate whether there was 
differential expression of men genes relating to different stages of in vivo BCG infection 
in Balb/c mice. Thus, BCG was delivered intravenously at a high dosage of 108 colony-
forming units (cfu) per mouse. The bacterial load in the liver, spleen and lung were 
analysed at day 35 and day 60 (fig. 10a). Comparing these two time-points, while 
bacterial load in the lungs increased markedly, there was a decline in bacterial counts in 
the liver and a small increase in the spleen. 





















Figure 10.  BCG growth and differential expression of menA in murine 
organs 
(a) Bacterial load in infected organs of mice. Balb/c mice were infected i.v. with 108 BCG and 
organs harvested on day 35 and 60 for counting colony-forming units (cfu) Each point is the mean 
of the results obtained from 3 to 4 mice. Asterisks indicate significant differences between day 35 
and 60 (p<0.05). One of three independent experiments with similar results is shown. (b) 
Differential expression of menA in BCG extracted from infected organs. BCG menA expression 
was determined by RT-PCR and normalised to 16S rRNA expression. Each bar represents data 
from pooled RNA from 3 to 4 mice. p.i. = post-infection.  
 
Analysis of BCG RNA using RT-PCR at the same two time points showed that 
menA gene expression markedly increased in bacteria recovered from spleen and lung 
(fig. 10b), suggesting an increasing bacterial requirement for MK with chronicity of 
infection in vivo. Notably, bacterial counts in these two organs were also higher at day 60 
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increase further (fig. 10b). Thus, we concluded that increase in BCG requirement for MK 
may be associated with the extent of bacterial load in respective organs. 
To determine the host tissue response in the infected mouse, histology of the 
organs of uninfected mice were compared with the day 60 infected mice (fig. 11). 
Infected mice had clear evidence of a chronic inflammatory process; the organs showed a 
dense cellular infiltrate especially at the periarterial areas. There were several distinct 
granulomas typical of the cellular immune response to mycobacterial infection; these 
were noted in the parenchyma of the lung, spleen and liver. 






















Figure 11. Pathological features observed in infected murine tissues 
Histopathology studies (H&E, x 40) of organs harvested from Balb/c mice infected with 108 cfu 
BCG i.v. 60 days after infection (right: b, d, f) compared with uninfected mice (left: a, c, e). Arrows 
denote areas of granuloma formation. Sections are representative of tissues obtained from 4 
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2.3.4 Vitamin K1 treatment inhibited growth of BCG in vitro.   
Vitamin K1 (phylloquinone) is a structural analogue of MK. The next experiment 
was carried out as a preliminary investigation of whether exogenous quinones could 
influence endogenous men gene expression and growth of BCG. Because of the earlier 
observation that men genes were most upregulated during growth under conditions of 
progressive oxygen depletion (Wayne in vitro latency model), stirring Wayne cultures 
were used to test the effects of vitamin K1. A small-scale experiment (not shown) was 
conducted to find a suitable working concentration for vitamin K1, and based on the 
results, 12 µg/ml was chosen. At this concentration, vitamin K1 inhibited growth of BCG 
in vitro during anaerobiosis-induced NRP as shown by optical density reading (fig. 12a) 
and colony enumeration (fig. 12b). Based on the colony counts, the extent of growth 
inhibition due to vitamin K1 (fig. 12c), was initially low (26 to 27%) prior to the NRP-1 
stage but increased sharply on days 8 and 12 (75% and 82% respectively) upon entry into 
NRP-2. This trend was not precisely paralleled in the absorbance readings, which failed 
to fully reflect the extent of bacterial death particularly during NRP stages. The reasons 
for this discrepancy may be significant with respect to the action of vitamin K1 on 
‘dormant’ BCG, this will be discussed later. The growth inhibition in vitamin K1-treated 
stirred cultures was associated with markedly higher levels of expression of menA on day 
12 at the late NRP-2 phase, which was the peak of hypoxia (fig. 12d). The above 
experiments thus showed that under conditions of oxygen limitation, vitamin K1 can act 
as a growth inhibitor of BCG and suggest that the inhibition is associated with an 
increased bacterial requirement for MK, particularly at NRP-2 stage during the treatment. 
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It provides a preliminary indication that exogenous quinones significantly affect 
mycobacterial endogenous MK requirements. 
Based upon these results studying cultures treated with one single concentration 
of vitamin K1, a larger scale experiment testing the activity of different MK structural 
analogues (vitamin K1, K2 and K3) at a range of concentrations was performed in 
subsequent experiments described in chapter 4.  

























Figure 12. Effects of vitamin K1 on BCG in state of non-replicating 
persistence 
(a) Growth curve (OD at A600) of BCG with vitamin K1 treatment (12 µg/ml) or with diluent alone 
(‘control’), in stirring cultures using the Wayne model. Each point is the mean of 3 to 10 replicate 
tubes per time-point, error bars represent 2SD. (b) Colony-forming units in treated and control 
stirred cultures. Asterisks indicate significant differences between treated and untreated tubes (p 
<0.05). (c) Extent of growth inhibition by vitamin K1 in treated stirred cultures, as determined by 
optical density and by colony-forming units. % inhibition is calculated as 100% - (treated/control) x 
100%.  (d) Normalised menA expression levels in treated and control stirring cultures at days 8 
and 12 (corresponding to early and late stages of NRP-2 respectively), were obtained. The data 
shows the ratio of menA expression in treated over control tubes, indicating the fold increase in 
menA expression in vitamin K1-treated over the untreated cultures.   
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2.4 DISCUSSION 
The ability of Mycobacterium tuberculosis (MTB) to remain latent in 
immunocompetent individuals is a characteristic feature of MTB infection.  There is 
increasing interest in the mycobacterial mechanisms involved in adaptation to prolonged 
intracellular survival during this latent phase, because these mechanisms may be the 
‘Achilles heel’ of MTB that could be targeted for killing the pathogen. The adaptation to 
hypoxia appears to be one of the important mechanisms (Timm et al., 2003). In human 
and murine TB infection, the central region of the human granuloma becomes devoid of 
blood vessels and hypoxic (Tsai et al., 2006; Ulrichs and Kaufmann, 2006), so latent 
mycobacteria must adapt to hypoxia.  
Under anaerobic growth conditions, the facultative anaerobe, Escherichia coli (E. 
coli) (Bishop et al., 1962; Lester and Crane, 1959) utilises menaquinone (MK) as the 
major electron carrier between membrane-bound complexes in the ETC, preferentially 
over ubiquinone (UQ). This is due to the differences in mid-point potential between UQ 
and MK – MK has a lower redox potential than UQ. Thus, MK is more suitable for an 
anaerobic respiratory chain with lower potential electron acceptors such as fumarate, 
whereas UQ is well-suited for oxygen and nitrate respiration (Soballe and Poole, 1999). 
This is evidenced by the observation that E. coli cells grown aerobically had four to five 
times higher UQ concentration than MK concentration. Under anaerobic conditions, UQ 
concentrations are lowered 10-fold and reach only one-third of the E. coli MK 
concentrations (Wallace and Young, 1977a, b; Wissenbach et al., 1992). Therefore, by 
analogy, it is reasonable to hypothesise that MK is required more than UQ in latent 
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mycobacteria, based on Wayne’s observations that latency is an adaptation to reduced 
oxygenation. 
MKs are present in Mycobacterium phlei (Azerad et al., 1965) and MTB (Collins 
et al., 1977; Noll and Jackim, 1958). The functionality of MK was demonstrated when it 
reactivated the NADH oxidase system isolated from MTB (Kusunose and Goldman, 
1963; Segel and Goldman, 1963). Although MTB has traditionally been regarded as an 
obligate aerobe, the occurrence of fully reduced cytochromes in MTB indicates its ability 
to adapt to the changing aerobicity by the utilisation of anaerobic or facultative anaerobic 
metabolic pathways (Segal, 1984; Barclay et al., 1989). In addition, the MTB genome 
contains homologues of almost all of the E. coli men genes responsible for menaquinone 
biosynthesis (Cole et al., 1998). Therefore, mycobacteria are likely to synthesise MK by 
a pathway similar to E. coli.  
Actively replicating MTB cultures die rapidly when abruptly deprived of oxygen 
(Wayne and Diaz, 1967). However, MTB can shift into a state of dormancy or non-
replicating persistence when allowed to adapt gradually to a decreasing supply of oxygen 
(Wayne, 1976). The link between MTB dormancy and hypoxia was proven when Wayne 
demonstrated that MTB in the NRP state are ‘dormant’ and yet still ‘persistent’ (not 
dead) because they undergo synchronised division about 12 h after re-aeration of the 
dormant cultures (Wayne, 1977).  This in vitro model has now been accepted in the field 
as representative of the adaptation of MTB to growth-suppressive conditions in 
inflammatory and necrotic tissues. The evidence supporting the probability that Wayne 
cultures reflect the physiological state of in vivo mycobacteria may be summarised as 
follows. Viable tubercle bacilli have been recovered from approximately 20% of oxygen-
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deprived closed tuberculous lesions in surgical specimens from human subjects in whose 
sputum the bacilli could no longer be detected (Salkin and Wayne, 1956). Gene 
transcriptional changes in MTB adaptation to hypoxia in vitro are similar to those 
observed in MTB recovered from infected murine tissues (Shi et al., 2003; Stewart et al., 
2005; Timm et al., 2003). MTB that has undergone metabolic shift-down into latency for 
persistence in the host are characteristically partially or complete resistant to 
conventional anti-TB drugs, hence the high incidence of re-activation if treatment is not 
prolonged (Parrish et al., 1998). The bacilli grown under progressive oxygen depletion in 
Wayne cultures are similarly resistant to the effects of anti-TB drugs and only susceptible 
to metronidazole, a drug that acts specifically on anaerobes (Wayne and Sramek, 1994). 
It is for the above reasons that we have chosen the Wayne model as our in vitro model of 
mycobacterial dormancy. 
Several key mycobacterial genes are up-regulated in dormancy – it is suggested 
that such genes provide clues to pathways necessary for mycobacteria intracellular 
persistence (Boon et al., 2001; Boon and Dick, 2002; Desjardin et al., 2001). That was 
the basis for the study of men genes in the present study. The results showed for the first 
time that genes of the BCG MK biosynthetic pathway are up-regulated under conditions 
of low oxygen tension, both in an in vitro model of non-replicating persistence and in 
vivo during murine infection. The men gene expression studies (fig. 9) revealed 
differential BCG MK requirements in aerobic and hypoxic conditions.  Based on the 
assumption that a requirement for MK leads to up-regulation of genes involved in its 
biosynthesis, the data provide strong evidence that MK requirements are markedly 
increased in BCG during hypoxia-induced dormancy. The dynamics of the changes in 
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men gene expression relative to the growth curve are also significant. The data show that 
the magnitude of up-regulation of men gene expression is linked to the extent of hypoxia. 
Therefore, at the time-points where the bacteria were growing aerobically (early log 
phase in shaking cultures), there was a decline in men gene expression, whereas with 
progressive hypoxia in stirred tubes (NRP) and even in aerobically-grown tubes (at 
saturation phase), the men gene expression increased in parallel. Most importantly, men 
gene expression declined upon culture re-aeration, corresponding once again with aerobic 
growth, thus demonstrating that requirement for MK is reversible upon re-establishment 
of aerobicity.  The dynamics of men gene transcription thus showed clearly the link 
between mycobacterial MK requirement, hypoxia and dormancy in this model. 
Importantly, the specificity of requirement for MK was distinguished from UQ since 
expression of ubiE was significantly greater in shaking cultures. The small increase in 
expression of ubiE under both aerobic and anaerobic conditions could be in response to 
other factors in the environment such as pH changes (Hill et al., 1990).  
Up-regulation of menA expression in BCG grown under nutrient-limitation and 
within macrophages (intracellular BCG) has been shown by our laboratory (data not 
shown). In the present thesis, the menA expression profile of BCG extracted from mouse 
organs (fig. 10b) revealed an increase in expression at a later stage of infection (day 60) 
relative to 35 days post-infection in the spleens and lungs. This is consistent with 
observations that after the first 2 to 4 weeks of unimpeded growth in the host (Orme, 
1994), the immune system starts to control bacterial replication and bacterial numbers 
reach a plateau. However, it takes some time before host immunity can substantially 
reduce bacterial numbers in the lung or spleen after this point, thus there is a period of 
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persistent or chronic infection (Flynn et al., 1998; Orme, 1988). This is characterised by 
the persistence of high numbers of bacteria in the lungs and spleen. The increased 
expression of menA could be related to exposure of the BCG to hypoxia in the host and 
perhaps other host mycobactericidal mechanisms (e.g. production of reactive nitrogen 
intermediates) during this phase of persistent infection. The exposure of MTB to low 
concentrations of nitric oxide is known to up-regulate the DosR-S regulon (Roberts et al., 
2004; Voskuil et al., 2003). This global ‘stress-response regulator’ is also up-regulated 
under microaerophilic conditions (Sherman et al., 2001; Voskuil et al., 2003). Taken 
together, these observations support the notion that menA up-regulation in vitro (fig. 9) 
and in vivo (fig. 10) is a BCG adaptive response to the host environment. It therefore 
suggests that MK has a role in bacterial survival under conditions of 
dormancy/persistence.  
One MTB study using transposon mutagenesis (Sassetti et al., 2003) reported that 
menA, menB and menG genes were non-essential genes for survival, whereas menD, 
menC and menE transposon mutants were slower growing in vitro when subjected to a 
second plating on agar. This does not necessarily mean that the early men genes like 
menD, menC and menE are more important than the late men genes (menA, menB and 
menG). Our observations of the transcript profiles of men genes in fig. 9 showed that the 
late men gene, menA, was the most highly induced gene among the other early men genes 
studied. This indicates that under conditions where MK is required, the late men genes 
are the ones that most reflect the physiological needs of the bacteria. Several reasons for 
slower growth of early men mutants and apparent lack of growth disadvantage of late 
men transposon mutants could be suggested. The transposon could have been inserted in 
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a non-essential region of the gene that did not disrupt the gene function to give an 
observable phenotype. The authors also admitted that the stringent criteria used in the 
study most likely excluded some mutants with actual growth defects. The level of 
physiological complexity in the bacteria may have obscured the actual requirement of the 
gene, especially since only a single growth criterion (growth on minimal agar) was 
investigated. It is most likely necessary to construct targeted MTB men mutants by 
homologous recombination, with substantial portion of the gene replaced, and to subject 
it to various conditions related to mycobacterial dormancy in order to be certain of the 
essentiality of each gene for persistence. 
Although many microarray studies reviewed by Kendall et al. (Kendall et al., 
2004b) were carried out to elucidate the global MTB transcriptome in response to in vitro 
conditions of stress, such as acid (Fisher et al., 2002), hypoxia (Bacon et al., 2004; 
Muttucumaru et al., 2004; Voskuil, 2004), starvation (Betts et al., 2002; Hampshire et al., 
2004), nitric oxide (Ohno et al., 2003; Voskuil et al., 2003), interaction with 
macrophages (Schnappinger et al., 2003) and mice (Talaat et al., 2004), the MK 
biosynthetic pathway has not been investigated in a gene-directed manner for any 
mycobacterium to date. The above studies fail to mention whether the men genes are 
changed under the conditions studied except where Voskuil et al. demonstrated that the 
men genes in cultures at NRP were not up-regulated more than 3-fold relative to mid-
exponential phase cultures in a microarray performed using the Wayne model (Voskuil et 
al., 2004). Although, this work studied similar time-points as our studies, the typical 
method of using all gene-specific spots on the microarray to normalize the reference and 
experimental fluorescence intensities from each spot was not used. Instead, a simple 
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experimental and computational method to reduce normalisation errors was used and that 
this normalisation protocol has not been systematically evaluated, with admission from 
the authors that the fold-change ratios should not be interpreted as precise induction and 
repression ratios.  
Differences between studies are not likely to be due to investigations of BCG 
versus MTB as the men genes are identical in the two species (100% similarity, except 
for the gene, menE, which showed 99% similarity) and overall there has been no 
published evidence that respiratory metabolic pathways differ between them. It is evident 
that microarray studies carried out in similar in vitro and in vivo mycobacterium studies 
have reported diverse results, and it has already been commented by authors attempting 
to do a meta-analysis, that the models are not always easy to reproduce (Kendall et al., 
2004b). If microarray data are not validated by quantitative RT-PCR, some smaller 
mRNA changes may not be observed as differential gene expression. It was for this 
reason that we chose to utilise quantitative RT-PCR instead of microarray studies, as we 
had a specific gene set to target in our studies. 
The data from the present studies of vitamin K1 (menaquinone analogue) revealed 
an inhibitory effect on BCG growth during dormancy and significantly reduction in the 
ability of the dormant BCG population to re-activate from hypoxia-induced dormancy 
(fig. 12). We hypothesise that vitamin K1 could be limiting the ability of the BCG under 
those conditions to utilise its native or endogenous MKs, possibly by competitive 
inhibition. This hypothesis is supported by the evidence that menA expression is 
concurrently upregulated at the NRP-2 stage in treated cultures (fig 12d), implying an 
increased demand for production of endogenous MK. Such a mechanism can explain the 
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inhibitory effects exerted by 6-cyclo-octylamino-5,8-quinolinequinone (CQQ), which is 
active against MTB (Gangadharam et al., 1978). The common feature between the CQQ, 
vitamin K1 and natural MTB menaquinone is the naphthoquinone ring.  
Perturbations to electron transport in mycobacteria are highly tuberculocidal in 
vivo. An MTB cydC mutant (defective in the cytochrome bd oxidase-associated 
transporter) displayed reduced ability to survive the transition from acute to chronic 
infection. This provided initial evidence that the bd oxidase pathway is required to re-
route electron flow for MTB adaptation to host immunity by entering into different 
respiratory states (Shi et al., 2005). The increased expression of the menA gene after 
contact with vitamin K1 under hypoxic conditions (fig. 12d) suggests that vitamin K1 
treatment results in increased requirement for endogenous MK activity. We hypothesise 
that exogenous vitamin K1 competes with MK and in the bacterial electron transport 
chain, but vitamin K1 is poor at electron transfer in mycobacteria. The up-regulation of 
menA in vitamin K1-treated cultures is a bacterial response to the disrupted electron flow 
and compensatory increased synthesis of MK may be able to displace the exogenous 
quinone and restore MK in the redox cycle, necessary for mycobacterial membrane and 
energy homeostasis. The postulation that vitamin K1, as an MK analogue, disrupts the 
electron flow mediated by endogenous MK, would not only account for the increased 
menA expression, but also the 90% inhibition of BCG survival upon re-aeration (fig. 12b-
c).  
It is noteworthy that there was a significant discrepancy between bacterial growth 
inhibitions demonstrated by broth turbidity readings versus actual colony counts (fig. 
12c) particularly from day 8 onwards when the bacteria were entering NRP-2. Optical 
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density does not distinguish between viable and non-viable bacteria, but colony counts 
reveal the true ‘survivors’ or ‘persistors’ at the stage of dormancy. Thus, with vitamin K1 
treatment, it appears that at day 2 and day 5, only up to 20% of the bacteria were 
inhibited in growth, and the rest were able to progress to the NRP-2 stage. At the early 
exponential phase when oxygen was less limited, there was only a small difference in 
colony counts between treated and control tubes (fig. 12b). However, after NRP-2 stage 
(severe oxygen limitation); whereas turbidity measurements did not change much, there 
was a significant decline in viability such that only 10% of the treated cultures in 
dormancy (NRP-2) were able to persist to form colonies upon re-aeration (fig. 12c). This 
suggests that vitamin K1 has a greater impact on BCG viability after the bacteria enter 
dormancy induced by oxygen-limitation. This has two important implications. First, if the 
postulation that vitamin K1 blocks endogenous MK activity is true, then there is evidently 
greater need for such activity by mycobacteria during the NRP-2 or dormant phase – this 
supports results of our menA expression studies at different phases. Second, it is 
consistent with the notion that vitamin K1 treatment would be preferentially effective 
against dormant than actively growing mycobacteria, thereby holding some potential as a 
compound which targets persistent mycobacteria. 
There is no known mechanism for the uptake of MK in mycobacteria. A possible 
reason for how exogenous MK could be taken up into the bacterial cell must be inferred 
from other organisms. Bacillus subtilis secretes a vitamin K2-binding factor into the 
extracellular medium which is specific for only vitamin K2 and not menadione, which is 
another napthoquinone analogue (Ikeda and Doi, 1990). This may be to facilitate the 
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delivery of a highly water-insoluble molecule like MK across the cell membrane. Perhaps 
a related vitamin K1 uptake system exists for in mycobacteria.  
Latent MTB in host macrophages down-regulate their metabolic activity. 
Conventional drugs that target active processes in bacteria such as protein synthesis are 
therefore ineffective and fail to eradicate persistent mycobacteria. There is clearly a need 
for drugs that target latent mycobacteria. The experiments presented in this chapter 
illustrate that persistent mycobacteria can up-regulate their biosynthetic pathways in a 
specific response to survive intracellular conditions encountered in the host, and 
generation of MK is one such pathway that responds to hypoxia. We therefore believe 
that understanding the role of MK biosynthesis in mycobacteria is important due to its 
potential as a target in the design of drugs against latent MTB, which remains largely 
elusive in the current chemotherapy regime for TB.   
  96 
CHAPTER 3: CHARACTERISATION OF menA KD BCG 
3.1 INTRODUCTION  
Having shown the increased requirement for menaquinone (MK) in BCG 
adaptation to hypoxia and survival in vivo (chapter 2), we hypothesised that reduced 
production of MK will negatively influence its ability to survive conditions inducing 
mycobacterial dormancy. Hence, in this chapter, a BCG menA gene ‘knock-down’ strain 
(menA KD) was constructed, and results are presented tracking its survival under various 
dormancy-related conditions attempting to mimic the intracellular phagosomal 
microenvironment.  
These ‘dormancy model’ conditions, to which the BCG strains were subjected, 
are based on models established in published work. Those, in turn, were based on 
evidence that the host microenvironment is an anoxic environment, containing reactive 
nitrogen intermediates (RNI) and reactive oxygen intermediates (ROI) that exert 
oxidative stress (Ohno et al., 2003; Voskuil et al., 2003). It is also a nutritionally 
deprived environment (Betts et al., 2002). MTB adaptation to these conditions involves 
up-regulation of genes that are responsive to hypoxia, oxidative and nitrosative stress as 
well as alternative carbon and lipid metabolism (Kendall et al., 2004a; McKinney et al., 
2000; Schnappinger, 2001; Schnappinger et al., 2003; Shi et al., 2005; Timm et al., 
2003). However, it is not clear whether MK may contribute to adaptation to all or merely 
some of these conditions within the host. Hence, in vitro conditions designed to mimic 
different aspects of the host intra-phagosomal microenvironment were studied in this 
chapter, in order to understand if MK is required for mycobacterial survival. It was 
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assumed that an MK-deficient BCG would be impaired in survival under those specific 
conditions in which MK plays a crucial role. 
 
Objectives of the work presented in this chapter: 
(1) To construct a BCG strain with reduced menA gene expression (menA KD) by 
episomal introduction of anti-sense menA gene, and to verify that the strain has 
reduced MK production.  
(2) To study the effects of reduced MK on BCG survival under the following 
conditions simulating different aspects of the host intra-phagosomal 
microenvironment: 
a.  Aerobic growth and adaptation to hypoxia-induced persistence (Wayne 
model)  
b. Growth in minimal nutrient medium as a model for nutrient starvation 
c. Exposure to hydrogen peroxide as a model for oxidative stress 
d. Exposure to acidified sodium nitrite as a model for nitrosative stress, and 
to analyse the anaerobic nitrate reductase activity  
e. in vitro infection of murine macrophages and pneumocytes, and to test the 
cytotoxicity induced  
f. in vitro infection of human blood monocyte-macrophages 
g. in vivo murine infection, and to analyse the changes in expression profile 
of genes involved in the respiratory and metabolic pathways of 
intracellular bacteria 
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(3) To investigate the effects of exogenous vitamin K1 on growth and endogenous 
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3.2 MATERIALS AND METHODS 
 
3.2.1 Bacterial strains and growth conditions 
Mycobacterium bovis bacille Calmette-Guérin (BCG) Pasteur strain and 
Escherichia coli (E. coli) DH5α strain were used for generating transformants in this 
chapter.  BCG was cultured in Middlebrook 7H9 broth or 7H10 agar (Difco) 
supplemented with oleic albumin-dextrose catalase enrichment (BD), and 0.1% Tween 
80. Clumping of broth-grown BCG was minimised by methods described in chapter 2. 
Viable BCG colony-forming units (cfu) were determined by dilution plating. E. coli 
DH5α strain was used for plasmid propagation and grown using Luria-Bertani (LB) broth 
and agar (Difco).     
 
3.2.2 Cloning of menA anti-sense and sense plasmids  
Primers for amplifying the MTB menA gene were designed based on the gene 
Rv0534c in Tuberculist (http://genolist.pasteur.fr/TubercuList/), which is 100% identical 
to the equivalent BCG0578c in BCGList (http://genolist.pasteur.fr/BCGList/). To 
generate the anti-sense construct, the forward and reverse primers 5’-
gcggatccattagctcaactgaccaaacgc-3’ and 5’-gcgaattcgtggccagtttcgcacagtg-3’ (flanked 
respectively by BamH1 and EcoR1 restriction sites) were used, with genomic DNA from 
Mycobacterium tuberculosis H37Rv strain  (Cole et al., 1998) as template. To generate 
the sense construct, the respective primers were 5’-gcggatccagtggccagtttcgcacagt-3’ and 
5’- gcgaattcttagctcaactgaccaaacgc-3’. These amplicons were cloned into plasmid, pUC18, 
which carries a gene for antibiotic resistance to ampicillin, and a lacZ gene for the 
enzyme β-galactosidase. The plasmids were used for E. coli (DH5α) transformation 
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followed by screening for white colonies bearing the plasmids on plates containing 40 µl 
X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) (20 mg/ml), 40 µl IPTG 
(isopropyl-β-D-thiogalactopyranoside) (100 mM) and 20 µg/ml ampicillin (antibiotic 
selection marker). Plasmid DNA was extracted from the colonies, and restriction enzyme 
analysis was performed to verify the plasmid inserts. Sequencing of the cloned gene 
inserts from the N-terminus of β-galactosidase on the plasmid was conducted using the 
forward (M13F): 5'-GTAAAACGACGGCCAG-3' and reverse sequencing primers 
(M13R): 5'-CAGGAAACAGCTATGAC-3' and this confirmed the identity and sequence 
of the two inserts. The mycobacterial episomal plasmid pMV261 (Stover et al., 1991) 
was the parental plasmid used for generating the sense and anti-sense plasmids. The 
BamH1 and EcoR1-digested sense and anti-sense DNA were directionally cloned behind 
the heat-shock protein promoter in to generate sense (pMV261-SmenA) and anti-sense 
(pMV261-ASmenA) plasmids. These constructs and an empty pMV261 vector control 
(without any gene insert) were used for BCG transformation by electroporation. 
Kanamycin-resistant transformants were analysed by recovery of the relevant plasmids 
for restriction enzyme analysis.  
 
3.2.3 Bacterial transformation 
For chemical transformation of E. coli DH5α, cells were grown to mid-log phase 
(OD A600= 0.7), harvested by centrifugation and treated with CaCl2 to become competent 
cells. Briefly, the cells were left on ice for 10 min, centrifuged at 2000 x g for 15 min at 
4°C. The supernatant was decanted and the cell pellet was gently resuspended in cold 0.1 
M CaCl2. The cells were left on ice for another 20 min, prior to centrifugation as stated. 
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The supernatant was discarded and cell pellet resuspended in half the volume of cold 0.1 
M CaCl2, after which the cells were dispensed into 300 µl aliquots, snap-frozen in liquid 
nitrogen before transfer to -80°C for storage. To chemically transform cells, competent 
cells were mixed with the 1 µl of plasmid DNA on ice for 15 min, followed by a brief 
heat shock at 42°C for 30s. Then, cells were incubated in 1 ml of LB medium and 
allowed to express the kanamycin-resistance gene for 60 min at 37°C, shaking at 200 rpm 
for aeration prior to plating on LB agar with 20 µg/ml kanamycin (Sigma).  
Competent BCG cells were prepared by growing cells to density A600= 0.6-0.9 
and harvesting by centrifugation at 2000 x g for 15 min at 18°C.  The harvested cells are 
washed thrice with 10% sterile glycerol at room temperature, resuspending cells each 
time very gently and thoroughly. The volume of glycerol used was reduced by half after 
every wash i.e. 40 ml to 20 ml to 10 ml. The final resuspension volume was 1/100 of the 
initial culture volume in 10% sterile glycerol at room temperature. BCG competent cells 
were preferably used fresh or snap-frozen in 0.2 ml aliquots in liquid nitrogen and kept at 
-80°C for storage. For electroporation, 0.2 ml of cells were mixed with plasmid DNA in 
microcentrifuge tubes for 10 min at room temp and subsequently transferred to a 0.1 cm 
electroporation cuvette pre-cooled to 4°C. Electroporation was conducted at 1000Ω, 1.7 
kV, 25 µF (BioRad Gene Pulser). Immediately after electroporation, 1 ml of 7H9 without 
antibiotic was added and the cells were grown overnight at 37°C, shaking at 200 rpm for 
aeration to allow expression of antibiotic resistance. The transformants were plated on 
selective plates (7H10 or 7H11 with 20 µg/ml kanamycin) and incubated at 37°C for 3-4 
weeks. 
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3.2.4 Lipid extraction and thin layer chromatography 
Lipid extraction and analysis was performed according to Minnikin’s method 
(Minnikin et al., 1984) for extracting non-polar lipids from different BCG strains 
according to experimental conditions. A fixed dry weight of each bacterial pellet (50 mg) 
was lyophilised and extracted with 50 ml chloroform-methanol (2:1). The chloroform-
methanol-lipid mixture was evaporated to dryness and the lipid extracts were re-
solubilised in 1 ml of acetone. The lipid extracts were applied to a Merck TLC F254 glass-
backed plate (20x10cm) and developed in petroleum ether-acetone (95:5 v/v). Vitamin K1 
(Sigma) was used as a standard to locate bands corresponding to menaquinones (RF 0.8-
0.9) (Minnikin et al., 1993) . Purified quinones were revealed by brief irradiation under 
short wavelength UV at 254 nm and the spots captured (CHEMIgenius2, Bioimaging 
system).   
 
3.2.5 Wayne model of non-replicating persistence 
The established Wayne model for inducing a state of non-replicating persistence 
in mycobacteria was used (Wayne and Hayes, 1996) and was carried as described in 
chapter 2. The only exception was that the transformed BCG strains used were grown in 
7H9 broth with kanamycin to maintain the plasmids in BCG.  
 
3.2.6 Vitamin K1 treatment of Wayne cultures  
Recombinant BCG broth cultures in 7H9 were set up according to the Wayne 
model as described above and treated with vitamin K1. Vitamin K1 (Sigma) was diluted 
in dimethylsulfoxide (DMSO) to a stock concentration of 250 mg/ml and stored at -20°C 
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protected from light. The stock concentration was serially diluted until a final 
concentration of 1.25 mg/ml in 7H9 with 0.5% DMSO and 20 µg/ml kanamycin was 
achieved. Vitamin K1-treated and control tubes (diluent of 0.5% DMSO) were set up in 
triplicates. Bacteria were harvested after 9 days and plated in triplicates for colony 
enumeration. For lipid extraction, the bacteria harvested were washed 5 times with sterile 
water and pellet was collected by centrifugation at 2,500 g for 15 min prior to 
lyophilisation. Lipids were extracted and analysed by thin layer chromatography 
(described above). 
 
3.2.7 Nutrient starvation 
Control and menA KD BCG cultures were grown in roller bottles to mid-log 
phase in 7H9 broth. Bacterial cultures were diluted to ODA600 of 0.04 in Hartmans De 
Bont (HDB) media (Smeulders, 1999), a carbon-limited minimal medium for 
mycobacteria containing 0.02% glycerol (HDB components in appendix 1) or 7H9 broth. 
They were grown in triplicate 25 cm2 vented tissue culture flasks over five days at 37°C.  
Growth was monitored by spectrophotometric turbidity measurements and by plating on 
7H10 agar.  
 
3.2.8 Susceptibility to reactive oxygen and nitrogen intermediates 
Mid-log phase BCG cultures were diluted to a final ODA600 of 0.04 in 7H9 
containing 0.35% hydrogen peroxide or acidified sodium nitrite at 6mM (pH 5.3). 
Controls were set up with 7H9 alone. The cultures were grown in triplicate 25 cm2 vented 
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tissue culture flasks at 37°C over five days. Growth was monitored by spectrophotometric 
turbidity measurements and by plating on 7H10 agar.  
3.2.9 Nitrate reductase assay 
BCG cultures were grown in roller bottles till mid-log phase. To test for nitrate 
reductase activity, 1 x 106 bacilli ml-1 were incubated for 10 days in triplicate 25 cm2 
vented tissue culture flasks within an anaerobic workstation (MACS-MG1000; DW 
Scientific). The cultures were grown in MB medium according to published studies 
(Weber et al., 2000). Briefly, 1 L of MB medium contains 1 g KH2PO4, 2.5g Na2HPO4, 2 
g K2SO4 and 2 ml trace elements (per litre contains 40 mg of ZnCl2, 200 mg of 
FeCl3·6H2O, 10 mg of CuCl2·4H2O, 10 mg of MnCl2·4H2O, 10 mg of Na2B4O7·10H2O 
and 10 mg of (NH4)6Mo7O24·4H2O). This medium was supplemented with 0.5 mM 
MgCl2, 0.5 mM CaCl2, 0.2% glycerol, 0.05% Tween 80, 10% ADS and 10 mM NaNO3 
and filter-sterilised. For measurement of nitrite production at various time points, 0.1 ml 
of sulphanilic acid (1% sulfanilamide in 5% phosphoric acid) and 0.1 ml of N, N-
dimethyl-1-naphthylamine dihydrochloride (dissolved in distilled water) were added into 
1 ml of culture for 30 min. The supernatants from triplicate flasks were harvested for OD 
readings at A540 using an automated microtitre plate reader (Tecan-Magellan) and 
compared with known standard concentrations of nitrite from 10-6 to 10-3 M. Growth was 
determined by colony counting on 7H10 agar.  
 
3.2.10 Intracellular infection and cytotoxicity  
J774A.1 murine cells (ATCC TIB-67) were cultured at 37°C in 5% CO2 
atmosphere with DMEM supplemented with 10% fetal calf serum (Biological Industries) 
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and 10 mM HEPES (Sigma) using 75cm2 flasks (Falcon). The human lung cell line A549 
(ATCC, CCL-185) was cultured in Ham’s F12 medium (Gibco) supplemented with 10% 
fetal calf serum (Dobos et al., 2000).  
The macrophages were activated with 0.35 µg/ml of phorbol 12-myristate-13-
acetate (Sigma) 24 h before infection. Using 12-well plates, 1 x 106 macrophages were 
seeded per well in triplicates and infected with BCG strains (M.O.I.=1:10). Ferric 
ammonium citrate (50 µg/ml) was added to promote the intracellular survival of BCG 
during infection. Extracellular bacteria were killed with gentamicin (0.1 mg/ml) added 2 
h post-infection and cells were washed after 2 h to remove gentamicin. At various time-
points, supernatants from triplicate wells of infected macrophages were collected for 
measurement of lactate dehydrogenase release (described below). Macrophages were 
washed thrice with complete medium and lysed with 0.1% saponin for 5 min. The lysates 
from triplicate wells were centrifuged at 200 x g, 5 min at 4°C to remove cellular debris 
and the supernatants collected were centrifuged again at 2000 x g, 15 min at 4°C to 
collect the bacterial pellet. Colony enumeration was carried out by serial dilutions on 
7H10 agar. 
 
3.2.11 Measurement of Lactate dehydrogenase release from infected cells 
The release of cytoplasmic enzyme lactate dehydrogenase (LDH) from BCG-
infected cells was used as an indication of cell lysis. LDH was measured at 4, 24 and 48 h 
post-infection using the Cytotox 96® Non-radioactive Cytotoxicity Assay kit (Promega; 
USA) according to manufacturer’s instructions. Briefly, 50 µl of supernatant were added 
into an equal volume of re-constituted substrate mix in a flat-bottom 96-well plate and 
incubated in the dark at room temperature for 30 min. The reaction was stopped with 
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50 µl of stop solution and readings were taken at OD A490 using an automated plate 
reader (Tecan-Magellan). The percentage of lysed cells was determined using the 
following calculation: [(release of LDH from infected cells – background release)/ 
(maximum release of LDH – background release)] x 100. 
 
3.2.12 PBMC extraction and infection 
Peripheral blood mononuclear cells from anonymous healthy human subjects 
were isolated by differential centrifugation on Ficoll-Paque PLUS (Amersham 
Biosciences), and 4 x 105 cells per well were cultured in 96-well plates in RPMI-1640 
containing 10% fetal calf serum. After overnight incubation, non-adherent cells were 
discarded and adherent cells were washed twice before use. These peripheral blood 
monocyte-derived macrophages were infected with single-cell suspensions of BCG at 
multiplicity of infection (MOI) 1:1 for 24 h. Extracellular bacteria were killed with 
gentamicin (0.1 mg/ml) added 2 h post-infection and cells were washed after 2 h to 
remove gentamicin. Prior to cell lysis, the supernatants from triplicate wells were 
collected for measurement of tumour-necrosis factor alpha (TNF-α). The macrophages 
were then lysed using 0.1% saponin for 5 min. The lysate was subjected to differential 
centrifugation at 200 x g, 5 min at 4°C to remove cellular debris and at 2000 x g, 15 min 
at 4°C to collect the bacterial pellet.  The bacteria were serially diluted and plated in 
triplicates on 7H10 agar. Colony-forming units (cfu) were counted and recorded as a 
measure of viable intracellular mycobacteria in each well. 
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3.2.13 Measurement of TNFα from infected macrophages 
The production of TNF-α from infected cells was measured using the TNF-α 
ELISA kit (BD Biosciences OpEIA) according to the manufacturer’s instructions.  
Briefly, the culture supernatants from triplicate wells were added to TNF-α specific 
capture antibody-coated wells in a 96-well flat-bottom plate. After incubation and 
washing to remove unbound cytokines, the detection antibody coupled with avidin-HRP 
reagent was added and further incubated.  A substrate solution was subsequently added 
after washing to induce a coloured reaction product and was kept in the dark. The 
reaction was terminated with stop solution after 30 min and the plate was read at an 
absorbance of 450 nm using an automated microtiter plate reader (Tecan-Magellan). The 
intensity of the coloured reaction is a direct measure of the concentration of the cytokine 
TNF-α present in the culture supernatant. Quantitation of unknown samples was based on 
a standard curve based on a dilution series of recombinant protein standards.  
 
3.2.14 Infection of mice 
The protocols used were approved by the departmental animal care committee. 
Broth cultures of various transformed BCG strains were washed with PBS and 
centrifuged at 2000 x g for 10 min to recover the pellet – this washing procedure was 
done 5 times to remove traces of kanamycin. Female Balb/c mice (6-8 weeks old) were 
injected with 108 cfu in 0.1 ml volumes of PBS containing either parental or anti-sense 
BCG via the lateral tail vein. Organs were harvested at indicated times, incubated in 200 
U collagenase D (Roche) at 37°C for 1 h and homogenised in PBS with 0.05% Tween 80 
using 60µm cell strainers (BD Biosciences). Homogenates were serially diluted and 
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plated onto kanamycin-supplemented 7H10 agar for colony enumeration at 37°C. The 
plates were read for colony counts after 3 to 4 weeks.   
 
3.2.15 BCG RNA isolation and removal of mammalian RNA 
 The methods used for studying gene expression in BCG recovered from infected 
mice are as described in chapter 2. 
 
3.2.16 Gene expression analysis  
Expression analysis of several mycobacterial genes, with 16S rRNA as control, 
was performed by reverse transcription and polymerase chain reaction (RT-PCR) as 
described in chapter 2.  The cycling parameters, primer pairs and product sizes for the 
genes are listed in Table 8. Results were expressed as [target mRNA]/ [16S rRNA].  
 
  109 
Gene Primer Sequences Annealing PCR product PCR parameters
temp (°C) (bp)
cydA (F) 5'-acgcacgccgactcagatac-3' 55 722 10 min at 96°C,  
40 s at 98°C, (40 cycles)
30 s at 55°C, 
(R) 5'-agcagccagcaccagatgac-3' 1 min at 72°C 
with a final cycle of 10 min at 72°C
devR (F) 5'-ggtcggcgatctgcttgttg-3' 55 479 10 min at 96°C,  
40 s at 98°C, (40 cycles)
30 s at 55°C, 
(R) 5'-gcgtcgtggtctggttgact-3' 30s at 72°C 
with a final cycle of 10 min at 72°C
frdA (F) 5'-cgtcgccggtcttgatgttc-3' 55 557 10 min at 96°C,  
40 s at 98°C, (40 cycles)
30 s at 55°C, 
(R) 5'-caatccgcacctggatctgg-3' 1 min at 72°C 
with a final cycle of 10 min at 72°C
narX (F) 5'-gtggagcggaccaccttgt-3' 55 100 10 min at 96°C,  
40 s at 98°C, (40 cycles)
30 s at 55°C, 
(R) 5'-gatctcggcggatctgcgta-3' 30s at 72°C 
with a final cycle of 10 min at 72°C
(F) 5'-cacagcgcaaccacctcgta-3' 55 631 10 min at 96°C,  
ndh 40 s at 98°C, (40 cycles)
30 s at 55°C, 
(R) 5'-ggcggcgtcaagcagaatca-3' 1 min at 72°C 
with a final cycle of 10 min at 72°C
(F) 5'-ctggcggcgtgcttaacaca-3' 55 718 10 min at 96°C,  
16S rRNA 40 s at 98°C, (40 cycles)
30 s at 55°C, 
(R) 5'-cgctcctcagcgtcagttac-3' 1 min at 72°C 
with a final cycle of 10 min at 72°C
 
Table 8. Table of PCR amplification parameters and primers for genes 
encoding enzymes involved in MK-dependent electron transport 
 
3.2.17 Statistics  
 Statistical comparisons for data of triplicate experiments were performed using 
Student t-test, and in all figures, data shown represent mean + 2 standard deviations 
unless otherwise stated. Each set of experiments was performed at least three times. The 
differences between groups were considered stastically significant if p<0.05.  
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3.3 RESULTS 
3.3.1 Reduced menA production in menA KD BCG 
Schematic diagrams of the cloned vectors are shown in figure 13. We introduced 
a plasmid carrying a menA anti-sense construct (fig. 13a) into wild-type BCG to generate 
a menA ‘knock-down’ strain (menA KD) and a menA sense construct (fig. 13b) for a 
menA ‘over-expressing’ strain (menA sense). The control strain carried an empty 
pMV261 (fig. 13c) without any gene insert (vector control). The cultures were grown 
under good aeration in roller bottles starting at a optical density reading of A600=0.040. At 
the early log phase (day 2), menA expression in the menA KD strain was approximately 
2.5 logs lower than in the control strain (fig. 14a). We also compared, by 
chromatography, the quantity of MK production in the menA KD strain and menA sense 
strain against the control strain, studying lipids extracted from the same dry weight of 
bacteria in each case. Using a previously published solvent system for mycobacterial 
lipid analysis (Minnikin et al., 1984), we observed that MK was reduced in the menA KD 
strain compared to the control strain (fig. 14b) whereas the menA sense BCG (bearing 
plasmid pMV261-SmenA) had more MK production. Thus, we verified that the anti-sense 
vector had reduced menA expression and menaquinone production in the menA KD strain 
whereas the sense vector led to increased menaquinone production.  
 The growth kinetics of the menA sense BCG (bearing plasmid pMV261-SmenA) 
was compared to the pMV261 vector control BCG under aerobic shaking conditions 
using the Wayne model (Wayne and Hayes, 1996). Interestingly, the menA sense BCG 
showed significant growth reduction by optical (OD) readings when compared to the 
control BCG (fig. 14c). The difference was particularly evident during the exponential 
  111 
growth phase, and diminished at the saturation phase. There was much less difference in 
the growth kinetics of the two strains under stirring conditions (data not shown). This 
observation suggests that overproduction of MK in the menA sense BCG was in fact 
detrimental to the bacteria in aerobic growth conditions.  










































Figure 13. Vector maps 
(a) menA anti-sense construct (pMV261-ASmenA) (b) menA sense construct (pMV261-SmenA) 
(c) pMV261 vector control. Restriction sites used for cloning are shown. groEL represents the 




































































Figure 14. Reduced menA expression in BCG menA KD strain 
(a) Analysis of menA expression normalised to 16S rRNA expression by RT-PCR using RNA 
extracted from pMV261 vector control and menA KD (pMV261-ASmenA) BCG strains in aerobic 
early exponential growth phase cultures grown in roller bottles. Results shown are based on 
triplicate cultures from one of two independent experiments with similar results. (b) Lipids 
extracted from three BCG strains were subjected to thin layer chromatography and visualised 
under UV at 254nm, with a commercially purchased vitamin K1 (K1) as a reference. Control = 
vector control strain with pMV261 plasmid alone. KD = menA KD strain. Sense = BCG with menA 
vector in sense orientation. (c) Cell density by absorbance at 600 nm in shaking cultures. menA 
sense (pMV261-SmenA) BCG and pMV261 vector control BCG in tubes were set up according to 
the Wayne model. Means of triplicate cultures shown ± 2SD. Asterisks indicate significant 
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3.3.2 An in vitro model of progressive oxygen limitation 
The Wayne model for in vitro generation of dormant mycobacteria (Wayne and 
Hayes, 1996) was next used for comparing growth of menA KD and control BCG in 
‘dormancy’ conditions in sealed stirred broth cultures, relative to fully aerobic shaking 
cultures where active replication is expected. In this model, bacteria in the stirred broth 
cultures enter a state of non-replicating persistence (NRP) representing mycobacterial 
dormancy, which is reversible upon re-aeration. At almost all time-points from the start 
of the cultures at a very low density (A600 = 0.004), there was a small but significant 
reduction in the growth rate of the menA KD strain relative to the control strain (fig. 15a) 
in both the shaking and stirring cultures. Initially, the extent of reduction in viability by 
bacterial counts was similar in shaking cultures (1.4-fold) and stirring cultures (1.1-fold) 
at day 5 (fig. 15b). When the stirring cultures reached the second stage of NRP where no 
further increase in cell density was seen (day 12), viability of the menA KD strain 
underwent further reduction to 2.2-fold below the control whereas the viability ratio 
remained constant in shaking cultures.  
However, the most striking differences were noted upon re-aeration of the stirred 
culture coupled with dilution of cultures to the original density in fresh media. The menA 
KD strain was less able to recover from NRP after resumption of aerobic growth. The 
second cycle of exponential growth showed a marked increase in the viability gap 
between the two strains – two weeks after resumption of aerobic conditions, the menA 
KD strain was 8.3-fold less viable than the control strain (fig. 15b). Overall, these 
experiments show that the menA KD strain had reduced ability to recover from hypoxia-
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induced NRP, an established model for mycobacterial latency, thus suggesting that MK 
















Figure 15. Reduced growth rate of menA KD BCG strain in progressive 
oxygen limitation and impaired recovery after reaeration. 
menA KD BCG and pMV261 vector control BCG stirring and shaking cultures in tubes were set 
up according to the Wayne model. The arrow ↓ indicates the point when stirred cultures were re-
aerated by 1:100 dilution into fresh media and transferred into new shaking tubes for subsequent 
aerobic culture. Means of triplicate cultures shown ± 2SD. Asterisks indicate significant 
differences (p<0.05) between menA KD and control BCG at each time point and condition. (a) 
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3.3.3 Nutrient limitation 
MTB are able to survive intracellularly within the acidic environment of 
phagosomes as well as in necrotic TB lesions limited in nutrients (Betts et al., 2002; 
Fisher et al., 2002; Hampshire et al., 2004; Rodriguez et al., 2002; Sherman et al., 2001). 
To study the effects of menaquinone on mycobacterial growth in nutrient starvation, 
well-aerated mid-log phase cultures of both the menA KD and control strains were diluted 
to equal cell densities, then transferred to either Hartman De Bont minimal media 
(Smeulders et al., 1999) or nutrient-rich 7H9 broth for comparison of the growth 
achieved in 5-day cultures. Both strains exhibited, as expected, greater than 2-log 
reduction in growth in HDB media (fig. 16a). The impact of starvation on the viability of 
menA KD strain was comparable to the control strain at the early time-points. Only at day 
5, the effect on the KD strain was greater than the control strain (592-fold vs 497-fold 
viability reduction respectively). Thus, we concluded that MK limitation exerts only a 












































Figure 16. menA KD BCG strain exhibited attenuated growth under nutrient 
limitation and increased susceptibility to hydrogen peroxide and acidified 
sodium nitrite 
pMV261 vector control and menA KD BCG were grown in Middlebrook 7H9 (7H9) broth in roller 
bottles to A600 0.400 and diluted 10-fold into 25cm2 vented tissue culture flasks at the start of this 
experiment. The culture media contained either 7H9 alone or one of the following: (a) Hartmans 
De Bont (HDB) minimal media, (b) 7H9 with 0.35% hydrogen peroxide (H2O2), (c) 7H9 with 6mM 
acidified sodium nitrite (NaNO2). Growth was monitored by culturing the bacteria from each well 
on agar and counting colonies. Means of triplicate cultures shown ± 2SD. Asterisks denote 
significant differences between control and menA KD strains at each given time-point (p<0.050). 
One of 2 independent experiments with similar results is shown.  
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3.3.4 Response to reactive oxygen and nitrogen intermediates 
The ability to adapt to antimicrobial defences of host macrophages, such as 
reactive oxygen intermediates (ROI) and reactive nitrogen intermediates (RNI), are 
crucial for MTB survival in dormancy within macrophages (Flesch and Kaufmann, 1987; 
Jackett et al., 1978; Jagannath et al., 1998; Laochumroonvorapong et al., 1997; Manca et 
al., 1999; O'Brien et al., 1994; Yu et al., 1999). To investigate the effects of MK 
limitation on the bacterial response to ROI and RNI, the two BCG strains were treated 
with 0.35% hydrogen peroxide and 6mM acidified sodium nitrite at pH 5.3 in broth 
culture. These concentrations were previously shown to exert a bacteriostatic effect on 
MTB in vitro (Firmani and Riley, 2002). At the first 24 hours post-hydrogen peroxide 
treatment, the menA KD mutant showed a much greater reduction in viable counts when 
compared to the control strain (50-fold vs 12-fold) (fig. 16b), but not at later time-points. 
With the nitrite treatment, menA KD strain was slightly more attenuated in growth than 
control strain (17-fold vs 12-fold) after 5 days (fig. 16c) but the magnitude of attenuation 
was comparable at earlier time-points. Taken together, these results suggest that whereas 
MK significantly influences the early mycobacterial response to reactive oxygen 
intermediates, thereby possibly affecting its early survival in host macrophages; it may 
not have a very significant role in the mycobacterial response to nitrosative stresses.  
 
3.3.5 Anaerobic nitrate reduction  
 BCG adapt to anaerobiosis by shifting down from aerobic growth to a state of 
latency by alternative substrate utilization, such as using nitrate for respiration (Fritz et 
al., 2002; Hutter and Dick, 1999). In E. coli, MK is involved in the redox process 
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resulting in anaerobic nitrate reduction (Wissenbach et al., 1990). We thus investigated 
whether limiting MK production affects the ability of BCG to reduce nitrate under 
anaerobic conditions. Log phase cultures of the menA KD and control strains grown in 
nutrient-rich 7H9 broth were transferred to MB medium with 10mM nitrate and 
incubated anaerobically for 10 days. The menA KD strain showed a small (1.4-fold) 
reduction in viable counts relative to control BCG at day 5, but the attenuation was 
extremely marked (>3 logs lower counts than control) at the end of 10 days (fig. 17a). 
Nitrate reductase activity measured by the Greiss method was 2-fold lower in the menA 
KD strain after 10 days (fig. 17b), we speculate that this reduced nitrate reductase activity 
in the menA KD strain affected its growth. Nitrate reductase activity in control strain 
increased between days 5 and 10, consistent with a prior publication (Weber et al., 2000). 
The data support the likelihood that, as in E. coli, mycobacterial menaquinones may aid 
the organism in surviving anaerobicity by acting as an electron transport mediator in 













Figure 17. Decreased anaerobic nitrate reductase activity in menA KD BCG 
pMV261 vector control BCG (‘control’) and menA KD BCG grown in 7H9 broth in roller bottles to 
A600 0.400 were diluted 10-fold into vented 25cm2 tissue culture flasks, which were incubated in 
an anaerobic chamber at 37°C over 10 days. At days 5 and 10, aliquots were taken to measure 
growth by (a) colony counts and (b) quantification of nitrite produced by the Greiss method. 
Means of triplicate cultures shown ± 2SD. Where error bars are not seen, the error values fall 
within the symbols.  Asterisks denote significant differences between control BCG and menA KD 
(p<0.05). One of 2 independent experiments with similar results is shown.  
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3.3.6 Growth in murine macrophages and lung cells 
We next investigated the growth kinetics of the menA KD strain when interacting 
intracellularly with host cells, using the murine macrophage cell line (J774A.1) either at 
resting state or pre-activated with phorbol myristate acetate (PMA). At 24 hours post-
infection (fig. 18a), menA KD strains in resting and pre-activated macrophages showed a 
greater reduction in viability compared to the control strains (1.5-fold and 1.6-fold lower 
respectively). Similar results were also observed at 48 hours in infected resting 
macrophages and activated macrophages. Lung cells (pneumocytes) were also used to 
investigate the growth kinetics of menA KD strain. The menA KD strains had lower 
colony counts after 24 and 48 hours than the control strain, but the difference was not 
statistically significant (fig. 18c).  
To investigate whether differential survival between the strains was due to 
differential cell death of macrophages hosting the two strains, supernatants from infected 
cells were assayed for release of lactate dehydrogense (LDH) from host cells as a 
measure of cytotoxicity. Significant differences in cell lysis were noted in activated 
macrophages harbouring the two strains at 4 and 24 hours post-infection – the menA KD 
strain resulted in 4 - 14.2% less lysis of activated macrophages compared to the control 
strain (fig. 18b). The difference was not significant in pneumocytes (fig. 18d).  
In summary, intracellular growth of menA KD strain was impaired in 
macrophages and especially in activated macrophages this was accompanied by reduced 
ability of the BCG to cause cell lysis. 



























Figure 18. Reduced intracellular growth of menA KD BCG  
Murine macrophages (J774A.1 cell line, a and b) or human lung cells (A549 cell line, c and d) 
were used as host cells for infection with either pMV261 vector control BCG (‘control’) or menA 
KD BCG at a 10 bacteria : 1 cell ratio (MOI 10:1). Extracellular bacteria were killed after 2 hours. 
(a and c) Cells were lysed at specific time-points and intracellular bacteria cultured on agar to 
determine surviving bacterial counts, expressed as cfu per million BCG at the point of infection. (b 
and d)  Prior to cell lysis, supernatants were collected for assay of host cell lysis by measuring 
release of intracellular lactate dehydrogenase. Means of triplicates shown ± 2SD. Asterisks 
denote significant differences between control and menA KD at each time-point (p<0.05). One of 
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3.3.7 TNF-α production in human monocyte-derived macrophages  
Monocyte-derived macrophages from human peripheral blood mononuclear cells 
(PBMCs) were used to investigate the cytokine response of these cells to menA KD – the 
cytokine TNF-α was assayed in cell culture supernatants at 24 h post-infection. 
Interestingly, TNF-α production from menA KD-infected cells was increased relative to 
control BCG-infected cells (fig. 19a). Intracellular survival of the menA KD strain was 
also assessed by lysing the macrophages to release bacteria for viability counts. 
Consistent with the data from murine macrophage cell line (fig. 18a), menA KD strain 
was significantly less viable in the ex vivo PBMC-derived monocytes-macrophages after 
24 hours when compared to the control strain (fig. 19b). Thus, in the host-pathogen 
interaction between the menA KD strain and primary macrophages, there is a larger host 














Figure 19. menA-KD BCG infection elicited more TNF-α production in 
monocyte-derived macrophages 
pMV261 vector control BCG (‘control’) and menA KD BCG were used for infection of human 
peripheral blood monocyte-derived macrophages at a multiplicity of infection (M.O.I) of 10:1 for 
24 hours. (a) Supernatants were collected for TNF-α production assay by ELISA. In control wells, 
no BCG was added to the macrophages (‘uninfected’). (b) Cells were then lysed to release 
intracellular bacteria for counting viable BCG by culture on agar. Means of triplicate cultures 
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3.3.8 Vitamin K1 treatment: effects on menA KD survival at NRP-2 
 Having shown that menA KD exhibited significant growth defects under different 
stress conditions that mimicked the intracellular host environment in the previous 
experiments; we investigated the effects of adding a menaquinone analogue (vitamin K1) 
at 1.25 mg/ml exogenously to the growth medium under anaerobic conditions using the 
Wayne model of non-replicating persistence. Under anaerobic (stirring) conditions, 
vitamin K1 treatment resulted in a significantly greater reduction in colony counts in 
control BCG than menA KD (fig. 20a). At NRP-2 phase (day 9), menA KD exhibited a 
4.4-fold reduction in colony counts in the presence of vitamin K1, while control BCG 
exhibited a 66.7-fold reduction (fig. 20b). In conclusion, exogenous vitamin K1 was less 
inhibitory to the menA KD strain than to the control strain, resulting in a 20% less growth 
inhibition under anaerobic conditions (fig. 20c).  
Lipid extractions carried out from an equivalent dry weight of the two strains 
grown to NRP-2 phase with oxygen-limitation in stirring Wayne cultures (fig. 20d), 
showed increased menaquinone production in both strains upon vitamin K1 treatment. 
However, the control strain evidently reached much higher levels of MK production after 
treatment than the menA KD strain, possibly related to the fact that the pre-treatment MK 
levels were already different. This is consistent with our previous observation that 
vitamin K1 treatment appears to drive increased menA expression in the wild-type strain 
(fig. 12d) and suggests the possibility that exogenous vitamin K1 may inhibit the function 
of endogenous MK, resulting in increased endogenous MK production as a compensatory 
response. 



















Figure 20. Reduced susceptibility of menA KD BCG to vitamin K1 treatment 
All experiments were conducted on pMV261 vector control BCG (‘control’) and menA KD BCG 
cultures grown in stirring tubes for nine days (NRP-2 phase) based on the Wayne model. 
Cultures were either treated with vitamin K1 (1.25 mg/ml) or untreated (diluent alone added). (a) 
colony counts, (b) fold reduction in bacterial counts due to treatment, calculated by ratio of counts 
in untreated over treated cultures, (c) % growth inhibition by colony counts, calculated by 100% - 
(treated/control) x100% (d) Thin layer chromatography of lipids extracted from 50 mg dry weight 
of cells, with and without vitamin K1 treatment. All experiments were conducted three times and 






















































Lane 1: Vitamin K1 standard
2: menA KD  treated
3: menA KD non-treated
4: pMV261 vector  control  
treated
5: pMV261 vector  control  
non-treated
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3.3.9 Growth in immunocompetent mice 
 To assess whether reduced MK production affects the in vivo growth of BCG in 
an immunocompetent host, Balb/c mice were intravenously infected with either menA 
KD or control strains. The inoculum counts at the point of infection were not 
significantly different between the menA KD and control BCG cultures (5 x 108 
 cfu/mouse). Viable The menA KD strain was recovered in significantly lower numbers – 
1 to 1.5 log below the bacillary load of control BCG – in the infected murine livers, 
spleens and lungs throughout the course of infection (figs. 21a to c). counts of the menA 
KD strain were lower than the control strain by 3-fold after 14 days and 20-fold after 56 
days in the livers, and in the spleens by 5-fold and 19-fold respectively at the same time-
points.  However, in the lungs, menA KD counts were reduced to a much larger extent at 
14 days post-infection (67-fold), but the difference was reduced to 13-fold by 56 days 
post-infection. Thus, the growth defects of the menA KD strain observed in vitro were 
also seen upon in vivo host infection, suggesting that menaquinone limitation negatively 
affects mycobacterial survival in the host.  








































Figure 21. Reduced in vivo survival of menA KD BCG in infected mice 
Balb/c mice were infected i.v. with 108 cfu of pMV261 vector control BCG (‘control’) and menA KD 
BCG. (a) liver, (b) spleen and (c) lungs of infected mice were harvested at specific time-points for 
counting viable bacteria by culture on agar. Mean results from at least 3 mice per group are 
shown ± 1SD. Where error bars are not seen, the error values fall within the symbols. Asterisks 
denote significant differences between control and menA KD strains at a given time-point 
(p<0.05). Results shown represent one of 2 independent experiments with similar results.  
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3.3.10 In vivo gene expression analysis in menA KD 
MK in E. coli is a major electron carrier in anaerobic respiration, transferring 
electrons to various electron acceptors (Lin, 1987). If there were an equivalent role for 
MK in mycobacteria, it is anticipated that reduced MK production would have an impact 
on downstream electron acceptors (fig. 7), particularly in conditions of hypoxic stress.  
In order to investigate which menaquinone-dependent pathways were affected in 
the early, middle and chronic phases of infection, RNA extracted from menA KD strains 
harvested from day 14, 35 and 56 post-infection murine spleens were used to measure 
transcript levels for genes involved in electron flow generated from NADH through MK 
(see fig. 7). devR (global response regulator in MTB dormancy adaptation) is upregulated 
in the mycobacterial stress response to hypoxia (Boon and Dick, 2002; Sherman et al., 
2001), thus expression of this gene was also measured as indicator of the hypoxic stress 
response. At 14 days post-infection (Table 9), correlating to the onset of Th1-mediated 
immunity, induction of devR and cydA genes were increased by 192-fold and 12.5-fold, 
respectively, in the menA KD. This induction parallels observations in other studies that 
up-regulation of DevR, is required to mediate bacterial entry into long-term persistence in 
the mice after expression of Th1-mediated immunity in the mice. At 35 days post-
infection, the menA KD strain showed the highest transcript levels for genes (cydA, frdA) 
involved in electron flow generated from NADH through MK and a small increase in ndh 
which is involved in increasing electron transfer to MK under anaerobic conditions 
(Table 9). Increased expression of cydA and frdA, reflect the changes in energy and 
respiratory states as the bacteria adapt to a metabolic-inactive and non-replicative 
persistence. At day 56, we found that transcript levels for cydA (bd-type menaquinol 
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oxidase) and frdA (fumarate reductase) decreased to 2.4 and 1.8-fold higher respectively 
in the menA KD strain relative to control strain (Table 9), whereas narX (‘fused’ nitrate 
reductase) transcript levels were 4-fold lower in the menA KD strain. devR expression 
was still 16.8-fold higher in the menA KD strain over the control strain at day 56. We 
conclude that reduced MK production in the menA KD strain perturbed pathways 
involved in MK-mediated electron transport as predicted for the respiratory chain of 
MTB (fig.7), adding further evidence that MK is indeed involved in mycobacterial 
anaerobic respiration and alternative substrate utilisation pathways required for 





Table 9. Differential expression of genes in menA KD BCG from infected 
mice 
Expression of genes encoding proteins associated with MK functions analysed by RT-PCR using 
RNA extracted from pMV261 vector control BCG and menA KD BCG pooled from 3 to 4 mouse 
spleens at different stages of murine infection (56 days post-infection). Expression of each gene 
was first normalised to 16S rRNA for each strain and then presented as an expression ratio of 
menA KD over control BCG. Results shown are from one of the two independent experiments 
with similar results. Rv numbers refer to the systematic numbering of MTB genes based on 
TubercuList   (http://genolist.pasteur.fr/TubercuList). “-” indicates where there was insufficient 
cDNA to perform the assay.  
Rv no. Gene Day 14 Day 35 Day 56 Protein function
1623c cyd A 12.5 189.7 2.4 component of aerobic respiratory chain under low aeration
3133c dev R 192.2 268.1 16.8 2-component response regulator
1552 frd A 0.2 6.7 1.8 interconversion of fumarate and succinate
1736c nar X - - 0.4 nitrate reduction and persistence
1854c ndh 0.7 4.8 2406.9 transfer of electrons from NADH to the respiratory chain
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3.4 DISCUSSION 
Menaquinone (MK) studies in E. coli have shown that menA-defective mutants of 
E. coli fail to produce MK and are unable to survive anaerobically on glucose medium 
unless uracil is added (Wallace and Young, 1977a). This is due to the role of MK role in 
pyrimidine biosynthesis and alternative energy metabolism under anaerobiosis (Newton 
et al., 1971). menA mutants are also unable to grow on succinate as a sole source of 
carbon (Shineberg and Young, 1976; Young, 1975) under aerobic conditions. In addition, 
E. coli men mutants are unable to reduce other electron acceptors such as fumarate 
(Guest, 1977, 1979) and tetrahydrothiophene 1-oxide (Meganathan and Schrementi, 
1987) anaerobically. All the above evidence point to the role of MK in electron transfer 
chains that couple reduction of electron acceptors to generation of energy in E. coli 
(Tyson et al., 1997). Similarly, the present study reveals that in the menA KD strain, 
reduced MK production (fig. 14) results in growth attenuation in vitro (fig. 15) and in 
vivo (fig. 21), especially under anaerobic conditions. However, an excess of MK 
production is also inhibitory (fig. 14c) and this appears to be particularly a problem in 
aerobic conditions when MK is least required by the bacteria, as evidenced by our earlier 
expression studies (fig. 9). This supports a selective demand for MK in BCG in hypoxic 
conditions that drive latency. It has also been observed in S. aureus menaquinone-
deficient mutants that concentrations of 0.1 to 1.0 µg per ml menadione fully restored 
growth and respiration but higher concentrations were inhibitory (Sasarman et al., 1969, 
1971).  
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We chose to knock-down expression of menA rather than genes encoding 
enzymes in the earlier part of the MK biosynthesis pathway because the loss of a late men 
gene (menA) product allows the effects of the loss of both demethylmenaquinone (DMK) 
and MK to be investigated. The earlier gene products are responsible for the conversion 
of chorismate and 2-ketoglutarate to the napthalenoid compound 1,4-dihydroxyy-2-
napthoic acid (DHNA) (fig. 5), whereas the menA gene encodes the enzyme responsible 
attaching octaprenylphosphate to DHNA leading to the formation of DMK prior to 
methylation to MK (Bentley and Meganathan, 1982; Meganathan, 2001). Thus, both 
DMK and MK are reduced in the menA KD strain. In E. coli, DMK has been implicated 
as a mediator in trimethylamine N-oxide (TMAO) reduction (Wissenbach et al., 1990) 
and can serve as a redox mediator in fumarate, and to some extent in dimethylsulfoxide 
(DMSO) respiration, but not in nitrate respiration (Wissenbach et al., 1992). The risk in 
knocking down an early men gene in the pathway is that there might be other 
compensatory pathways in the bacteria that allow formation of the naphthoquinone 
structure downstream and therefore may generate DMK.  
Although MTB is an obligate aerobe, it can persist chronically in conditions of 
low oxygen tension. Weinstein et al. noted that the MTB genome contains a respiratory 
chain with a quinol oxidase branch (cytochrome bd oxidase) and a cytochrome oxidase 
branch (cytochrome c oxidase) (fig. 7). The MK pool is predicted to be the electron donor 
to both branches of the mycobacterial respiratory chain (Weinstein et al., 2005). It has 
been demonstrated that the d-type oxidase is induced in mycobacteria under low-oxygen 
conditions and is crucial for microaerobic growth (Kana et al., 2001). The oxygen- and 
NO-regulated Dos system in MTB (Roberts et al., 2004; Voskuil et al., 2003) have been 
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implicated in the ‘mycobacterial dormancy response’ – the ability of mycobacteria to 
adapt to hypoxic environmental conditions. These conditions up-regulate the 
mycobacterial dosR-devR stress response regulon (Boon and Dick, 2002; Georgellis et 
al., 2001; O'Toole et al., 2003) and are believed to be the primary trigger for MTB 
adaptation to hypoxia (Park et al., 2003). It has been suggested that Dos response could 
be mediated by cytochrome aa3  (Voskuil et al., 2003). Hence, we postulated that a 
deficiency in MK is likely to limit the function of both oxidase branches and thereby 
impair the mycobacterial response to hypoxia. 
Prior studies (Sassetti et al., 2003) have shown a crucial requirement for devR for 
optimal growth and as a regulator for the hypoxic response in mycobacterial latency 
(Sherman et al., 2001). Thus, in the chronic phase of murine infection (day 56), that the 
menA KD strain had markedly greater devR expression (16-fold) than the control BCG 
suggests the former required a larger adaptation to hypoxia. According to prior work on 
mycobacteria under hypoxic conditions (Sherman et al., 2001), triggering the Dos 
regulon up-regulates the cydABCD operon encoding cytochrome bd oxidase (Boshoff et 
al., 2004), and frdA, the gene that encodes fumarate reductase (Jones and Gunsalus, 
1985) which participates as an alternate electron acceptor from the MK pool and is 
present in the phagosome (Boshoff and Barry, 2005). As cydA and frdA genes were more 
highly expressed in the menA KD than control strain (Table 9) in murine organs, we 
postulate that over-expression of the dosR-devR stress response regulon in the MK 
limited strain may drive increased production of downstream electron acceptors from 
MK. Increased production of these enzymes may be the compensatory response of the 
menA KD strain to maximise utilisation of the limited MK. Another gene, ndh, that codes 
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for a type II NADH dehydrogenase, fold-induction was greatest at the chronic phase (day 
56) instead of 35 days post-infection when compared to the other genes studied (Table 9). 
In wild-type MTB, expression of ndh decreased in the chronic phase of infection (Shi et 
al., 2005). This opposite response in the menA KD strain could be because in this strain, 
the lack of MK imposed a significant limitation to the re-cycling of NADH generated 
from intermediary metabolism – this may have led to a necessity for up-regulation of the 
ndh gene encoding the dehydrogenase enzyme to provide sufficient NAD+ for recycling 
back to the glyoxylate cycle during anaerobic respiration (McKinney et al., 2000). It is 
thus evident that MK limitation increases demands on the pathways involved in the 
electron transport chains mediating energy and respiratory demands under conditions of 
latency-induced stress.  
Given the above, we were surprised to note that expression of narX (fused nitrate 
reductase), another MK electron acceptor, was actually reduced in the menA KD strain 
over the control (Table 9). We postulate that this could be due to a failure of the menA 
KD strain to shift to nitrate respiration in spite of up-regulation of the Dos regulon (Boon 
and Dick, 2002; Voskuil et al., 2003). The reshaping of MTB energy metabolism is 
required in MTB latency. A role for nitrate reductase in maintaining ATP levels in MTB 
during hypoxia has been demonstrated from work with pyrazinamide (Wade and Zhang, 
2004; Zhang et al., 2003). Nitrate reduction contributes to redox balance (Moreno-Vivian 
et al., 1999; Richardson, 2000; Schnappinger et al., 2003) by re-oxidation of reduced 
components of the electron transport chain generated by β−oxidation of fatty acids 
(McKinney et al., 2000; Schnappinger et al., 2003), the lack of oxygen and the presence 
of NO (Sohaskey, 2005). A BCG narG-deficient mutant has provided evidence that 
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nitrate is an alternative electron acceptor required by BCG grown in anaerobic conditions 
(Weber et al., 2000). The shift to nitrate as the preferred terminal electron acceptor and 
the utilization of the cytochrome bd oxidase under microaerophilic respiration (Kana et 
al., 2001; Sohaskey and Wayne, 2003) may function simultaneously to balance energy 
generation with growth in intracellular mycobacteria. This adaptation allows tubercle 
bacilli to survive microaerophilic conditions that may exist in granulomas or 
macrophages. Since MK is required to direct electron flow to nitrate under these 
conditions(Weber et al., 2000; Wissenbach et al., 1990), failure to up-regulate narX  
would explain why the menA KD strain showed decreased anaerobic survival (fig. 17a) 
and diminished anaerobic nitrate reductase activity (fig. 17b). As the menA KD strain was 
also attenuated in vivo (fig. 21), we postulate that MK insufficiency may have disrupted 
the shift to anaerobic nitrate respiration, and this is one of the limitations that retard its 
growth in hypoxic conditions.  
In addition to the possible failure to shift to anaerobic nitrate respiration, the 
limitation of electron flow through the cytochrome chain by MK deficiency may also 
result in a decreased rate of cellular respiration. In a S. aureus MK mutant, MK reduction 
causes a general decrease in respiratory chain efficiency by limiting the synthesis of other 
electron transport chain components (Goldenbaum et al., 1975). This is supported by a 
similar observation in Bacillus subtilis (Farrand and Taber, 1973) and in the E. coli menA 
deficient mutant defective in anaerobic growth (Newton et al., 1971; Shaw et al., 1982). 
Such changes in electron flow in the respiratory chain can create an imbalance of 
intracellular NADH/NAD+, which may disrupt mycobacterial entry and maintenance of 
dormancy (Weinstein et al., 2005) as discussed above. In the menA KD strain, some or all 
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of these mechanisms could explain its attenuated phenotype, particularly its more severe 
growth limitation under hypoxic than aerobic conditions, as well as impaired recovery 
from NRP (fig. 15).  
A study of the relative growth disadvantage of the menA KD strain compared to 
control strain in nutrient starvation (fig. 16a), oxidative stress (fig. 16b), nitrosative stress 
(fig. 16c) and hypoxia (fig. 15) suggests that hypoxia was the in vitro condition which 
most induced a demand for mycobacterial MK since this resulted in the greatest growth 
inhibition. This supports the use of the Wayne model as a model for generating 
conditions driving MK demand. Taken together with this model’s proven associations 
with mycobacterial latency, and that the menA KD also shows an attenuated phenotype in 
vivo (fig. 21), this is strong evidence that MK demand is indeed increased in dormant 
mycobacteria. 
The menA KD strain was much less susceptible to the exogenous menaquinone 
analogue (vitamin K1) than the control strain, although its growth was still significantly 
reduced relative to diluent-treated cultures at the NRP-2 phase (fig. 20a). This was a very 
exciting observation as it complements our earlier observation in the menA 
overproducing strain (fig. 14c). Since excess MK is inhibitory to BCG growth, it would 
be expected that strains deficient in MK would be more tolerant of exogenous vitamin K. 
The reduced susceptibility could also be because the menA KD strain may have partially 
adapted to the state of reduced MK by modifications to its electron exchange partners 
(discussed above). In chapter 2, the possibility of vitamin K1 acting as a competitive 
inhibitor to endogenous MK was suggested; perhaps a smaller role of MK in electron 
transfer in the menA KD strain could result in its relatively lower susceptibility to vitamin 
  135 
K1 as compared to the control strain.  However, it is also clear that the menA KD strain is 
not free from the requirement for MK, as evidenced by its growth attenuation in 
anaerobic conditions in vitro (fig. 15) and in vivo (fig. 21), relative to the control strain.   
It was observed that the menA KD strain caused less host murine macrophage 
lysis than the control strain in the first 24 hours of intracellular growth (fig. 18b), 
particularly in activated macrophages, and at 48 hrs there was significantly reduced 
survival within the macrophages (fig. 18a). The observation of reduced intracellular 
viable count of the menA KD strain in host macrophages is therefore not an artefact of 
reduced host cell survival since in fact more host cells survived when cultured with this 
strain. The reduced lysis could be due to reduced intracellular multiplication of the strain. 
It is well-established that reactive oxygen intermediates (ROI) production is increased in 
activated macrophages (Flesch and Kaufmann, 1991; Manca et al., 1999; Shiloh et al., 
1999). Our earlier observation that the menA KD strain showed a marked degree of 
susceptibility to ROI at 24 hours (fig. 16b) may provide one reason for the differential 
cytotoxicity of the strains. Intracellular growth attenuation of menA KD strain is likely to 
be related to its markedly poorer response to oxidative stress encountered in the 
phagosome particularly within activated macrophages. There is clearly a more effective 
host response against the menA KD strain, because TNF-α production in primary human 
macrophages infected with the strain was higher than control bacteria-infected cells (fig. 
18a). These data, taken together, suggest that MK limitation increases the difficulties of 
mycobacteria in adapting to the macrophage environment. In contrast, the menA KD 
strain showed minimal survival disadvantage or difference in lysis of pneumocytes (fig. 
18c, d). Differences between the macrophage and pneumocyte data is probably because 
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the lung cell has less microbicidal mechanisms than the macrophage. If the pneumocyte 
intracellular environment is highly permissive for BCG survival and does not drive the 
stress adaptation that increases MK demand, it would explain the minimal phenotypic 
differences. 
In data not shown, we investigated the aminoglycoside susceptibility of the menA 
KD strain because others have suggested that menaquinone-deficient mutants of S. 
aureus are less susceptible to antibiotics like neomycin (Sasarman et al., 1968). However, 
the menA KD strain was identical in susceptibility to gentamicin and streptomycin, 
compared to the control and wild-type BCG. This could mean that the mechanism for 
aminoglycoside resistance in S. aureus is different from mycobacteria, and that for the 
latter, MK-deficiency does not play a role.  
Overall, the studies on the menA KD strain in this chapter show that the reduced 
production of menaquinone results in impaired survival in vitro under conditions of 
progressive oxygen depletion, within macrophages and in mice. The changes in nitrate 
reductase activity, expression of electron exchange partners and tolerance to starvation, 
oxidative and nitrosative mechanisms in this strain all suggest that MK is part of the 
mycobacterial respiratory and intermediary metabolism required for intracellular 
persistence in the host, and MK therefore constitutes a significant part of the 
mycobacterial dormancy programme. 
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CHAPTER 4: EFFECTS OF VITAMIN K ON LATENT MYCOBACTERIA 
4.1 INTRODUCTION  
Studies of quinones as anti-bacterials have shown that naphthalenoid compounds, 
particularly substituted naphthoquinones, are inhibitory to the growth of bacteria in vitro 
(Armstrong et al., 1943; Leahy et al., 1968). Importantly, some anti-mycobacterial 
activity is shown by analogues to both menaquinone (MK) and ubiquinone (UQ) 
(Gangadharam et al., 1978). Interestingly, the naphthoquinone moiety in menadione, 
which is another menquinone analogue (Panisset et al., 1952), is also present in 
rifampicin, an effective anti-mycobacterial drug in clinical use (Prelog, 1963).  
In this chapter, vitamins K1 and K2 are tested for their anti-mycobacterial 
properties because these compounds have been known to be administered in humans up 
to 1 mg/day for vitamin K1 (Braam et al., 2003) and 45 mg/day  (Iwamoto et al., 2001; 
Vermeer et al., 1995) for vitamin K2 with no apparent side-effects (Cockayne et al., 
2006).  
Persistence is the hallmark of tuberculosis. Non-replicating or dormant TB bacilli 
are resistant to conventional anti-TB drugs (Wayne, 1994). Understanding the effects of 
exogenous quinone analogues on mycobacteria will help to elucidate whether the MK 
biosynthetic pathway is a plausible anti-mycobacterial drug target. The efficacy of 
quinones as anti-bacterials has not been investigated specifically against mycobacteria in 
a non-replicating state, but this is highly relevant to tackling the problem of 
mycobacterial latency in human hosts. Since our earlier work has indicated that BCG has 
an increased requirement for MK in hypoxia-induced NRP and deficiency leads to an 
attenuated growth phenotype in in vitro and in vivo latency models, we are particularly 
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interested in whether MK analogues like vitamin K1 and K2 act differentially on latent 
and actively growing mycobacteria, and whether there is evidence that they act by 
influencing activity of endogenously produced MK.  
 
Objectives of work presented in this chapter: 
(1) To develop an optimal diluent system for vitamins K compounds such that the 
diluent provides maximal solubility with minimal toxicity to BCG 
(2) To investigate if vitamins K1 and K2 at various doses influence BCG growth in 
the aerobic state versus the state of hypoxia-induced persistence (Wayne model)  
(3) To investigate whether the in vitro effects of vitamins K1 and K2 are dependent on 
culture conditions and exposure duration – utilisation of broth microdilution 
method (BMM) of susceptibility testing, with assays of minimal inhibitory 
concentration (MIC), minimal bactericidal concentration (MBC) and colony 
counts at MBC.  
(4) To investigate whether endogenous MK deficiency influences the effects of 
vitamins K1 and K2 by testing effects on menA KD BCG in vitro 
(5) To determine if combining vitamins K1 or K2 with standard anti-mycobacterial 
drugs improves their bacteriostatic and bactericidal activity on various different 
Mycobacterium species in vitro, under aerobic and anaerobic culture conditions.  
(6) To study the effects of vitamin K1 on wild-type BCG survival in mice, when 
administered to mice at different time points after infection, and to analyse effects 
of such treatment on bacterial endogenous MK biosynthesis. 
(7) To study the effects of vitamin K1 on preventing in vivo mycobacterial 
reactivation from latency by treating BCG-infected mice with vitamin K1 
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followed by steroid-induced host immunosuppression to favour reactivation of 
latent mycobacteria.  
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4.2 MATERIALS AND METHODS 
4.2.1 Bacterial strains and growth conditions.  
In this chapter, besides the wild-type strain of Mycobacterium bovis bacille 
Calmette-Guérin (BCG) Pasteur strain used previously, two other recombinant BCG 
strains harbouring plasmid pMV261 were used – construction of these recombinant 
strains was described in chapter 3 (fig. 13).  The ‘control’ strain harbours the empty 
vector (pMV261) and the ‘menA KD’ strain has the anti-sense menA plasmid (pMV261-
ASmenA). Standard growth conditions for these strains have been previously described. 
Growth conditions for M. avium and M. chelonae are as described for BCG in chapter 2. 
Where antibiotics or vitamin K were added to the growth media, the full description of 
the growth conditions is given below.  
For some experiments, BCG broth cultures were set up according to the Wayne 
model, using both stirred and shaking tubes. This model and details of its set-up have also 
been fully described in chapter 2 (fig. 8). Growth was monitored daily by broth turbidity 
measurements
 
(absorbance at 600 nm, A600). In parallel, bacteria from triplicate tubes per 
time-point were harvested at various stages and plated on agar in triplicates for colony 
enumeration.  
 
4.2.2 Vitamin K preparation  
All vitamin K compounds were purchased from Sigma. Stock preparations were 
stored at -20°C, protected from light. Vitamin K1 (2-Methyl-3-phytyl-1,4-
naphthoquinone, alternatively known as 3-Phytylmenadione or Phylloquinone) and 
Vitamin K2 (Menatetrenone, alternatively called Menaquinone-4 or 2-methyl-1,4 
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napthoquinone) and vitamin K3 (Menadione sodium bisulfite or 2-methyl-1,4-
naphthoquinone) were diluted in neat DMSO to a stock concentration of 250 mg/ml. The 
working concentration of each vitamin was achieved by serial dilution using 0.5% 
DMSO in Middlebrook 7H9 broth (diluent), such that the final concentration of DMSO 
was always 0.5% in the final test medium. To test the effects of vitamin K treatment on 
the growth of BCG, treated and control (diluent alone) tubes/wells were set up in 
triplicates.  
 
4.2.3 Preparation of antibiotics  
All antibiotics were purchased from Sigma. Stock solutions of isoniazid 
(Isonicotinic acid hydrazide or Isonicotinic hydrazide), streptomycin and ethambutol 
(2,2'-(1,2-Ethanediyldiimino)bis-1-butanol dihydrochloride) were prepared in sterile 
distilled water at concentrations of 10 mg/ml as recommended by the National 
Committee for Clinical Laboratory Standards (NCCLS) (NCCLS, 2002). Rifampicin (3-
(4-Methylpiperazinyliminomethyl)) was dissolved in neat DMSO. Solutions were 
sterilized using a 0.2 µm membrane filter and stored in small aliquots at -80°C. Working 
solutions of 1 mg/ml were stored at 4°C for up to a month. The final concentration of 
antibiotics used was achieved by serial dilution with sterile distilled water. Pyrazinamide 
(Pyrazinecarboxamide or Pyrazinoic acid amide) was dissolved in 7H9 broth at a 
concentration of 10 mg/ml and further dilutions were made in 7H9 adjusted to pH 5.5 
(Wade and Zhang, 2004).  
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4.2.4 Antibiotic susceptibility testing by broth microdilution method (BMM)  
Antibiotics were serially diluted two-fold in 7H9 broth to achieve the range of 
concentrations to be tested. Aliquots of 0.1 ml volumes containing different antibiotic 
concentrations were dispensed into 96 well plates (Nunc). The range of concentrations 
used was as follows: rifampicin (RIF; 0.0004 to 0.0128 µg/ml), isoniazid (INH; 0.031 to 
1 µg/ml), streptomycin (STR; 0.0625 to 2 µg/ml) and ethambutol (EMB; 0.5 to 16 µg/ml) 
for BCG. For M. avium and M. chelonae, the antibiotics tested were rifampicin (RIF; 0.5 
to 64 µg/ml), isoniazid (INH; 4 to 8200 µg/ml), streptomycin (STR; 2 to 128 µg/ml) and 
ethambutol (EMB; 2 to 512 µg/ml). For pyrazinamide (PZA), a range of 12.5 to 50 µg/ml 
was used for MIC testing, but 100 µg/ml was used for aerobic versus anaerobic testing 
conditions. For testing combination of the Vitamin Ks with standard anti-mycobacterial 
antibiotics, vitamin K1 or K2 solubilised in 0.5% DMSO was added at 1.25 mg/ml (final 
concentration). 
Following the recommendations of the National Committee for Clinical 
Laboratory Standards (NCCLS) (NCCLS, 2002), BCG cultures grown to mid-log phase 
in roller bottles were diluted from an initial cell density of A600 1.0 (2.5 x 108 cfu/ml) to 
2.5 x106 cfu/ml by 10-fold serial dilutions. Subsequently, in 96-well plates, 0.01 ml of 
bacterial cultures were added to triplicate wells containing different drug concentrations 
or no drug (control) to achieve 2.5 x 104 cfu per well. The plates were sealed with 
parafilm and incubated at 37°C for 14 days. All plates were read after 7 and 14 days by 
observing for macroscopic growth as recommended by the NCCLS (NCCLS, 2002), 
except for PZA-treated cultures which were read after 5 days. The MIC100 was defined as 
the lowest concentration of antibiotic at which no visible growth was seen. On day 14, 
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10% (v/v) of the treated cultures were plated onto agar for colony counting. Untreated 
cultures from the same experiments were plated as a control. The plates were incubated at 
37°C and colony counting was performed after 3 to 4 weeks of incubation. The MBC99 
was defined as the lowest concentration of antibiotic at which treated cultures yielded 
<1% of colonies compared to untreated (control) cultures. For M. chelonae, a rapid-
grower, macroscopic growth was read after 5 days. For PZA, additional testing of MIC 
and MBC under anaerobic conditions was also performed. This was done by growing the 
treated and untreated cultures in 96-well plates, without shaking, within an anaerobic 
workstation (MACS-MG1000; DW Scientific). 
 
4.2.5 Gene expression analysis  
Details of experimental set-up, primers and PCR amplification parameters are as 
described in chapter 2. Expression of BCG menA gene normalised to 16S rRNA gene 
was studied in this chapter. 
 
4.2.6 Infection of mice and drug dosing 
Different doses of BCG were used to infect female Balb/c mice (6-8 weeks old) in 
separate experiments – 103 BCG (low dose) or 105 BCG (moderate dose) in 0.1 ml PBS 
were injected via the lateral tail vein. The low-dose model was used to test effects of 
vitamin K1 on the reactivation of BCG. Groups of 3 to 4 mice were administered with 
vitamin K1 (500 µg/kg body weight/day) from 35 days post-infection until 56 days post-
infection. Prednisolone (3 mg/kg body weight/day) was given orally 56 days post-
infection until mice were sacrificed at 120 days post-infection. Previous studies have 
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shown that steroid treatment causes lowering of host immunity and reactivation of latent 
mycobacteria (Hernandez-Pando et al., 1998; Phyu et al., 1998; Rook et al., 1987) and 
this was the purpose of prednisolone administration. The moderate-dose model was used 
to test the effect of vitamin K1 when administered at different time-points in the course of 
mycobacterial infection. Therefore mice were dichotomised to receive vitamin K1 (500 
µg/kg body weight/day) starting from either 21 days (early) or 35 days (late) post-
infection until 56 days post-infection when all the mice were sacrificed for determination 
of bacterial burden.  
Prednisolone and vitamin K1 were administered to the mice via their drinking 
water. To ensure that an accurate dose of oral drugs was taken up by the mice, 
preliminary experiments were carried out to determine the average volume of water 
consumed per mouse and the concentration of drugs in the water was determined 
accordingly. During drug administration, the volumes of water consumed were monitored 
regularly throughout the experimental period. At different time-points post-infection, the 
mice were sacrificed by CO2 asphyxiation. Spleen, liver and lung from each mouse were 
harvested. For the extraction of bacteria from the murine tissues, the tissues were 
incubated in 200 U collagenase D (Roche) at 37°C for 1 h and then homogenised in PBS 
with 0.05% Tween 80 through 60 µm cell strainers (BD Biosciences). The cell 
suspensions were diluted and plated on agar for colony enumeration. 
 
4.2.7 Statistics 
Statistical comparisons for data from triplicate experiments were performed using 
Student t-test. In all figures, data shown represent means + 2 standard deviations unless 
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otherwise stated. Each set of experiments was performed at least twice. The differences 
between groups were considered stastically significant if p<0.05.  
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4.3 RESULTS 
4.3.1 Optimisation of vitamin K diluent 
Vitamin K is not water-soluble. The concentration of diluent chosen must be high 
enough to permit full solubility at higher concentrations to be used for susceptibility 
testing, and yet at that concentration, the diluent should be minimally toxic to BCG. 
Thus, prior to testing the effects of vitamin Ks on mycobacterial growth, toxicity of 
different diluents alone was tested on wild-type BCG. Some prior studies indicated that 
there was 12.5% toxicity noted with DMSO itself after two to three weeks of exposure 
for M. avium and M. tuberculosis (MTB) (Tran et al., 2004). A study conducted by 
Gangadharam et al. (Gangadharam et al., 1978) used compounds that were initially 
dissolved in 95% ethanol with subsequent dilutions made that recorded no significant 
toxicity after 4 days of exposure to M. intracellulare and MTB. Vitamin K1 is available 
commercially supplied in hexane. We tested a few diluents for minimal toxicity to BCG 
while preserving its solubility. Lipid solvents such as chloroform have been suggested by 
other studies (Collins et al., 1980).  However, in our own experiments, we found a 35 to 
50% growth inhibition of BCG broth cultures with 2% ethanol plus 2% chloroform or 2% 
DMSO-treated cultures (fig. 22a). As this level of toxicity was not acceptable, the diluent 
concentration was titrated downwards. With 0.5% DMSO the best balance between 
growth inhibition (3 to 5 % over 12 days) and solubility was achieved (fig. 22b), thus this 
was used as the final diluent for vitamin K preparations used in this chapter. 














Figure 22.  Inhibitory effects of vitamin K diluents 
Ethanol-chloroform (1:1 vol/vol) or DMSO at (a) 2% and (b) 0.5% were tested for growth inhibition 
(by optical density measurements) of wild-type BCG cultures grown in aerated tubes, shaking at 
230 rpm. % inhibition is calculated as 100% - (treated/control) x 100%. Significant differences 
between control (untreated) and DMSO-treated (p <0.05) cultures are indicated by asterisks (*). 
Significant differences between control and ethanol-chloroform treated cultures are indicated by 
(+). EtOH and Chl = Ethanol and choloroform. Results shown represent one of 2 independent 
experiments with similar results. 
 
4.3.2 Dose response: effects of vitamins K1, K2 and K3 treatments on BCG in vitro   
Earlier experiments presented in chapter 2 (fig. 12) showed up to 90% BCG 
growth inhibition at 12 µg/ml of vitamin K1 in Wayne cultures. To broaden the test range, 
growth inhibition was further tested from 0.5 - 300 µg/ml vitamin K1 under both shaking 
and stirring conditions (fig. 23). A dose-dependent effect (fig. 23) was observed upon 
increasing vitamin K1 concentration. Based on bacterial counts in shaking cultures, the 
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DMSO EtOH DMSO EtOH
2 68.2 68.2 31.8 31.8
5 96.9 80.8 3.1 19.2
8 96.4 93.0 3.6 7.0
12 94.6 92.7 5.4 7.3
% treated over control % inhibition
Days
DMSO EtOH DMSO EtOH
2 64.9 37.8 35.1 62.2
5 49.3 57.2 50.7 42.8
8 55.3 71.3 44.7 28.7
12 97.3 55.3 2.7 44.7
% treated over control % inhibition
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maximum inhibition observed was 9, 16 and 29-fold reduction corresponding to 12, 60 
and 300 µg/ml of vitamin K1-treated cultures (fig. 24a). In stirring cultures, the maximum 
inhibition observed was 9, 32 and 77-fold reduction corresponding to 12, 60 and 300 
µg/ml of vitamin K1-treated cultures (fig. 24b). Thus, a significantly higher inhibition 
was noted in stirring than in the shaking cultures.  
Upon increasing concentration of vitamin K1, it was notable that colony counts 
did not correspond to the optical density readings. At the highest concentration of vitamin 
K1 tested (300 µg/ml), in stirring cultures, 1.2-fold reduction in absorbance was noted on 
day 8 but 77-fold reduction was noted by colony counts (fig. 23e, h). Vitamin K1 
treatment was bactericidal to a large proportion of the non-replicating bacteria in stirred 
cultures, since after re-aeration of stirring cultures (day 15), there was still a 62.5-fold 
reduction in viable counts in treated tubes relative to untreated tubes. Thus, these hypoxic 
bacteria failed to recover from ‘latency’. By comparison, the re-aerated shaking cultures 
showed a lower extent of growth inhibition (11.6-fold) attributable to treatment.  
In summary, there was clearly a greater inhibitory effect of vitamin K1 on BCG 
viability in oxygen-limited cultures than aerobic cultures. At the highest concentration of 
vitamin K1 tested, only about 1.3% of the bacteria were cultivable when compared to the 
untreated cultures after they were re-aerated.  














































Figure 23. Legend on next page 
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Figure 23 (previous page). Dose effects of vitamin K1 on wild-type BCG in 
Wayne model 
Growth curve of BCG with vitamin K1 treatment (‘treated’) or with diluent alone (‘control’) at (a) 0.5 
(b) 2.4 (c)12 (d) 60 (e) 300 µg/ml in shaking and stirring cultures. Figs. (f) – (h) show 
corresponding bacterial counts. Each point is the mean of triplicate tubes ± 2SD. Arrows indicate 
the time-point at which cultures were opened for re-aeration and diluted 1:100 into fresh media. 
Asterisks denote significant differences between treated and control tubes at the same time point 
and the same aeration condition (p < 0.05). Results shown from one representative experiment 
















Figure 24. Fold reduction in growth of wild-type BCG due to vitamin K1 
treatment in Wayne model 
Based on the raw data presented in fig. 23, the fold reduction in bacterial counts due to vitamin K1 
treatment was calculated as the mean colony counts in control over treated cultures in (a) 
shaking and (b) stirring cultures at vitamin K1 concentrations of 12, 60 and 300 µg/ml. Horizontal 
broken line indicates no change after treatment (i.e. fold reduction = 1).  
 
Vitamin K2 treatment resulted in a different response. There was a dose-
dependent growth inhibition in shaking cultures (fig. 25) but the extent of inhibition was 
much lower than for vitamin K1 — only up to 7-fold reduction was noted in colony 
counts in the log growth phase (up till day 5) at the highest dose tested (fig. 26a). In the 
stirring cultures, there was no dose-dependent response at log phase, and the extent of 
inhibition was similar to the shaking cultures. Moreover, during the NRP-2 phase (days 8 
and 12),
 
not only was there no enhancement of the growth inhibition in stirring cultures 
(as found in vitamin K1), but paradoxically, cultures treated with 300 µg/ml vitamin K2 
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showed slightly better growth (fig. 25h). With the lower concentrations (12 to 60 µg/ml) 
of vitamin K2 there was little effect of treatment at NRP-2 time-points. It was intriguing 
to note that with vitamin K2, it was the shaking cultures which showed the greater loss of 
viability upon re-aeration as compared to the stirring cultures (4.7-log reduction in 
shaking vs 5.6 fold-reduction in stirring at 300 µg/ml). It is possible that in stirred 
cultures at NRP-2 when there is increased demand for MK (described in chapter 2), the 
addition of high concentrations of vitamin K2 could have a supplementary effect and 
reduce the susceptibility of NRP cultures to oxygen depletion.  









































Figure 25. Dose effects of vitamin K2 on wild-type BCG in Wayne model 
Growth curve of BCG with vitamin K2 treatment (‘treated’) or with diluent alone (‘control’) at (a) 0.5 
(b) 2.4 (c)12 (d) 60 (e) 300 µg/ml in shaking and stirring cultures. Figs. (f) – (h) show 
corresponding bacterial counts. Each point is the mean of triplicate tubes ± 2SD. Arrows indicate 
the time-point at which cultures were opened for re-aeration and diluted 1:100 into fresh media. 
Asterisks denote significant differences between treated and control tubes at the same time point 
and the same aeration condition (p < 0.05). Results shown from one representative experiment 
out of three independent experiments. 
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Figure 26. Fold reduction in growth of wild-type BCG due to vitamin K2 
treatment in Wayne model 
Based on the raw data presented in fig. 25, the fold reduction in bacterial counts due to vitamin K2 
treatment is calculated as the mean colony counts in control over treated cultures in (a) shaking 
and (b) stirring cultures at vitamin K2 concentrations of 12, 60 and 300 µg/ml. Horizontal broken 
line indicates no change after treatment (i.e. fold reduction = 1). 
 
Vitamin K3 showed the greatest inhibitory effect, when compared to vitamin K1- 
or vitamin K2-treated cultures. This was evident even at the low concentration of 12 
µg/ml where 72.5-fold reduction in optical density readings were noted at NRP-2 in 
stirring cultures (fig. 27). The stirred cultures showed more inhibition at this 
concentration (12 µg/ml) than shaking cultures (42-fold reduction). There was a clear 
dose-dependent response at the range of 0.5 to 12 µg/ml in both shaking (1.3 to 42-fold 
reduction) and stirring cultures (1.2 to 72.5-fold reduction). At the highest dose tested (12 
µg/ml), both the shaking and stirring cultures showed more than 99% inhibition after re-
aeration.  It was evident that vitamin K3 had the greatest mycobacterium inhibitory effect 
of all the three vitamin K compounds tested. The inhibitory effects are consistent with 
prior studies which were carried out aerobically only (Armstrong et al., 1943; 
Gangadharam et al., 1978; Leahy et al., 1968; Tran et al., 2004). However, since vitamin 
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K3 is hepatotoxic (O'Brien, 1991) and unlikely to be suitable for human use, its effects at 
higher concentrations were not further investigated.  











































Figure 27. Growth curve of BCG with vitamin K3 treatment (‘treated’) or with 
diluent alone (‘control’) at (a) 0.5 (b) 2.4 (c)12 µg/ml in shaking and stirring cultures. Arrows 
indicate the time-point at which cultures were opened for re-aeration and diluted 1:100 into fresh 
media. Results shown from one representative experiment out of three independent experiments. 
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4.3.3 Susceptibility of control and menA KD BCG to vitamin K by broth 
microdilution method  
The Wayne model used so far for testing effects of vitamin K in shaking and 
stirring cultures is very useful for studying relative effects of compounds on hypoxic 
(‘latent’) and non-hypoxic mycobacteria. However, it requires large culture volumes with 
corresponding large quantities of vitamin K, and is also highly labour-intensive. Hence, 
the NCCLS broth micro-dilution method (BMM) of antimicrobial susceptibility testing 
for mycobacteria in clinical diagnostic labs, using 96-well plates, was adopted for the 
purpose of miniaturising the process and to allow higher throughput testing. A larger 
range of concentrations of vitamins K1 and K2 were tested for BCG growth inhibition at 
day 5. In addition to looking for macroscopic growth in the wells, colony counts were 
obtained for each vitamin K concentration. The highest concentration of vitamin K tested 
was 1.25 mg/ml because the vitamins were not fully soluble in 0.5% DMSO beyond this 
concentration, and increasing the DMSO concentration would cause significant diluent-
induced bacterial growth inhibition (see fig. 22).  
Unexpectedly, with BMM for testing susceptibility (fig. 28), the concentration of 
vitamin K required to produce a significant decline in colony counts was much higher 
than with either the shaking or stirring cultures in the Wayne model. With BMM, there 
was a significant decline in colony counts only at or above 625 µg/ml of either vitamin 
K1 or vitamin K2 and the extent of inhibition was much lower than in Wayne cultures. 
For vitamin K1 at 1.25 mg/ml, there was only a 1.8-fold reduction in bacterial counts 
tested in 96-well plates whereas there was a 21.7 and 9.1-fold reduction in colony counts 
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respectively in shaking and stirring cultures at just 300 µg/ml on day 5 in the Wayne 
model (fig. 24). Possible reasons for this will be discussed later.  
Next, a comparison was made between the relative susceptibility of pMV261 
control BCG and menA KD BCG (figs. 29, 30). With 1.25 mg/ml of vitamin K1, 
treatment of the pMV261 control BCG resulted in a 37.7% inhibition (1.6-fold 
reduction), similar to the wild-type BCG result. Under the aerobic BMM testing method, 
the menA KD BCG had a similar susceptibility to vitamin K1 and K2 as the control BCG.  

































Figure 28. Broth microdilution method for testing response to Vitamins K1 
and K2 
Wild-type BCG (1 x 106/well) were treated with increasing concentrations of  (a) vitamin K1 and 
(b) vitamin K2 in 96-well plates incubated aerobically without shaking. After 5 days, surviving 
bacterial counts were enumerated by plating on 7H10 agar. Each point is the mean of triplicates, 
error bars represent 2 SDs. Asterisks denote significant differences between treated and 
untreated (diluent alone) tubes (p < 0.05). One representative experiment out of two independent 
experiments with similar results is shown. 
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Figure 29. Survival of control BCG versus menA KD BCG with 14 day 
vitamin K1 treatment 
Vector control BCG carrying pMV261 plasmid (‘control BCG’) and menA KD BCG were used. The 
two strains of BCG (1 x 106/well) were treated with increasing concentrations of vitamin K1 in 96-
well plates incubated aerobically without shaking. After 14 days, surviving bacterial counts were 
enumerated by plating on 7H10 agar. Data are presented as bacterial counts per ml (a, c) and as 
% viability following vitamin K1 treatment (b, d). % viability is defined as bacterial counts in 
(treated/control) x 100%. For bacterial counts, means of triplicate wells ± 2 SDs are shown. 
Asterisks denote significant differences between treated and untreated (diluent alone) tubes (p < 
0.05). One representative experiment out of two independent experiments is shown. 
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Figure 30. Survival of control BCG versus menA KD BCG with 14 day 
vitamin K2 treatment 
Vector control BCG carrying pMV261 plasmid (‘control BCG’) and menA KD BCG were used. The 
two strains of BCG (1 x 106/well) were treated with increasing concentrations of vitamin K2 in 96-
well plates incubated aerobically without shaking. After 14 days, surviving bacterial counts were 
enumerated by plating on 7H10 agar. Data are presented as bacterial counts per ml (a, c) and as 
% viability following vitamin K2 treatment (b, d). % viability is defined as bacterial counts in 
(treated/control) x 100%. For bacterial counts, means of triplicate wells ± 2 SD are shown. 
Asterisks denote significant differences between treated and untreated (diluent alone) tubes (p < 
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4.3.4 Synergistic effects of anti-mycobacterial drugs and vitamin K 
It was of interest to determine whether vitamin K compounds could enhance the 
mycobactericidal activity conferred by conventional anti-mycobacterial drugs. The 
results obtained from combined treatment are shown in Table 10, and are based on the 
BMM (for MIC100) plus colony counting (for MBC99). M. chelonae (a fast-grower) and 
M. avium (a slow-grower) were also tested in parallel. The latter is genetically very 
















Table 10. MIC100 and MBC99 for combinations of anti-mycobacterial 
antibiotics with vitamin K against BCG, M. avium and M. chelonae 
Susceptibility testing by the broth microdilution method in 96 well plates according to NCCLS 
protocol (described in Methods). All conditions were tested in triplicate wells. In addition, 
bactericidal effects were determined by plating growth-inhibited broth cultures on agar to test for 
viable counts. MIC100 means the lowest concentration of antibiotic at which no visible growth of 
mycobacteria was observed after 14 days. MBC99 means the the lowest concentration of 
antibiotic at which treated cultures yielded <1% of colonies compared to untreated (control) 
cultures. MIC were read after 14 days except against Mycobacterium chelonae (5 days). Where 
vitamins K1 and K2 were added, a standardised 1.25 mg/ml (final concentration) of each vitamin 
was tested. ‘control BCG’ refers to BCG bearing empty vector pMV261 as control for menA KD 
strain. The results shown represent one out of three independent experiments with similar results. 
 
Analysing the MIC100 and MBC99 values for wild-type BCG, the addition of 
vitamin K2 to rifampicin (RIF) and isoniazid (INH) increased both values by 2-fold. 
Similar effects were noted for RIF + vitamin K1 whereas no changes were observed with 
MIC100 MBC99 MIC100 MBC99 MIC100 MBC99 MIC100 MBC99 MIC100 MBC99
Rifampicin 0.0016 0.0016 0.00313 0.0016 0.0016 0.0016 4 4 16 16
Rifampicin + K1 0.0008 0.0008 0.0016 0.0016 0.0008 0.0016 2 2 8 8
Rifampicin + K2 0.0008 0.0008 0.0008 0.0016 0.0016 0.0016 2 2 8 8
Isoniazid 0.125 0.125 0.125 0.125 0.0625 0.0625 64 32 8200 8200
Isoniazid + K1 0.125 0.125 0.125 0.125 0.0625 0.0625 16 32 4100 4100
Isoniazid + K2 0.125 0.0625 0.125 0.125 0.0625 0.125 16 64 8200 8200
Streptomycin 0.250 0.125 0.250 0.250 0.125 0.125 4 4 32 32
Streptomycin + K1 0.250 0.250 0.250 0.250 0.125 0.125 4 4 8 16
Streptomycin + K2 0.250 0.125 0.250 0.250 0.125 0.125 8 8 16 16
Ethambutol 2 2 4 4 2 2 4 2 128 128
Ethambutol + K1 2 2 4 4 4 4 4 4 32 64
Ethambutol + K2 2 2 4 4 4 4 4 4 32 32
M. chelonae (ug/ml)wild-type BCG (ug/ml) control BCG (ug/ml) anti-sense BCG (ug/ml) M. avium (ug/ml)
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other combinations. The addition of vitamin K2 to either INH or EMB resulted in higher 
resistance in menA KD BCG to the antibiotics. However, the addition of vitamin K to the 
antibiotics did not significantly modify the bactericidal activity (MBC99) to either control 
or menA KD BCG.  
In M. avium, the addition of both vitamin Ks increased the inhibition of RIF 
alone, but decreased the inhibitory effects of EMB. Decreased inhibition against M. 
avium was only observed with vitamin K2 when combined with INH or STR. The 
susceptibility of M. chelonae to all four drugs was increased by vitamin K1 (2-fold 
change). Vitamin K2 showed more divergent results; higher inhibitory effects with RIF, 
STR and EMB-treated M. chelonae but not with INH.  
Overall, the results obtained in Table 10 showed very minimal effects, in terms of 
the concentration at which inhibitory activity was observed (MIC), when exogenous 
vitamin K was added to conventional anti-mycobacterial agents. This suggests that based 
upon MIC tested through the BMM, there is no significant synergy between conventional 
anti-mycobacterial agents with vitamin K in vitro. Wayne (hypoxic) cultures were not 
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4.3.5 Additive effect of vitamin K to bactericidal activity of standard anti-
mycobacterial antibiotics  
Table 10 indicates the concentrations of antibiotics at which inhibitory activity 
was observed but it does not show the actual extent of growth inhibition (bacterial 
viability) at that concentration. To investigate this, actual colony counts of viable 
mycobacteria post-treatment at MBC99 for each antibiotic was examined, with or without 
addition of vitamin K (fig. 31, 32).  This is to test whether and to what extent addition of 
vitamin K to standard antibiotics has an additional effect in increasing the bactericidal 
activity. 
For control pMV261 BCG, addition of vitamin K1 to INH, STR and EMB 
increased the bactericidal activity – vitamin K1 gave an additional 5.8-fold increase in 
killing over STR alone (fig. 31). This is a synergistic effect as the earlier results (fig. 29) 
suggest that vitamin K1 alone only gives a 1.6 fold reduction in bacterial counts when the 
cultures were grown according to the BMM. Vitamin K2 improved the bactericidal 
activity of RIF and EMB against control BCG but by a smaller extent, which could not be 
considered synergistic. Similar results were seen with wild-type BCG (data not shown). 
Notably, there was no additive effect of either of the two vitamins to the bactericidal 
activity of antibiotics against menA KD BCG (fig. 31) except for EMB.  
In fig. 32,  M. avium (clinical strain), the additive effect of vitamin K1 and vitamin 
K2 to the bactericidal activity of EMB was highly significant (1265-fold and 569-fold 
respectively). For vitamin K1 there was also a large effect in combination with INH 
(1277-fold reduction attributable to vitamin K1). Additive effects in M. chelonae (clinical 
strain) were more modest, with less than 5-fold increase in killing when combined with 
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RIF, STR and EMB (vitamin K1) while vitamin K2 only showed synergistic effects with 
RIF  (6.6-fold additional killing).  This trend was similar to the differential contribution 


















Figure 31. BCG: Reduction in bacterial counts attributable to additive 
effects of vitamin K 
In 96-well plates incubated aerobically without shaking, control pMV261 BCG or menA KD BCG 
(1 x 106 cfu) were either treated with the minimum bactericidal concentration (MBC99) of standard 
anti-mycobacterial drugs, or to the same antibiotic concentration plus 1.25 mg/ml of vitamin K (K1 
or K2 in separate wells). Viable bacterial counts post-treatment were enumerated by plating on 
7H10 agar after 14 days of exposure. Each bar represents the fold reduction in bacterial counts 
attributable to vitamin K. Fold reduction is defined in this graph as the ratio of bacterial counts in 
the antibiotic-treated cultures over cultures with antibiotics combined with vitamin K1 or K2. The 
horizontal broken line represents fold reduction =1 (i.e. no additive effect of vitamin K). One of 2 

































































































Figure 32. M. avium and M. chelonae : Reduction in bacterial counts  
attributable to additive effects of vitamin K 
In 96-well plates incubated aerobically without shaking, Mycobacterium avium and 
Mycobacterium chelonae (1 x 106 cfu) were either treated with the minimum bactericidal 
concentration (MBC99) of standard anti-mycobacterial drugs, or to the same antibiotic 
concentration plus 1.25 mg/ml of vitamin K (K1 or K2 in separate wells). Viable bacterial counts 
post-treatment were enumerated by plating on 7H10 agar after 14 days (M. avium) or 5 days of 
drug exposure (M. chelonae). Each bar represents the fold reduction in bacterial counts 
attributable to vitamin K. Fold reduction is defined in this graph as the ratio of bacterial counts in 
the antibiotic-treated cultures over cultures with antibiotics combined with vitamin K1 or K2. The 
horizontal broken line represents fold reduction =1 (i.e. no additive effect of vitamin K). One of 
two independent experiments with similar results is shown.  
 
4.3.6 Synergism between vitamin K and pyrazinamide 
Pyrazinamide (PZA) is unique for being more active against semi-dormant 
organisms in stationary phase cultures (Wade and Zhang, 2004) and at relatively acidic 
pH, akin to phagosomal conditions in which intracellular mycobacteria reside (Zhang et 
al., 1999; Zhang and Mitchison, 2003; Zhang et al., 2003). PZA treatment of control 
BCG and menA KD BCG under aerobic and anaerobic conditions were studied in parallel 
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Under aerobic conditions, with control pMV261 BCG, vitamin K1 alone did not 
affect bacterial counts and vitamin K2 was also not highly effective (2.2-fold reduction) 
relative to untreated cultures (fig. 33c)  – these results are consistent with data presented 
earlier (figs. 29, 30). The combination with PZA was not synergistic in aerobic conditions 
as the addition of vitamin K1 and K2 to PZA made no contribution at all to BCG killing 
relative to PZA alone (fig. 33d). Vitamin K1 treatment alone surprisingly resulted in a 
small 3.3-fold reduction of menA KD BCG (more than the 0.9-fold reduction in control 
BCG, fig. 33c), relative to untreated cultures. The apparent discrepancy in this result 
from fig. 29 is discussed later. However, the addition of either vitamins K1 or K2 did not 
add to the bactericidal activity of PZA against menA KD BCG under aerobic conditions 
(fig. 33d). 
Under anaerobic conditions (fig. 33b, c), the results were remarkably different. 
The biggest difference from aerobic cultures (fig. 33a) was that the efficacy of all three 
compounds (PZA, vitamin K1 and K2) was markedly increased against both strains. 
Inhibitory effects of PZA alone on control BCG increased from 6.5-fold in aerobic to 
14.5-fold in anaerobic cultures, comparing counts in untreated over treated cultures. The 
equivalent data against menA KD were 5.5-fold vs 44.1-fold respectively (fig. 33c). 
However, the most impressive increase of efficacy in anaerobic conditions were seen 
with vitamin K1 as there was a 348-fold suppression of control BCG bacterial counts (vs 
only 0.9-fold reduction in aerobic cultures). Vitamin K2 showed a smaller increase in 
efficacy under anaerobic conditions (9.4-fold reduction vs 2.2-fold in aerobic cultures). 
Relative to untreated cultures, there was a larger extent of inhibition in both strains to 
vitamin K1 than with vitamin K2, alone and in combination with PZA (fig. 33c). Most 
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importantly, combination with vitamin K1 increased the bactericidal activity of PZA 
against control BCG by 32.1-fold under anaerobic condition (fig. 33e), whereas there was 
no additional contribution of vitamin K2 to PZA-mediated killing. Against menA KD 
BCG, there was a lesser contribution of combination with vitamin K1 (8.2-fold increase) 
and minimal with vitamin K2 (2-fold increase) relative to PZA alone (fig. 33e).  





































Figure 33. Effects of pyrazinamide and Vitamin K combinations under 
aerobic and anaerobic conditions 
Control BCG and menA KD BCG (1 x 106/well) were treated with either 100µg/ml of pyrazinamide 
alone or with 1.25mg/ml of vitamin K1 or vitamin K2 in 96-well plates under (a) aerobic and (b) 
anaerobic conditions. After 5 days, surviving bacterial counts were enumerated by plating on 
7H10 agar. Each point is the mean of triplicate wells, error bars represent 2 SD. Asterisks denote 
significant differences between treated and untreated (diluent alone) tubes (p < 0.05). (c) Mean 
fold reduction of six replicates from 2 independent experiments (ratio of bacterial counts in 
untreated over treated cultures). (d, e) Mean fold reduction due to Vitamin K1 under aerobic and 
anaerobic conditions respectively from six replicates in 2 independent experiments, calculated as 
bacterial counts in PZA-treated/PZA+vit.K-treated cultures. The horizontal broken line represents 
fold reduction =1. 
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Overall, the combination of vitamin K1 with PZA did not enhance PZA 
bactericidal effects on BCG in aerobic cultures but killing activity attributable to vitamin 
K1 was very significantly increased in anaerobic cultures (32-fold enhancement of killing 
attributable to vitamin K1). This is likely to be because each of vitamin K1 and PZA alone 
are much more effective in anaerobic conditions. This supports our observation from 
Wayne cultures (figs. 23, 24) and explains why those earlier data differed significantly 
from the aerobic BMM (fig. 28) in terms of vitamin K1 efficacy. Vitamin K2 did not 
enhance the activity of PZA against BCG under aerobic conditions, but there was a small 
increase in killing (9.4-fold reduction attributable to vitamin K2) when they were 
combined under anaerobic conditions. The menA KD generally showed less susceptibility 
to the combination than the control BCG under both conditions.  
 
4.3.7 Vitamin K1 treatment of BCG-infected mice  
Human clinical trials investigating the effects of vitamin K1 and vitamin K2 on 
bone calcium and osteoporosis have used, respectively, up to 1 mg over 36 months and 
45 mg per day over 24 months without ill effects (Cockayne et al., 2006). Hence, we 
assumed this was the maximum clinically relevant dose range of exogenous vitamin K. 
To study in vivo effects of vitamin K1 on established mycobacterial infection, mice were 
given a moderate dose of wild-type BCG (105 cfu) intravenously and 5 weeks post-
infection, they were dichotomised to receive continuous oral treatment of either 500 µg 
vitamin K1/kg body weight per day or vitamin K1 diluent alone, then sacrificed for 
bacterial load determination at 8 weeks post-infection (fig. 34a). There was a 1 to 2 log 
reduction in bacterial count recovered from infected mouse organs in the treated group, 
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compared to controls fed with diluent (data not shown). The bacterial load reduction was 
most significant in the liver (85%), followed by lungs (75%) and spleen (69.7%) (fig. 
34b). This shows that in vivo vitamin K1 treatment alone has functional mycobactericidal 
activity against bacteria in the host organs. 





































Figure 34. BCG growth inhibition and differential expression of menA in 
BCG in murine organs after vitamin K1 treatment 
(a) Schematic diagram of murine infection and treatment schedule. (b) % suppression is defined 
as 100-(colony counts from organs of treated mice over counts in control mice) x100%. This is a 
measure of inhibition of bacterial growth in vitamin K1 treated mice relative to diluent-treated 
(control) mice. Each point is the mean of the results obtained from 3 to 4 mice, results are one of 
the two independent experiments with similar results. (c) Mice were either treated for 3 weeks 
with vitamin K1 (treated) or diluent alone (control) according to treatment schedule shown in (a). 
Bacterial RNA was extracted from BCG in organs of infected mice at day 56 post-infection, as 
described in Methods. RNA was pooled from 3 to 4 mice per group. menA expression was 
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4.3.8 MK biosynthetic pathway is differentially expressed within host tissues  
Using mice infected with 105 cfu of BCG (fig. 34), we investigated whether genes 
encoding enzymes in the MK biosynthetic pathway were differentially expressed in BCG 
within host tissues upon treatment with vitamin K1. RNA from bacteria in various organs 
were extracted and analysed for menA expression. At day 56, there was a 0.5-log increase 
in expression in the livers and a 3.5-log increase in lungs of vitamin K1-treated mice (fig. 
34c). However, a smaller 0.5-log reduction in menA expression was observed in spleens 
of treated mice, suggesting a possible differential effect of vitamin K1 on utilisation of 
MK by BCG sequestered in different organs.  
 
4.3.9 Differential effects of vitamin K1 on in vivo bacteria at different stages of 
infection 
The moderate dose (105 cfu) BCG infection was also used to study if vitamin K1 
had differential inhibitory effects on bacteria when administered early (3 weeks post-
infection) or late (5 weeks post-infection) in the course of infection. The early treatment 
would correspond to the active stage of infection when there is a rising bacterial burden 
and the late treatment would be in the chronic stage of the infection when there is a stable 
bacteria load in organs (Orme, 1994). A 2-log reduction in colony counts in the lungs was 
observed after early and late treatment (fig. 35b). Fig. 35c showed that vitamin K1 
administration in the early stages of infection (day 35) reduced BCG counts to a slightly 
greater extent than in later stage (90% vs 85% suppression in 3 weeks). Based on these 
observations, vitamin K1 treatment was only slightly more efficacious if administered 
earlier in the infection (in the active rather than chronic stage). 

































Figure 35. Effect of vitamin K1 treatment early and late post-BCG infection  
(a) Infection and treatment schedule showing early and late treatment at 3 and 5 weeks post-
infection respectively. 
(b) Comparison of colony counts in lungs of infected mice in treated and non-treated (diluent 
treated) groups. Each point shows the means of 3-4 mice per group ± 2SD. Where error bars 
are not seen, the error values fall within the symbols. Arrows indicate the time-points at which 
vitamin K1 was administered. Asterisks denotes significant differences between treated 
(early) and control mice (p<0.05) whereas ‘+’ denote significant difference between treated 
(late) and control mice (p<0.05). 
(c) % suppression is defined as 100 – (colony counts from organs of treated/control mice) x 
100%. This is a measure of inhibition of bacterial growth in vitamin K1 treated mice relative to 
diluent-treated (control) mice at 56 days post-infection. Each bar shows the average data 
from of 3-4 mice per group.One out of the two independent experiments with similar results is 
shown. 
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4.3.10 Effect of vitamin K1 in an in vivo murine model of latent infection    
In human patients with asymptomatic latent tuberculosis infection, there is a 10% 
lifetime risk of reactivation resulting in active disease. It is thought that in latently 
infected people, there are low levels of persistent mycobacteria lying ‘dormant’ under 
suppressive effects of host immunity, and reactivation is related to events reducing this 
immunity. To study the in vivo effects of vitamin K1 treatment on mycobacterial 
reactivation, a model of latent murine infection was set up (fig. 36a). Balb/c mice were 
given a low dose (103 cfu) of BCG intravenously and after 5 weeks of infection, some 
mice were orally given 21 days of 500 µg vitamin K1/kg body weight per day, while 
others were given vitamin K1 diluent (control) alone. All mice were treated with 
prednisolone three weeks later to suppress host immunity, for the purpose of inducing 
mycobacterial reactivation. The infected mice were sacrificed for lung bacterial load 
determination 120 days from the start of infection.  
After 3 weeks of vitamin K1 treatment, a 4-fold bacterial load reduction in the 
lungs was observed (day 56, treated compared to control mice) (fig. 36b). Four weeks 
after immune suppression by treatment with prednisolone (day 84), bacterial load was 
significantly reduced by 147-fold in treated mice compared to untreated mice. The 
difference was still evident 9 weeks after the start of prednisolone treatment (120 days 
post-infection, fig. 36b). Hence, vitamin K1 treatment alone significantly limited the 
extent of reactivation of mycobacteria in vivo, in spite of suppressed host immunity over 
a prolonged period of infection. However, such treatment alone was insufficient to fully 
eliminate the BCG over the period of observation. 















Figure 36. Effect of vitamin K1 on reactivation of BCG on host 
immunosuppression 
Infection and treatment schedule for this experiment. Following 5 weeks of low dose BCG 
infection (103 cfu in 0.1 ml PBS), mice were either treated with vitamin K1 or its diluent orally for 
21 days, followed by oral prednisolone from day 56 till day 120. Viable bacterial counts in lungs of 
treated and control mice at various time-points. Each point shows the means of 3 mice per group 
± 2SD. Where error bars are not seen, the error values fall within the symbol. Asterisks denote 
significant differences between treated and control mice (p <0.05). Thin arrow indicates the start 
of vitamin K1 administration and thick arrow indicates point of prednisolone administration. Figure 
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4.4 DISCUSSION 
The increasing prevalence of tuberculosis, in addition to the dire consequences of 
human immunodeficiency virus co-infection with TB (Dye et al., 2002), have fuelled an 
urgent need for the development of new and more efficient anti-mycobacterial drugs. A 
growing threat is the increase of drug-resistant TB strains to INH and RIF, two frontline 
anti-TB drugs (O'Brien and Nunn, 2001; WHO, 2000). There have been no new TB drugs 
developed in the past 40 years (Khasnobis et al., 2002) except for one new candidate 
(Andries et al., 2005) that belongs to a new class of inhibitors that blocks the function of 
an essential membrane-bound enzyme (ATP synthase) responsible for synthsis of 
adenosine triphosphate (ATP). This inhibition may lead to ATP depletion and imbalance 
in pH homeostasis, both contributing to decreased survival (Deckers-Hebestreit and 
Altendorf, 1996; Rao et al., 2001). Such a discovery has shown the potential of using 
specific enzymes involved in energy metabolism and redox balance in MTB as drug 
targets.  
As anti-bacterials are often inhibitors of certain bacterial enzymes, all enzymes 
specific to bacteria can be considered as potential drug targets (Galperin and Koonin, 
1999). This is supported by computational metabolic pathway analysis (Anishetty et al., 
2005). In the work by Annishetty, proteins which are involved in ubiquinone/menquinone 
biosynthesis, energy metabolism (cytochrome bd oxidase subunit I) and anaerobic 
phosphorylative electron transport chain (fumarate reductases) have potential as drug 
targets because there are no human homologues. Work on NADH dehydrogenase 
inhibitors as anti-TB agents proves that it is reasonable to speculate that the modulation 
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of electron transport in mycobacteria could have a profound effect on the entrance and 
maintenance of dormancy (Weinstein et al., 2005).  
Several studies have shown that menaquinone is an electron carrier in the electron 
transport chain of MTB (Kusunose and Goldman, 1963; Segel and Goldman, 1963). At 
the start of our studies, we originally thought that vitamins K1 (phylloquinone) and K2 
(menatetrenone) could not be inhibitory to mycobacteria since we initially assumed that 
exogenous vitamin K would probably supplement rather than antagonise endogenous MK 
produced by BCG. The vitamin K forms that we tested are also analogues of ubiquinones, 
which has been shown to stimulate the growth of MTB (Norman and Williams, 1962). 
On the other hand, there is evidence that several compounds with a  naphthoquinone 
structure similar to MK have anti-mycobacterial activity against MTB (Panisset et al., 
1952) as shown by rifampicin which is a powerful anti-tuberculosis antibiotic in clinical 
use (Prelog, 1963). The mode of action of rifampicin is the inhibition of RNA synthesis 
(Table 2); it is not known to influence bacterial MK. In a study by Ganngadaharam et. al 
(Gangadharam et al., 1978), 6-cyclo-octylamino-5,8-quinolinequinone (CQQ) exhibited 
considerable activity in vitro against several strains of Mycobacterium intracellulare and 
MTB, including rifampicin-resistant strains but not against rapid-growers in the 
Mycobacterium genus. In a study using compounds such as plumbagin and juglone 
(active component is a quinone), the MIC against M. avium was 12.5 µg/ml but a higher 
MIC of 400 µg/ml were observed in MTB. This shows that  quinones could have unique 
activity against mycobacteria (Tran et al., 2004). Those studies above neither test the 
compounds on latency against actively growing MTB and did not attempt to find out how 
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quinones might act. It is also not certain whether differential activity against various 
species relates to differences in the nature of MK produced.  
Vitamin K1 is produced in plants whereas vitamin K2 is produced in bacteria 
(Bentley and Meganathan, 1982). They share a common 2-methyl-1,4-naphthoquinone 
ring but differ in the structures of the side chain at the 3-position (Elston et al., 1995; 
Shearer, 1995). Vitamin K2 is distinguished from Vitamin K1 by unsaturated side chains 
of isoprenoid units varying in length from 1 to 14 repeats (fig. 4). This structural 
difference could account for our observations of a higher level of anti-mycobacterial 
effect in vitamin K1- (figs. 23, 24) than in vitamin K2-treated cultures (figs. 25, 26). It is 
reasonable to speculate that the spatial orientation of active sites to their respective 
binding partners might differ, resulting in a different level of activity in vitro. The 
differential inhibitory activity of vitamin K3 (fig. 27) versus vitamins K1 or K2 on the 
treated BCG cultures could possibly be accounted for by the fact that vitamin K3 has no 
isoprenoid side-chain (fig. 4) whereas the other two vitamin Ks do (Gant et al., 1988; 
Moore et al., 1987; Ross et al., 1986). There are no published reports to our knowledge 
specifically examining the mechanism of toxicity of quinones in mycobacteria.  
The closest prediction of the mode of toxicity to mycobacteria related to 
naphthoquinones comes from studies on phenothazines that target the type II 
NADH:menaquinone oxidoreductase in MTB (Weinstein et al., 2005; Yano et al., 2006). 
Phenothazine analogues exhibit tuberculocidal activity both in vitro and in vivo studies. It 
is postulated that phenothiazines act by blocking electron flow to MK, resulting in the 
oxidized state of the respiratory chain that prevents mycobacterial entry into dormancy or 
persistence in vivo (Georgellis et al., 2001; O'Toole et al., 2003). This is because MK is 
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likely to be required in the maintenance of the electron flow in MTB for the balance of 
the NADH/NAD+ ratio in the respiratory chain, which affects ATP production and pH 
balance in the bacteria (Deckers-Hebestreit and Altendorf, 1996; Rao et al., 2001). 
A second way in which vitamin K containing the 1,4-naphthquinone structure 
could interfere with electron transport was hypothesised by Holmes et al. (Holmes et al., 
1964). It was shown that a 1,4-naphthoquinone could be an effective growth inhibitor 
since its redox potential lies between than that of ubiquinone, flavoprotein II, vitamin K2 
and diphosphopyridine nucleotide (DPNH). Hence, 1,4-naphthquinones could react with 
nucleophiles, both the adduct and unreacted 1,4-naphthquinone could contribute to the 
observed growth inhibition.  
A third mechanism for the interference of 1,4 naphthoquinones with electron 
transport is suggested by growth inhibitory activities on S. aureus and E. coli (Leahy et 
al., 1968). These quinones react with a protein-thiol grouping in close proximity to 
endogenous quinones, short-circuiting one or other of the quinones present in the electron 
transport chain. This was supported by another study where several 1,4-naphthoquinones 
reacted with n-butane-thiol but not with primary amines (Silver and Holmes, 1967). 
Otherwise, they could interrupt the growth process by reacting with an essential 
metabolite (Boyer et al., 1963).  
The actions of 2-methyl-1,4-naphthoquinones (menadione or vitamin K3) was 
studied in Bacillus cereus (Klubes and Cerna, 1972). It was found that at 2.5 µM (430.5 
µg/ml) of menadione, the generation time of logarithmic phase cultures were doubled. 
Menadione specifically inhibited RNA synthesis in exponentially growing cells but not 
DNA, protein and cell wall synthesis. The inhibition of RNA synthesis involved both 
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ribosomal and soluble RNA, indicating that menadione blocked RNA synthesis at a step 
prior to or during polymerisation. In another study, menadione growth inhibition was 
attributed to decreased ATP levels, as menadione is a known uncoupler of bacterial 
oxidative phosphorylation (Brodie, 1965). Menadione also decreased the acid-soluble 
sulfhydryl content of inhibited cells. Depletion of cellular SH groups has been proposed 
as yet another mechanism to account for the antibacterial action of naphthoquinones 
(Webb, 1966). Menadione can act catalytically to oxidize bacterial NADPH (Brodie, 
1965) and limit the availability of NADPH for generation of bacterial glutathione (GSH) 
by GSH reductase. It is not clear whether vitamins K1 and K2 may have a similar mode of 
action as menadione although they share the same napthoquinone ring structure.  
Some forms of bacterial MK in the organisms described above are also present in 
BCG (Collins and Jones, 1981). The above evidence on the modes of action of 1,4-
naphthoquinones suggest many possible ways in which exogenous vitamin K1 may 
interfere with electron transport in BCG. However, there is still a need to propose a 
holistic mechanism to account for all the observed effects of vitamin K1 treatment of 
BCG, including the differential inhibition seen in different strains and under various 
aeration conditions.  
We begin with the hypothesis that exogenous vitamin K1 interferes with the 
components in the respiratory chain of mycobacteria (by one of the above mechanisms), 
thereby disrupting the electron transfer function of endogenous MK (hypothesis 1, fig. 
37). The lack of adequate electron transfer may result in a feedback mechanism to 
increase MK production, consistent with the observed overproduction of lipid MK upon 
treatment with vitamin K1 (fig. 20d) and the up-regulation of men gene expression in in 
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vitro treated cultures (fig. 12d) as well as in BCG extracted from vitamin K1–treated mice 
(fig. 34c). However, it is likely that excessive endogenous MK is toxic, as evidenced by 
the data that the BCG strain bearing the ‘sense’-menA plasmid driven by a constitutive 
promoter had poorer growth than the control strain especially in aerobic conditions (fig. 
14c) when MK is less required (fig. 9). Hence, MK overproduction (in the absence of 
increased demand) generates excess MK which is toxic, such that the wild-type BCG has 
reduced survival, even if overproduction of endogenous MK serves to partially or fully 
overcome the electron transport blockade. This would also explain why the menA KD 
strain shows less growth inhibition in the presence of vitamin K1 (figs. 29, 31, 33) since it 
constitutively produces less endogenous MK (figs. 14b, 20d). The up-regulation of MK 
in vitamin K1-treated menA KD cells merely restores the endogenous MK to levels 
equivalent to the untreated control strain (fig. 20d), thus menA KD strain does not face 
with the toxicity of excessive endogenous MK although it is still susceptible to the 
electron transport blockade, which accounts for the partial growth inhibition still 
observed.  










Figure 37. Hypothesis 1 for vitamin K1 mode of action: blockade of electron 
transport pathway mediated by endogenous menaquinone 
A hypothetical model of how exogenous vitamin K1 may block the binding of electrons to 
endogenous menaquinone pool, thus blocking the electron flow to the electron acceptors. This 
results in a compensatory response to restore the electron flow by up-regulating the production of 
MK, resulting in overproduction of MK. MK=endogenous menaquinone, Vit. K=exogenous vitamin 
K1, DHNA=1,4-dihydroxy-2-naphthoic acid, DHNA octaprenyltransferase is the gene product of 
menA that is involved in biosynthesis of endogenous bacterial MK. 
 
An alternative hypothesis for the actions of vitamin K1 is based on inactivation of 
the repressor of men genes (hypothesis 2, fig. 38). It is possible that the production of 
endogenous MK normally drives a negative feedback loop by the binding of MK to the 
repressor of men genes to form a complex, which then acts through the silencer region of 
the men gene promoter to block transcription of the men genes. If vitamin K1 binds and 
inactivates the repressor protein, and the vitamin K1–repressor complex fails to reduce 
transcription, then the feedback mechanism is lost, resulting in excessive MK production 
that is toxic to mycobacteria.  
Since MK requirement is likely to increase in anaerobic conditions, it can be 
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transcription, overproduction of endogenous MK, and increased toxicity. Thus, both the 
above hypotheses are consistent with our observations of selectively higher growth 
inhibition attributable to vitamin K1 treatment under hypoxic relative to active growth 
conditions (figs. 12, 20, 24b, 33b) and in vivo (fig. 34, 35, 36) where BCG adaptations to 
latency increase MK demand. 





















Figure 38. Hypothesis 2 for vitamin K1 mode of action: transcriptional 
regulation of men genes 
(a) A hypothetical model for feedback regulation of endogenous menaquinone production in BCG. 
(b) Proposed mechanism of vitamin K1 inhibition of the feedback pathway for the regulation of 
menaquinone biosynthesis. MK=endogenous menaquinone, Vit. K = exogenous vitamin K1, 
DHNA =1,4-dihydroxy-2-naphthoic acid, DHNA octaprenyltransferase is the gene product of 
menA that is involved in biosynthesis of endogenous bacterial MK. 
Excess MK binds Repressor 
of men genes 
Repressor-Silencer complex inhibit men expression of enzymes for 
biosynthesis of MK.
























b Exogenous vitamin K1 binds men gene repressor, preventing MK 
from binding
Repressor-vitamin K1 complex is of a different conformation and fails 
to bind optimally to Silencer
Lack of repression of men genes leads to MK overproduction
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A major drawback of existing TB drugs is that they target mainly cell processes in 
active growing bacteria such as cell wall biogenesis and chromosome replication except 
for RIF and PZA (Heifets and Lindholm-Levy, 1992). For this reason, in a TB patient 
who starts treatment, after the initial rapid bacterial burden reduction due to elimination 
of the actively growing bacteria, there remains a small population which may be in the 
‘dormant’ or ‘latent’ state which has been described in many studies as a ‘metabolically 
inactive’ or ‘non-replicating persistence’ state (Parrish et al., 1998). It is postulated that 
they are less susceptible to these conventional TB drugs (Mitchison, 1980) when they 
adapt to a persistent phase of infection (Gangadharam, 1980). This necessitates 
continuation of treatment for 6 to 9 months as it is reasoned that latent bacteria may begin 
multiplying during this time and become susceptible to the drugs (Duncan and 
Sacchettini, 2000). This prolonged treatment frequently leads to patient non-compliance 
and exposure to side-effects (Shakya et al., 2004). Combination therapy with drugs active 
against rapidly growing MTB as well as latent MTB is therefore likely to reduce the need 
for prolonged treatment; hence the search for the latter class of drugs is a key goal of 
current TB chemotherapeutic research. 
There is evidence that vitamin K1 has selective inhibitory properties against 
dormant bacteria. This is demonstrated through the differential magnitude of growth 
inhibition and markedly differential survival upon re-aeration in stirring versus shaking 
Wayne cultures (fig. 23, 24). However, the inhibitory properties of vitamin K1 were not 
seen in the aerobically incubated 96-well plate cultures (BMM), and dose-titration 
suggested that much higher amounts of vitamin K1 were needed to achieve less than 2-
fold inhibition (fig. 28a). It is likely that the level of oxygenation in the media crucially 
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affects bacterial physiology and thereby the efficacy of vitamin K1. Two lines of evidence 
support this contention. First, there were marked differences in the effects of vitamin K1 
on stirring versus shaking cultures, and this model was mainly designed to create a 
difference in extent of oxygenation (fig. 23). Second, that vitamin K1 markedly reduced 
the bacterial counts by the BMM method when this was performed anaerobically (fig. 
33c) but minimally for aerobically-incubated cultures suggests that it is not the testing 
vessel or volume but the aerobicity which was the critical factor.  
Treatment of mice with vitamin K1, at a weight-adjusted dosage considered safe 
for humans (Collins et al., 2006), showed a significant inhibitory effect on mycobacterial 
replication in mice (fig. 34). This is the first study showing this effect in vivo using 
vitamin K1. The in vivo efficacy suggests that the Wayne model is better than the aerobic 
BMM of susceptibility testing as an in vitro predictor of anti-mycobacterial efficacy. It 
further supports the contention that in vivo mycobacteria experience hypoxic conditions 
which the Wayne model seeks to mimic. The largest extent of inhibition was observed in 
the liver, followed by lung and spleen (fig. 34b). This corresponded with the increased 
menA expression in the liver and lung (fig. 34c), supporting the probability that there was 
increased requirement for endogenous MK in those organs in vitamin K1-treated mice. It 
also supports our earlier hypothesis that vitamin K1 treatment may reduce the endogenous 
MK apparently available to the mycobacterium. It is interesting to note the evidence for 
differential tissue-specific MK requirement in BCG – MK is probably less required by 
BCG in the spleen, since menA expression is not increased in the bacteria extracted from 
the spleen (fig. 34c). The same conclusion could likewise be inferred from the continued 
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survival of BCG lacking anaerobic nitrate reductase (narGHIJ mutants) in the spleen 
(Fritz et al., 2002), since MK mediates electron transfer to nitrate in anaerobic conditions.  
The in vivo experiment showing slightly greater growth inhibition when the 
compound was administered early in the course of BCG infection (fig. 35) is consistent 
with the postulate that modulation of electron transport in BCG by interference with MK 
biosynthesis earlier during the actively replicating phase of infection would have 
prevented more bacteria from entering the chronic phase of infection as proposed by 
Weinstein (Weinstein et al., 2005). The most interesting finding was that administration 
of vitamin K1 (fig. 36) reduced the ability of mycobacteria to reactivate upon 
immunosuppression. This model of latency and reactivation again supports the likelihood 
that vitamin K1 has an in vivo effect on mycobacteria under conditions of latency, and has 
important implications on the potential of this compound for the treatment of LTBI. 
It is apparent from our data that vitamin K2 was less inhibitory than vitamin K1 at 
concentrations above 300 µg/ml (figs. 25, 26) at NRP-2 stage of mycobacterial 
persistence. Instead, the actively replicating cultures were more affected. Hence, under 
conditions where there is an increased requirement for endogenous MK, vitamin K2 could 
actually be able to supplement the endogenous supply of menaquinone in BCG – this is 
fortunately not seen with vitamin K1.  In a study of a vitamin K-depleted Fusiformis 
nigrescens, the incubation of a higher concentration of 1,4-napthoquinone (10-6 M) than 
the concentration in the bacteria (10-9 M or less) resulted in a markedly higher 
incorporation of glucosamine into the bacterial cell walls (Martius et al., 1971). This 
indicates that vitamin K2, a closely-related analogue to bacterial endogenous MK 
(differing only in the length of the isoprenoid chain) might partake in other metabolic 
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activities necessary for bacterial survival or even reduce the need for endogenous MK. 
This account for the observation (fig. 33) that vitamin K2-treatment combined with PZA 
was less inhibitory than PZA-treatment alone. PZA acts by disrupting the electron 
transport kinetics especially under anaerobiosis and may generate an increased 
requirement for MK. Hence, the addition of vitamin K2 could possibly supplement the 
endogenous MK concentration and compensate for the inhibition exerted by PZA.  This 
is further supported by the observation that menA KD strain is generally less susceptible 
to the effects of exogenous vitamin K2 than the control BCG strain, raising the possibility 
that there exists a fine balance in the mycobacterial requirement for MK where either 
insufficiency or excess is negative for the bacterial survival. Toxicity of excessive MK 
would again explain why vitamin K2 is more inhibitory when bacterial MK is less 
required (e.g. in actively growing cultures, fig 25, as there would be an oversupply) and 
conversely, it is less inhibitory in conditions where MK is in demand (NRP in stirring 
Wayne cultures, fig. 25 or upon PZA treatment, fig. 33).   
An alternative explanation for the reduced efficacy of exogenous vitamin K 
against the menA KD strain is that it could have gradually adapted to a reduced 
requirement for MK, by altering the nature of substrates utilised in hypoxic conditions, or 
by utilising alternative electron transfer molecules other than MK. It is clear from our 
expression studies (Table 9) that a compensatory increase in production of electron 
acceptors may occur in this strain. This may explain the observation that menA KD strain 
in day 5 cultures (fig. 33) was slightly more susceptible to vitamin K1 than day 14 
cultures (fig. 29), if such adaptations occur over time. The increased production of MK 
with treatment (fig. 20d) may also play a role. We are limited in our observations by not 
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having a strain that completely lacks MK (men- BCG), since this strain would aid in 
assessing whether the complete loss of MK can be compensated by other mechanisms.  
Vitamin K1 generally worked with most anti-mycobacterials like INH, STR and 
EMB to increase the extent of mycobactericidal activity inhibition against wild-type 
BCG. Although the increase in killing by combination with vitamin K1 was relatively 
modest (2 to 6-fold range) (fig. 31), it should be remembered that these are only the in 
vitro results of aerobic experiments, since anaerobic testing was only done for PZA. 
Given the present knowledge that vitamin K1 has optimal efficacy in hypoxic conditions, 
it would be necessary to test these synergies anaerobically and in vivo to determine if 
there is potentially a greater effect within the host. The in vitro results with M. avium and 
M. chelonae were more variable – the biggest effect was in M. avium (fig. 32) with the 
combination of vitamin K1 with EMB and there was little synergy with M. chelonae (fig. 
32) which is a rapid-grower. This is probably due to metabolic difference in energy 
production and membrane energetics in different mycobacterium species, resulting in 
differential susceptibilities to exogenous vitamin K. It is also likely that rapid-growers in 
the Mycobacterium genus, largely environmental species, are less likely to establish a 
chronic latent infection whereas our experimental evidence strongly suggests that vitamin 
K1 is likely to have preferential efficacy against latent mycobacteria. 
Overall, these investigations have shown that vitamin K1 has greater inhibitory 
activity in hypoxic BCG cultures, probably by interference with MK-mediated electron 
transport. This feature makes it attractive as an inhibitor of latent mycobacteria, which 
have increased MK requirements. Vitamin K1 may therefore be considered for practical 
application as an adjunctive chemotherapy with conventional anti-TB drugs to target 
  190 
persistent, non-replicating mycobacteria to reduce the duration of TB treatment, and also 
in LTBI to reduce the risk of reactivation. Its parallel use with the established anti-TB 
agent PZA is striking – their dependence on anaerobicity for activity has important 
implications for new anti-TB drug discovery, since it would almost certainly render both 
compounds unidentifiable according to standard drug screening criteria. In the final 
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FINAL DISCUSSION AND FUTURE WORK 
The hallmark of Mycobacterium tuberculosis infection is the pathogen’s ability to 
maintain an in vivo state of persistence, from which it can reactivate after prolonged 
periods to cause active disease (Flynn and Chan, 2001a). This presents a significant 
obstacle to the total eradication of tuberculosis for two reasons. First, one-third of the 
world population has latent TB and constitutes a major reservoir of the pathogen (WHO, 
2005), and second, this dormant population is resistant to conventional anti-
mycobacterials (McDermott, 1959; Wayne and Sramek, 1994). Dormant MTB have been 
characterised to be in a state of non-replicating persistence  (Shi et al., 2003), and this 
state of latency has been linked to hypoxia as the most prominent driving factor 
(Cannetti, 1955; Hirsch, 1955; Hobby, 1957; Imboden and Schoolnik, 1998). Tubercle 
bacilli have been recovered from human tuberculous lesions and necrotic tissues where 
there is a scarcity of oxygen and poor permeability respectively (Hirsch, 1955; Russell et 
al., 1955).  Therefore, in this thesis, a state of mycobacterial latency has been defined in 
vitro by the hypoxia-driven Wayne dormancy model, and in vivo by BCG in chronic 
murine infection. Identifying the role of pathways for maintaining latency is relevant to 
understanding mycobacterial pathogenesis and for drug targeting. The focus of this thesis 
has been on analysis of the role of menaquinone (MK) on mycobacterial latency.  
The major findings in our studies are as follows. Gene expression for MK 
biosynthesis enzymes was upregulated under conditions of hypoxia (fig 9, 10). MK 
deficiency in menA KD BCG resulted in its growth attenuation in macrophages (fig. 18) 
and in mice (figs. 21), accompanied by changes in mycobacterial demands for various 
respiratory electron transport chain components (fig. 17, Table 9). There was a particular 
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defect in its recovery from hypoxia induced NRP (fig. 15) and it had reduced anaerobic 
nitrate reductase activity (fig. 17). Exogenous vitamin K1 significantly reduced growth of 
wild-type BCG, most notably under hypoxic conditions (figs. 12, 23), as it led to reduced 
ability to survive the stage of latency or NRP-2 in the Wayne model, whereas this was 
not seen in aerobic conditions. Indeed, under anaerobic conditions in vitro, the addition of 
vitamin K1 to pyrazinamide enhanced BCG killing by more than 30 fold (fig. 33). The 
mycobactericidal effects of vitamin K1 under anaerobic conditions were consistent with 
approximately 80% reduction in organ bacterial load in mice treated with vitamin K1 
alone (figs. 34, 35) and the treatment impaired in vivo reactivation of latent BCG upon 
host immunosuppression by up to 99% (fig. 36). Overall, the data support the hypothesis 
that MK has a role in mycobacterial survival in oxygen-limited conditions in the state of 
latency, and therefore identifies a dormancy-related pathway which could be targeted. 
Moreover, the finding that vitamin K1 is selectively inhibitory to latent mycobacteria 
suggests one such approach. This is the first study to elucidate the impact of MK on 
mycobacterial persistence and to comprehensively identify activity of vitamin K1 on 
mycobacteria.  
The results raise the practical issue of whether oral vitamin K1 can be considered 
as an adjunct to anti-mycobacterial therapy in clinical practice. There are several 
considerations. First, the safety issues should be considered. Vitamin K1 is already freely 
available in health supplement tablets without prescription in many developed countries 
including Singapore. The recommended dietary allowance is 1 µg/kg body weight per 
day (DH, 1991). Vitamin K1 is given to all newborns by intramuscular administration of 
0.5 – 1 mg to reduce incidence of intracranial haemorrhage due to birth trauma, and the 
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same dose can be used for treating haemorrhagic disease of the newborn. Oral dosage of 
between 2.5 – 10 mg is used for non-emergency correction of prolonged prothrombin 
time in patients on coumarin anticoagulants (e.g. warfarin), and rarely up to 50 mg can be 
used in an emergency according to dosage guidelines recommended by Food and Drug 
Administration (FDA) in the United States. Therefore there could be concern of a hyper-
coagulation state with prolonged treatment. However, there is clinical experience of 
administering large oral doses of vitamin K1 in humans (1 mg/day for up to 36 months) 
(Braam et al., 2003) with no major adverse effects associated with vitamin K (Cockayne 
et al., 2006; Shearer, 1995). Although the major dietary source of vitamin K is the plant 
form phylloquinone (vitamin K1), there have been more numerous clinical trials to date 
performed with a form of vitamin K2 (menaquinone-4) in the context of improving bone 
mineralisation.  
Second, if exogenous vitamin K1 was to negatively affect gut anaerobes 
(theoretically possible), this might be a disadvantage of such treatment, but there are no 
known studies specifically testing this. Circumstantial evidence suggests, however, that 
those on long term both vitamin K
 
supplementation for osteoporosis treatment have not 
shown increased incidence of diarrhoea or other gastrointestinal disorders (Cockayne et 
al., 2006). Third, the tissue bioavailability upon oral dosing should be considered. Based 
on studies in rats, phylloquinone (vitamin K1) can be converted into menaquinone (MK-
4) in tissues independent from gut bacteria (Davidson et al., 1998). Previous studies have 
suggested that vitamin K2 may be more efficiently absorbed than phylloquinone 
(Groenen-van Dooren et al., 1995). Unfortunately in our present study, it appears that 
vitamin K2 is less effective against latent mycobacteria than vitamin K1. There are 
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conflicting reports on the relative bioavailability of vitamin K1 from natural sources (e.g. 
broccoli, spinach) versus oral supplements (Booth and Centurelli, 1999; Gijsbers et al., 
1996). This conflict may be related to study methodology, specifically whether the 
vitamin K1 is consumed with a high lipid diet since this promotes its absorption (Gijsbers 
et al., 1996). A human fed 168 µg of labelled phylloquinone in broccoli has 80% serum 
enrichment in this compound at 4 -6 h post-consumption, and serum concentrations 
ranged from 0.29 to 3.10 nmol/litre (Dolnikowski et al., 2002). The vitamin K1 level 
achievable in the tissues (particularly in the lungs) in humans is less certain and there are 
no direct studies on this. Paediatric studies suggest that intramuscular dosing of vitamin 
K1 for treating haemorrhagic disease has efficacy for 2 months, whereas oral dosing lasts 
3 - 4 weeks (Loughnan and McDougall, 1996); this indirectly implies that there could be 
a prolonged bioavailability in human tissues, which is a good prospect if at least 6 months 
of treatment is required for the TB patient. 
Fourth, the potential ability of vitamin K1 as an antibiotic-sparing agent needs to 
be explored in vivo. In future work, it should ideally be investigated whether the dose 
and/or duration of administering standard anti-mycobacterial drugs may be reduced by 
adjunctive treatment with vitamin K1 by studies in humans. There is evidence for such a 
potential, given our findings that vitamin K1 was observed to target hypoxic, non-
replicating mycobacteria in an in vitro latency model, under anaerobic conditions (figs. 
24, 33) as well as intracellular mycobacteria in an in vivo murine model of LTBI (fig. 
36). The in vivo results suggest that there would be no problem with penetration of 
vitamin K1 into host tissues to eradicate even intracellular or latent mycobacteria 
harbouring within macrophages.  Poor activity against slow- or non-growing bacteria is 
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thought to be the main reason why conventional drugs take so long to eradicate 
tuberculosis (Mitchison, 1980). Hence, a compound that selectively targets latent 
mycobacteria by affecting bacterial mechanisms for maintaining non-replicating 
persistence should aid in reducing the duration of standard drug treatment. This is 
extremely important to improve compliance and reduce toxicity.  
Lastly, the appropriate dose of vitamin K1 to be used as adjunctive therapy is 
likely to be a matter of contention. A maximal concentration of 1.25 mg/ml of vitamin K1 
was used in this study because the diluent used could not solubilise the vitamin at higher 
concentrations. The study could be extended to test other different diluents (compatible 
with human usage) for better solubilisation properties in order to increase the vitamin K1 
concentration achievable. Dietary vitamin K intake is an order of 100–400 µg/day, but 
100 times higher doses are not apparently harmful (as discussed above). Generally an 
effective drug against MTB should ideally have an MBC90 of <1 µM, equivalent to 
4.5 x 10-4 µg/ml of vitamin K1. Based on the hypoxic cultures at NRP-2 (Wayne model, 
figs. 23, 24), we would need 12 µg/ml of vitamin K1 to achieve MBC90 and in the aerobic 
cultures tested by the BMM, this level of MBC is clearly not achieved even at 
1.25 mg/ml vitamin K1. Thus, if we rely on the in vitro data alone, it would appear that 
vitamin K1 may not be useful. However, in our murine study, oral dosing at 
500 µg/kg/day gave 70 to 85% reduction in BCG load (fig. 34), so the in vivo data seems 
to suggest that MBC85 is achievable with a dose known to be safe for humans. Hence, 
effective dose-ranging studies for this drug would most probably have to be performed 
directly on humans, and its status as an established oral drug with little toxicity even at 
high doses makes this task relatively easy. 
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Humans do not produce MK; thus targeting the MK biosynthetic pathway 
presents a potentially bacterium-specific treatment for latent TB infections with selective 
toxicity. However, it is not totally clear whether exogenous vitamin K1 actually directly 
influences bacterial MK as our hypotheses for the mechanism of action (figs. 37, 38) 
remain to be proven. Although the data from gene expression (fig. 12d) and MK 
extraction (fig. 20d) studies suggest that vitamin K1 treatment certainly increases the MK 
requirement in dormant BCG, it could be possible that this is a secondary or indirect 
effect and may not necessarily be related to direct competition.  Hence, further studies 
should be conducted to investigate the mechanisms of vitamin K inhibition on the MK-
dependent respiratory chain. This would involve identifying the binding partners of 
endogenous menaquinone as well as vitamin K1 so as to elucidate exactly how the 
compounds could block electron transport. There is also a need to uncover the binding 
affinity and selectivity of binding of vitamin K1 to different MK-binding partners under 
different respiratory states. In order to test our alternative hypothesis that vitamin K 
affects transcriptional control of the men gene expression, systematic deletions of gene 
segments within the men promoter region to identify elements responsible for activation 
and repression of the men genes could be performed.  
Recently mycobacterial inducible promoters have been developed (Blokpoel et 
al., 2005; Ehrt et al., 2005) using tetracycline responsive elements, from the Tn10 Tet 
repressor and a repressor-regulated Tet efflux system discovered in Corynebacterium 
glutamicum. Tetracyline and its derivatives can freely diffuse across membrane barriers 
with low toxicity in mammalian systems, these promoters could be used to control the 
expression of introduced men genes or to regulate the production of anti-sense transcripts 
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in animal models. This opens the door for studies using conditional loss of menaquinone 
production to identify the precise stage in murine TB infection when menaquinone may 
be most required by the bacteria. This would throw light upon the stage when vitamin K1 
therapy may be most useful in TB infection. The creation of a gene-targeted men knock-
out mutant may also be useful in characterising effects of complete menaquinone 
deficiency and to uncover redundant pathways in mycobacteria for electron transport. 
However, preliminary work we have done suggests that this may be a lethal mutation. 
Lastly, to investigate the feasibility of vitamin K1 as adjunctive chemotherapy, 
clinical trials are required involving human TB patients, where vitamin K1 is added to the 
current anti-TB regimen to test if it would reduce the time to sputum conversion, and/or 
be useful in drug-resistant cases. Clinical studies comparing the efficacy of vitamin K1 
alone versus isoniazid in prophylaxis of LTBI would also be needed as this holds promise 
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APPENDIX 
Appendix 1 
Nutrient starvation assay using complete Hartmans DeBont media 
 
1. Preparation of  1 litre HDB complete media: 
2g (NH4)2SO4 (15 mM) 
8 ml 10% glycerol or 0.2% v/v glycerol (27.4 mM) 
5 ml 10% Tween-80 or 0.05% v/v Tween-80 
Adjust to pH 7.0 and make up to 990 ml with distilled water 
Autoclave and when cooled, add 10 ml 100x autoclaved phosphate stock (100 ml)  
15.5g K2HPO4 (8.9 mM) 
8.5g NaH2PO4  (7.08 mM) 
Add 10 ml of trace elements (100x stock); filter sterilised: 
1 litre of trace elements 100x stock (prepared in the following order): 










2. Bacteria were grown in7H9 broth supplemented with 10% OADC in roller bottle until 
ODA600 reaches 0.7 to 1.0. 
3. Bacteria was washed thrice by centrifugation at 2,500 g for 15 min and resuspended 
in complete HDB media. Bacteria were de-clumped by cup-horn sonication in 3 
pulses of 30 s each. 
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4. Bacterial cultures were diluted to ODA600 0.040 in 5 ml of HDB in a 25cm2 vented 
tissue culture flask and incubated without shaking at 37 °C. Bacterial suspension was 
plated for cfu counting to verify starting bacterial count on day 0. 
5. Growth was monitored by spectrophotometer and cfu counting by plating on 7H10 
agar. Flasks that were opened for turbidity measurements and cfu plating were 
discarded. 
